<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral herbal therapies for treating osteoarthritis - Cameron, M - 2014 | Cochrane Library</title> <meta content="Oral herbal therapies for treating osteoarthritis - Cameron, M - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002947.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral herbal therapies for treating osteoarthritis - Cameron, M - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002947.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002947.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral herbal therapies for treating osteoarthritis" name="citation_title"/> <meta content="Melainie Cameron" name="citation_author"/> <meta content="University of the Sunshine Coast" name="citation_author_institution"/> <meta content="mcameron@usc.edu.au" name="citation_author_email"/> <meta content="Sigrun Chrubasik" name="citation_author"/> <meta content="University of Freiburg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD002947.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002947.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002947.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002947.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Boswellia; Chronic Disease; Drug Combinations; Osteoarthritis [*drug therapy]; Phytosterols [therapeutic use]; Phytotherapy [*methods]; Plant Extracts [therapeutic use]; Randomized Controlled Trials as Topic; Vitamin E [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002947.pub2&amp;doi=10.1002/14651858.CD002947.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002947\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002947\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","ru","ko","ja","hr","fr","ta","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002947.pub2",title:"Oral herbal therapies for treating osteoarthritis",firstPublishedDate:"May 22, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002947.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002947.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002947.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002947.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002947.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002947.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002947.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002947.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002947.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002947.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>17277 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002947.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0135"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0057"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0058"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0080"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-sec-0129"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/appendices#CD002947-sec-0140"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/table_n/CD002947StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/table_n/CD002947StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral herbal therapies for treating osteoarthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information#CD002947-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Melainie Cameron</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information#CD002947-cr-0003">Sigrun Chrubasik</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information/en#CD002947-sec-0150">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002947.pub2">https://doi.org/10.1002/14651858.CD002947.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002947-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002947-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002947-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002947-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002947-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002947-abs-0004">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002947-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002947-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002947-abs-0001" lang="en"> <section id="CD002947-sec-0001"> <h3 class="title" id="CD002947-sec-0001">Background</h3> <p>Medicinal plant products are used orally for treating osteoarthritis. Although their mechanisms of action have not yet been elucidated in full detail, interactions with common inflammatory mediators provide a rationale for using them to treat osteoarthritic complaints. </p> </section> <section id="CD002947-sec-0002"> <h3 class="title" id="CD002947-sec-0002">Objectives</h3> <p>To update a previous Cochrane review to assess the benefits and harms of oral medicinal plant products in treating osteoarthritis. </p> </section> <section id="CD002947-sec-0003"> <h3 class="title" id="CD002947-sec-0003">Search methods</h3> <p>We searched electronic databases (CENTRAL, MEDLINE, EMBASE, AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to 29 August 2013, unrestricted by language, and the reference lists from retrieved trials. </p> </section> <section id="CD002947-sec-0004"> <h3 class="title" id="CD002947-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of orally consumed herbal interventions compared with placebo or active controls in people with osteoarthritis were included. Herbal interventions included any plant preparation but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin. </p> </section> <section id="CD002947-sec-0005"> <h3 class="title" id="CD002947-sec-0005">Data collection and analysis</h3> <p>Two authors used standard methods for trial selection and data extraction, and assessed the quality of the body of evidence using the GRADE approach for major outcomes (pain, function, radiographic joint changes, quality of life, withdrawals due to adverse events, total adverse events, and serious adverse events). </p> </section> <section id="CD002947-sec-0006"> <h3 class="title" id="CD002947-sec-0006">Main results</h3> <p>Forty‐nine randomised controlled studies (33 interventions, 5980 participants) were included. Seventeen studies of confirmatory design (sample and effect sizes pre‐specified) were mostly at moderate risk of bias. The remaining 32 studies of exploratory design were at higher risk of bias. Due to differing interventions, meta‐analyses were restricted to <i>Boswellia serrata</i> (monoherbal) and avocado‐soyabean unsaponifiables (ASU) (two herb combination) products. </p> <p>Five studies of three different extracts from <i>Boswellia serrata</i> were included. Moderate‐quality evidence from two studies (85 participants) indicated that 90 days treatment with 100 mg of enriched <i>Boswellia serrata</i> extract improved symptoms compared to placebo. Mean pain was 40 points on a 0 to 100 point VAS scale (0 is no pain) with placebo, enriched <i>Boswellia serrata</i> reduced pain by a mean of 17 points (95% confidence interval (CI) 8 to 26); number needed to treat for an additional beneficial outcome (NNTB) 2; the 95% CIs did not exclude a clinically significant reduction of 15 points in pain. Physical function was 33 points on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 0 to 100 point subscale (0 is no loss of function) with placebo, enriched <i>Boswellia serrata</i> improved function by 8 points (95% CI 2 to 14); NNTB 4. Assuming a minimal clinically important difference of 10 points, we cannot exclude a clinically important benefit in some people. Moderate‐quality evidence (one study, 96 participants) indicated that adverse events were probably reduced with enriched <i>Boswellia serrata</i> (18/48 events versus 30/48 events with placebo; relative risk (RR) 0.60, 95% CI 0.39 to 0.92). Possible benefits of other <i>Boswellia serrata</i> extracts over placebo were confirmed in moderate‐quality evidence from two studies (97 participants) of <i>Boswellia serrata</i> (enriched) 100 mg plus non‐volatile oil, and low‐quality evidence from small single studies of a 999 mg daily dose of <i>Boswellia serrata</i> extract and 250 mg daily dose of enriched<i>Boswellia serrata</i> . It was uncertain if a 99 mg daily dose of <i>Boswellia serrata</i> offered benefits over valdecoxib due to the very low‐quality evidence from a small single study. It was uncertain if there was an increased risk of adverse events or withdrawals with <i>Boswellia serrata</i> extract due to variable reporting of results across studies. The studies reported no serious adverse events. Quality of life and radiographic joint changes were not measured. </p> <p>Six studies examined the ASU product Piasclidine®. Moderate‐quality evidence from four studies (651 participants) indicated that ASU 300 mg produced a small and clinically questionable improvement in symptoms, and probably no increased adverse events compared to placebo after three to 12 months treatment. Mean pain with placebo was 40.5 points on a VAS 0 to 100 scale (0 is no pain), ASU 300 mg reduced pain by a mean of 8.5 points (95% CI 1 to 16 points); NNTB 8. ASU 300 mg improved function (standardised mean difference (SMD) ‐0.42, 95% CI ‐0.73 to ‐0.11). Function was estimated as 47 mm (0 to 100 mm scale, where 0 is no loss of function) with placebo, ASU 300 mg improved function by a mean of 7 mm (95% CI 2 to 12 mm); NNTB 5 (3 to 19). There were no differences in adverse events (5 studies, 1050 participants) between ASU (53%) and placebo (51%) (RR 1.04, 95% CI 0.97 to 1.12); withdrawals due to adverse events (1 study, 398 participants) between ASU (17%) and placebo (15%) (RR 1.14, 95% CI 0.73 to 1.80); or serious adverse events (1 study, 398 participants) between ASU (40%) and placebo (33%) (RR 1.22, 95% CI 0.94 to 1.59). Radiographic joint changes, measured as change in joint space width (JSW) in two studies (453 participants) did not differ between ASU 300 mg treatment (‐0.53 mm) and placebo (‐0.65 mm); mean difference of ‐0.12 (95% CI ‐0.43 to 0.19). Moderate‐quality evidence from a single study (156 participants) confirmed possible benefits of ASU 600 mg over placebo, with no increased adverse events. Low‐quality evidence (1 study, 357 participants) indicated there may be no differences in symptoms or adverse events between ASU 300 mg and chondroitin sulphate. Quality of life was not measured. </p> <p>All other herbal interventions were investigated in single studies, limiting conclusions. No serious side effects related to any plant product were reported. </p> </section> <section id="CD002947-sec-0007"> <h3 class="title" id="CD002947-sec-0007">Authors' conclusions</h3> <p>Evidence for the proprietary ASU product Piasclidine® in the treatment of osteoarthritis symptoms seems moderate for short term use, but studies over a longer term and against an apparently active control are less convincing. Several other medicinal plant products, including extracts of <i>Boswellia serrata</i>, have moderate‐quality evidence for trends of benefits that warrant further investigation in light of the fact that the risk of adverse events appear low. </p> <p>There is no evidence that Piasclidine® significantly improves joint structure, and limited evidence that it prevents joint space narrowing. Structural changes were not tested for with any other herbal intervention. </p> <p>Further investigations are required to determine optimum daily doses producing clinical benefits without adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002947-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002947-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD002947-abs-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD002947-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002947-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002947-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD002947-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002947-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD002947-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002947-abs-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002947-abs-0009">Русский</a> </li> <li class="section-language"> <a class="" href="full/ta#CD002947-abs-0014">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002947-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002947-abs-0006" lang="en"> <h3>Oral herbal therapies for treating osteoarthritis</h3> <p><b>Background: what is osteoarthritis and what is herbal therapy?</b> </p> <p>Osteoarthritis (OA) is a disease of the joints (commonly knees, hips, hands). When joints lose cartilage, bone grows to try to repair the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become misshapen and make the joint painful and limit movement. OA can affect your physical function, particularly your ability to use your joints. </p> <p>Herbal medicines are defined as being finished, labelled medicinal products that contain as active ingredients aerial or underground parts of plants or other plant material, or combinations thereof, whether in the crude state or as plant preparations (for example extracts, oils, tinctures). </p> <p><b>Study characteristics</b> </p> <p>This summary of an update of a Cochrane review presents what we know from research about the effects of herbal therapies consumed orally by people with osteoarthritis. After searching for all relevant studies to August 2013, we included 45 new studies since the last review, giving a total of 49 studies (on 33 herbal interventions) that included 5980 participants, most with mild to moderate symptomatic osteoarthritis of the knee or hip. Thirty‐three different medicinal plant products were compared with placebo or active intervention controls and many comparisons had single studies only; thus, we have restricted reporting of results here to multiple studies of <i>Boswellia serrata</i> (monoherbal) and avocado‐soyabean unsaponifiables (ASU) (two herb combination) products<i>.</i> </p> <p><b>Key results</b> </p> <p><b><i>Boswellia serrata</i> </b> </p> <p>Pain on a scale of 0 to 100 points (lower scores mean reduced pain):</p> <p>‐ people who used 100 mg of enriched <i>Boswellia serrata</i> extract rated their pain 17 points lower (range 8 to 26 points lower) (17% absolute improvement) at 90 days compared with placebo; </p> <p>‐ people who used enriched <i>Boswellia serrata</i> extract 100 mg rated their pain as 23 points; </p> <p>‐ people who used a placebo preparation rated their pain as 40 points.</p> <p>Physical function on a scale of 0 to 100 points (lower scores means better physical function): </p> <p>‐ people who used 100 mg of enriched <i>Boswellia serrata</i> extract rated their physical function 8 points better (2 to 14 points better) on a 100 point scale (8% absolute improvement) at 90 days compared with placebo; </p> <p>‐ people who used 100 mg of enriched <i>Boswellia serrata</i> extract rated their physical function as 25 points; </p> <p>‐ people who used placebo rated their physical function as 33 points.</p> <p><b>Avocado‐soyabean unsaponifiables (ASU) product Piascledine®</b> </p> <p>Pain on a scale of 0 to 100 points (lower scores mean less pain):</p> <p>‐ people who used ASU 300 mg rated their pain 8 points lower (1 to 16 points lower) on a 100 point scale (8% absolute improvement) at 3 to 12 months compared with placebo; </p> <p>‐ people who used ASU 300 mg rated their pain as 33 points;</p> <p>‐ people who used placebo rated their pain as 41 points.</p> <p>Physical function on a scale of 0 to 100 mm scale (lower scores means better physical function): </p> <p>‐ people who used ASU 300 mg rated their physical function 7 mm better (2 to 12 mm better) on a 100 mm scale (7% absolute improvement) at 3 to 12 months compared with placebo; </p> <p>‐ people who used ASU 300 mg rated their physical function as 40 mm;</p> <p>‐ people who used placebo rated their physical function as 47 mm.</p> <p><b>Quality of the evidence</b> </p> <p>There is moderate‐quality evidence that in people with osteoarthritis <i>Boswellia serrata</i> slightly improved pain and function. Further research may change the estimates. </p> <p>There is moderate‐quality evidence that avocado‐soybean unsaponifiables (ASU) probably improved pain and function slightly, but may not preserve joint space. Further research may change the estimates. </p> <p>We are uncertain whether other oral herbal products improve osteoarthritis pain or function, or slow progression of joint structure damage because the available evidence is limited to single studies or studies that cannot be pooled, and some of these studies are of low to very low quality. Quality of life was not measured. </p> <p>Herbal therapies may cause side effects, however we are uncertain if there is an increased risk of these. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002947-sec-0135" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002947-sec-0135"></div> <h3 class="title" id="CD002947-sec-0136">Implications for practice</h3> <section id="CD002947-sec-0136"> <p>See: 'Summary of findings' tables.</p> <p>We have provided a tabulated summary of key clinical messages to assist practitioners in transferring the findings of this updated review into their clinical work. The current available evidence for herbal treatment of osteoarthritis (OA) is generally sparse. For most medicinal plant products there is insufficient evidence to support or discourage use. </p> <p>The original review concluded that there was consistent evidence that a proprietary product from avocado‐soybean unsaponifiables (ASU) can provide long term symptomatic relief, particularly for patients with chronic but stable OA of the hip, and that ASU may also help patients to reduce their consumption of non‐steroidal anti‐inflammatory drugs (NSAIDs). These results need to be reconsidered in the light of three new studies: one study over six months that supports the previous findings (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>), another longer term study that reported no improvements over placebo among people using 300 mg ASU daily for 12 to 24 months (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>), and the most recent showing ASU as not inferior to chondroitin sulphate (<a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>). Despite symptomatic improvements, ASU does not appear to have a major impact on joint structure in patients with OA. Similarly, non‐inferiority to chondroitin sulphate may mean little because chondroitin sulphate is not significantly effective in reducing osteoarthritic pain, and has only a small effect on joint space narrowing that occurs only with long term (two plus years) treatment (<a href="./references#CD002947-bbs2-0164" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , ReichenbachS , TrelleS . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ2010;341:c4675. [DOI: 10.1136/bmj.c4675] ">Wandel 2010</a>). We suggest that the length of intervention may be an important factor that differs among these studies, and recommend that clinicians consider monitoring pain and physical function as part of routine care for patients using ASU, particularly with prolonged use of this intervention. </p> <p>High tolerance of the medicinal plant products was demonstrated in all studies. Caution is warranted in interpreting safety. Although no serious drug‐related adverse events occurred in the studies so far, comprehensive safety data are still required for all medicinal plant products except for the mixture Phytodolor®. </p> </section> <h3 class="title" id="CD002947-sec-0137">Implications for research</h3> <section id="CD002947-sec-0137"> <p>Several studies were excluded from this review on the grounds of flawed research design, including unclear recruitment criteria and inadequate definition of the herbal interventions. Other studies were included but are of limited usefulness because the selection criteria were incomplete or data were manipulated post hoc to support the authors' preferred conclusions. High quality, adequately powered clinical studies investigating herbal interventions are required. We recommend that future researchers give attention to the detail of study design, ensuring that participant samples are well defined according to ACR criteria and recruited without bias; that herbal preparations are reported in detail, including dose, extraction method, and active principle; and that study results are recorded using reliable, valid outcome measures, in particular for the consensus criteria of the Outcomes Measures in Rheumatology‐Osteoarthritis Research Sicuety International (OMERACT‐OARSI) that combine pain and functional impairments in the identification of treatment response (<a href="./references#CD002947-bbs2-0145" title="PhamT , Van DerHeijdeD , LassereM , AltmanRD , AndersonJJ , BellamyN , et al. Outcome variables for osteoarthritis clinical trials: The OMERACT‐OARSI set of responder criteria. Journal of Rheumatology2003;30:1645‐54. ">Pham 2003</a>; <a href="./references#CD002947-bbs2-0146" title="PhamT , van derHeijdeD , AltmanRD , AndersonJJ , BellamyN , HochbergM , et al. OMERACT‐OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis and Cartilage2004;12:389‐99. ">Pham 2004</a>) be used in these studies to be able to compare the efficacy of different medicinal plant products. </p> <p>So far, longer term studies over one and two years have been carried out only for aqueous <i>Harpagophytum</i> extract with 50 mg harpagoside in a daily dosage (<a href="./references#CD002947-bbs2-0122" title="ChrubasikJE , RoufogalisBD , ChrubasikS . Evidence of effectiveness of herbal anti‐inflammatory drugs in the treatment of painful osteoarthritis including chronic low back pain. Phytotherapy Research2007;21:675‐83. ">Chrubasik 2007</a>) and the ASU product Piascledine® (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). Since OA is a chronic condition, future long term studies over several years are needed to prove the effective and safe use of medicinal plant products. </p> <p>OA of the knee, hip, and spine is a degenerative disease affecting the joint cartilage and the underlying subchondral cartilage. Progressive loss of articular cartilage, appositional new bone formation in the subchondral trabeculae, and formation of new cartilage and bone at the joint margins result in pain, stiffness, limitation of function, and diminished quality of life (<a href="./references#CD002947-bbs2-0149" title="SanghaO . Epidemiology of rheumatic diseases. Rheumatology2000;39 Suppl 2:3‐12. ">Sangha 2000</a>). Although there is no clear explanation for differences in effect among body regions, some investigators have reported that pain from hip OA responds better to treatment with a herbal medicinal product than does OA pain in other regions (<a href="./references#CD002947-bbs2-0118" title="ChrubasikS , FiebichB , BlackA , PollakS . Treating low back pain with an extract of Harpagophytum that inhibits cytokine release. European Journal of Anaesthesiology2002;19:209. ">Chrubasik 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>), suggesting that the site of joint disease may influence pain outcomes. We suggest that future researchers consider recruiting participants with particular joint involvement or stratify results according to site of disease. </p> <p>There is also a tendency to duplicate publications in this field, by publishing abstracts of conference presentations as well as complete papers, or publishing the same paper in multiple languages. Duplication of publications may be legitimate but tends to create the appearance of a larger body of evidence than actually exists. We advise caution in the duplication of publications and recommend that, where possible, authors indicate that a manuscript or part thereof has been previously published elsewhere. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002947-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002947-sec-0050"></div> <div class="table" id="CD002947-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Boswellia serrata for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> 999 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain 0‐3 (higher scores mean worse)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 2.50 (0 to 3 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention groups was<br/> <b>2.24 lower</b> <br/> (2.64 to 1.84 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 56% (46% to 66%); Relative improvement in pain was 80% (66% to 94%)<sup>5</sup>; NNTB = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Loss of function 0‐3 (higher scores mean worse)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 2.46 (0 to 3 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>2.16 lower</b> <br/> (2.56 to 1.76 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in function was 54% (44% to 64%); Relative improvement was 76% (62% to 90%)<sup>5</sup>; NNTB = 1 (95% CI 1 to 3). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse effects<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No (n=0) participants in the control group reported adverse events.</p> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Two (n=2) participants in the intervention group reported adverse events.</p> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b> <br/> (0.26 to 96.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 13% higher in the <i>Boswellia serrata</i> group (6% lower to 33% higher); Relative percentage change 400% worsening (74% to 9513% worsening); NNT n/a.<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events not reported as discrete outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Criteria for diagnosis of OA not specified.<br/> <sup>2</sup> Exploratory study design; power, effect, and sample size not determined a priori.<br/> <sup>3</sup> Ethical oversight not reported. </p> <p><sup>4</sup> Downgrade estimate due to single study. </p> <p><sup>5</sup> Control group baseline pain (SD) 2.80 (0.41), baseline disability 2.86 (0.35), from <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>. </p> <p><sup>6</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). Assumed a minimal clinically important difference of 1 point of a 0 to 3 point scale (pain, function). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) 100 mg for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 100 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) 100mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at the end of treatment was 40.02 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The weighted mean pain in the intervention groups was<br/> <b>16.57 lower</b> <br/> (26.47 to 8.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 17% (8% to 26%); Relative improvement in pain was 29% (15% to 43%)<sup>3</sup>; NNTB 2 (95% CI 1 to 6). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>1</sup> 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the control groups at the end of treatment was 33.13 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The weighted mean disability in the intervention groups was<br/> <b>8.21 lower</b> <br/> (14.21 to 2.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement was 8% (14% to 2%); Relative improvement was 20% (5% to 34%)<sup>3</sup>; NNTB 4 (95% CI 2 to 18). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Adverse event episodes (n) reported<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> <br/> (211 to 577) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/> (0.39 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 25% lower in the <i>Boswellia serrata</i> group (6% to 44% lower); Relative percentage change 40% improvement (61% improvement to 9% worsening); NNT = 4 (95% CI 3 to 22). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>, <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>, <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> <p><sup>2</sup> Confirmatory study design: statistical power 80%, alpha set at 0.05, but downgraded due to potential imprecision due to small number of participants; and lower limit of 95% CI does not preclude clincially insignificant change </p> <p><sup>3</sup> Control group baseline measures taken from <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>, the study most heavily weighted in the meta‐analyses. Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6). </p> <p><sup>4</sup> Downgrade estimate due to potential imprecision, eg, small number of events and participants from a single study. </p> <p><sup>5</sup> Number needed to treat (NNT) is not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/); NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). Assumed a minimal clinically important difference of 15 points on 0 to 100 mm pain scale, and 10 points on 0 to 100 mm function scale. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Boswellia serrata (enriched) 250 mg for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) 250mg for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 250mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) 250mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 41.76 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention group was<br/> <b>27.54 lower</b> <br/> (34.64 to 20.44 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 28% (20% to 35%); Relative improvement in pain was 48% (36% to 61%)<sup>3</sup> ; NNT = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>1</sup> </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 34.07 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention group was<br/> <b>16.8 lower</b> <br/> (21.23 to 12.37 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 17% (12% to 21%); Relative improvement in disability was 41% (30% to 51%)<sup>3</sup>; NNT = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Adverse event episodes (n) reported<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>526 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> <br/> (302 to 653) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/> (0.62 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 5% lower in the <i>Boswellia serrata</i> group (24% lower to 13% higher); Relative percentage change 10% improvement (38% improvement to 30% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> <p><sup>2</sup> Downgrade estimate due to single study. </p> <p><sup>3</sup> Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6), from <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>. </p> <p><sup>4</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Boswellia serrata (enriched) plus non‐volatile oil for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) plus non‐volatile oil for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 100mg plus non‐volatile oil </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) plus non‐volatile oil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: 30‐90 days<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at the end of treatment was 38.90 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the intervention groups was<br/> <b>16.09 lower</b> <br/> (20.37 to 11.81 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 16% (12% to 20%); Relative improvement in pain was 34%(25% to 42%)<sup>3</sup>; NNTB 2 (1 to 4)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>5</sup> normalised units </p> <p>(higher scores mean worse)<br/> Follow‐up: 30‐90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the control groups at the end of treatment was 34.90 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the intervention groups was<br/> <b>15.01 lower</b> <br/> (19.21 to 10.81 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 15% (11% to 19%); Relative improvement in disability was 37% (27% to 47%)<sup>3</sup>; NNTB 2 (1 to 3). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 30‐90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> <br/> (6 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.14 to 6.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 0% lower in the <i>Boswellia serrata</i> group (8% lower to 8% higher); Relative percentage change 2% improvement (86% improvement to 569% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: 30 day intervention. <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>: 90 day intervention.<br/> <sup>2</sup><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: Exploratory study design; power, effect, and sample size not determined a priori.<br/> <sup>3</sup> Control group baseline measures taken from <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>, the study most heavily weighted in the meta‐analyses. Control group baseline pain 47.6 (9.7), baseline disability 40.6 (9.5). </p> <p><sup>4</sup> Number needed to treat to benefit (NNTB), and harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> <p><sup>5</sup><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>, <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Boswellia serrata compared to valdecoxib for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> compared to valdecoxib for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> 999 mg<br/> <b>Comparison:</b> valdecoxib </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Valdecoxib</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> WOMAC‐VAS (Pain) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the valdecoxib group at the end of treatment was 17.08 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention groups was<br/> <b>0.51 lower</b> <br/> (7.26 lower to 6.24 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 1% (7% improvement to 6% worsening); Relative improvement in pain was 1%<sup>4</sup>; NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>5</sup> <br/> (higher scores mean worse) </p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the valdecoxib group at the end of treatment was 16.64 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>2.49 higher</b> <br/> (4.07 lower to 9.05 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening in disability was 3% (4% improvement to 9% worsening); Relative improvement in disability was 4%<sup>4</sup>; NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> <br/> (23 to 448) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.0</b> <br/> (0.39 to 10.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 6% higher in the <i>Boswellia serrata</i> group (8% lower to 20% higher); Relative percentage change 100% worsening (61% improvement to 918% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.0</b> </p> <p>(0.13 to 71.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported one (1) withdrawal possibly due to adverse events.</p> <p>Absolute risk of withdrawal due to adverse events was 3% higher in the <i>Boswellia serrata</i> group (5% lower to 11% higher); Relative percentage change 200% worsening (87% improvement to 7007% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Open trial. Medication regimens differ between active control and intervention. </p> <p><sup>2</sup> Downgrade estimate due to single study. Treatment effect crosses midline (no effect).<br/> <sup>3</sup> Exploratory study design; power, effect, and sample size not determined a priori. </p> <p><sup>4</sup> Baseline pain in valdecoxib group 49.2, baseline disability 51.6. Aggregate WOMAC scores converted to normalised scores for re‐analysis. </p> <p><sup>5</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: France (3), Belgium (1).<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: 3 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at end of treatment was 40.53 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the intervention groups was<br/> <b>8.47 lower</b> <br/> (15.90 to 1.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>651<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 8% (1% to 16%); Relative improvement in pain was 15% (2% to 29%)<sup>2</sup>; NNTB 8 (4 to 77)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Multiple tools<sup>4</sup> <br/> Follow‐up: 3 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at end of treatment was 47.10 mm, on VAS 0 to 100 mm scale (higher scores mean worse)<sup>5</sup>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>7 mm lower</b> <br/> (12 mm to 2 mm lower<sup>6</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>642<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.42 (95% CI ‐0.73 to ‐0.11), in favour of ASU 300mg</p> <p>Absolute improvement in disability was 7% (2% to 12%); Relative improvement in disability was 13% (4% to 23%)<sup>7</sup>; NNTB 5 (3 to 19)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 3 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>531 per 1000</b> <br/> (495 to 572) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events is 2% higher in the ASU group (2% lower to 7% higher); Relative percentage change 4% worsening (9% improvement to 12% worsening); NNT n/a<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>169 per 100</b> </p> <p>(108 to 267)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b> </p> <p>(0.73 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of participants withdrawing due to adverse events in 2% higher in ASU group (5% lower to 9% higher); Relative percentage change 14% worsening (27% improvement to 90% worsening); NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(306 to 517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.22</b> </p> <p>(0.94 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of serious adverse events is 7% higher in the ASU group (2% lower to 17% higher); Relative percentage change 22% worsening (6% improvement to 59% worsening); NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> <p>Change in Joint Space Width (JSW) from baseline</p> <p>(higher scores mean worse).</p> <p>Follow up: 24 to 36 months.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Weighted mean JSW change from baseline in the control groups at end of treatment was 0.65. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean JSW change from baseline in the intervention groups was <b>0.12 lower</b> (0.43 lower to 0.19 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute change</p> <p>NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgrade due to heterogeneity, inconsistency </p> <p><sup>2</sup> Calculations based on control group baseline pain measure taken from <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, the most heavily weighted study in the meta‐analysis. Control group baseline mean (SD) pain 54.3 (11.9). </p> <p><sup>3</sup> Number needed to treat to benefit (NNTB), or to harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/)NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office), assuming a minimal clinically important difference of 15 mm on a 0 to 100 mm pain scale, and 10 mm on a 0 to 100 mm function scale. </p> <p><sup>4</sup> Multiple tools: Disability VAS reported in one study only (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>); WOMAC change score reported in one study (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>); Lequesne algofunctional index reported in four studies, but to avoid over‐reporting, data were extracted on this outcome from three studies only (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>) </p> <p><sup>5</sup> From <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>: follow‐up disability score in the control group 47.10 mm (VAS 0 to 100 mm scale) </p> <p><sup>6</sup> Four trials pooled (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>, <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>) using SMD, and re‐expressed as MD by multiplying the SMD (95% CI) by the baseline SD in the control group of <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a> (16.78). </p> <p><sup>7</sup> Calculations based on data from <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>: control group baseline mean (SD) disability 52.5 (16.78), 0 to 100 mm VAS scale. </p> <p><sup>8</sup> Downgrade estimate due to imprecision: few participants. </p> <p><sup>9</sup> Treatment effect crosses midline (no effect). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: Belgium<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 </p> <p>(higher scores mean worse)</p> <p>Follow up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 42.4 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention group was<br/> <b>14.2 lower</b> <br/> (20.82 to 7.58 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 14% (21% to 8%); Relative improvement in pain was 26.5%<sup>2</sup>; NNT = </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Lequesne algofunctional index 0‐24 </p> <p>(higher scores mean worse)<br/> Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 7.8 (0 to 24 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention group was<br/> <b>1.3 lower</b> <br/> (2.38 to 0.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 1% (1% to 0%); Relative improvement in disability was 13.7%<sup>2</sup>; NNT = </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> <br/> (165 to 431) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/> (0.66 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events is 2% higher in the ASU group (11% lower to 15% higher); Relative percentage change 7% worsening (34% improvement to 74% worsening); NNT n/a.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events not reported as a discrete outcome in ASU 600mg subgroup. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events not reported as a discrete outcome in ASU 600mg subgroup.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Single study. </p> <p><sup>2</sup> Control group baseline mean (SD) pain 53.5 (13.9), baseline mean (SD) disability 9.5 (2.2), from <a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>. </p> <p><sup>3</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002947-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: Czech Republic, Slovak Republic, Hungary, Poland, Romania<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)<br/> <b>Comparison:</b> chondroitin sulphate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chondroitin sulphate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> WOMAC‐VAS (Pain) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the chondroitin sulphate group at the end of treatment was 22.88 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/> <b>1.41 higher</b> <br/> (2.68 lower to 5.50 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening of pain was 10% (10% improvement to 31% worsening); Relative worsening of pain was 3%<sup>3</sup>; NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean function in the chondroitin sulphate group at the end of treatment was 25.14 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the intervention group was<br/> <b>1.63 higher</b> <br/> (2.51 lower to 5.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening of disability was 28% (43% improvement to 98% worsening); Relative worsening of disability was 3%<sup>3</sup>; NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (139 to 304) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.59 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 3% lower in the ASU group (12% lower to 5% higher); Relative percentage change 14% improvement (41% improvement to 26% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events not reported as a discrete outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>17 per 1000</b> </p> <p>(2 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.92</b> </p> <p>(0.31 to 27.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of serious adverse events was 1% higher in the ASU group (1% lower to 3% higher); Relative percentage change 192% worsening (69% improvement to 2678% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> SIngle study. Treatment effect crosses midline (no effect). </p> <p><sup>2</sup> Chondroitin sulfate might not be active control. Non‐inferiority hypothesis may be flawed. </p> <p><sup>3</sup> Chrondroitin sulfate group baseline pain 49.08, baseline disability 49.07. Aggregate WOMAC scores converted to normalised scores for re‐analysis. </p> <p><sup>4</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002947-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002947-sec-0051"></div> <section id="CD002947-sec-0052"> <h3 class="title" id="CD002947-sec-0052">Oral herbal therapies for treating osteoarthritis</h3> <p>Herbal medicines have a long tradition in the treatment of osteoarthritis. Although the mechanism of action of oral medicinal plant products has not been fully elucidated, experimental studies indicate interactions with mediators of inflammation and cartilage destruction, providing a rational basis for the putative effectiveness of oral medicinal plant products in alleviating osteoarthritis. This review is an update of an earlier review from 2000. Four of the studies in the original review and 45 new studies are included in this review, evaluating the effects of 33 different oral medicinal plants or combinations of plants from Europe, Africa, Asia, and the Americas. The review shows that oral medicinal plant products may improve osteoarthritic complaints, but multiple studies providing moderate to high evidence of effectiveness are only available for proprietary products from avocado‐soyabean unsaponifiables (ASU) and <i>Boswellia serrata</i>. For the other medicinal plant products the quality and quantity of the studies are insufficient to draw definitive conclusions on effectiveness. Although the included studies did not report serious adverse events related to the products, safety data are limited. </p> <p>Herbal medicinal products are used in a variety of forms for the treatment of osteoarthritis (OA) worldwide. Although their mechanisms of action have not yet been elucidated in full detail, interactions with mediators of inflammation and cartilage destruction provide a rationale for using them to treat OA complaints (<a href="./references#CD002947-bbs2-0170" title="CameronM , GagnierJ , LittleC , ParsonsT , BlümleA , ChrubasikS . Evidence of the effectiveness of herbal medicinal products in the treatment of arthritis. Part A: Osteoathritis. Phytotherapy Research2009;23:1497‐515. [DOI: 10.1002/ptr.3007] ">Cameron 2009</a>). The knowledge on herbal medicine gleaned over centuries of medicinal use is collated in textbooks and monographs (for example the German Commission E monographs (<a href="./references#CD002947-bbs2-0106" title="BlumenthalM . The complete German Commission E Monographs. Austin, TX: American Botanical Council, 1998. ">Blumenthal 1998</a>)). All include empirical knowledge. The more recent Western monographs also include information on animal studies and clinical trials, for example the monographs of the European Scientific Cooperative on Phytotherapy (<a href="./references#CD002947-bbs2-0125" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003. ">ESCOP 2003</a>; <a href="./references#CD002947-bbs2-0126" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. Vol. Supplement, Stuttgart, New York: Thieme Press, 2009. ">ESCOP 2009</a>), the monographs of the American Herbal Pharmacopeia (www.herbal‐ahp.org), and the World Health Organization (WHO) monographs on selected medicinal plants (http://apps.who.int/medicinedocs/en/d/Js2200e/). Whereas the ESCOP and American and WHO monographs are not official, they provide scientific information on the safety, efficacy, and quality of medicinal plants and provide recommendations for their use in clinical practice (for example the doses, types of preparation). In contrast, the European Medicines Agency (EMA) monographs (www.ema.europa.eu/ema/index.jsp?curl=search.jsp&amp;q=Herbal+monographs&amp;btnG=Search&amp;mid=WC0b01ac05800240cf) serve as guidance for application dossiers to obtain marketing authorizations by the regulatory authorities of the individual countries in the European Union. These monographs, however, have not used an evidence‐based approach.   </p> </section> <section id="CD002947-sec-0053"> <h3 class="title" id="CD002947-sec-0053">Description of the condition</h3> <p>Lawrence and Felson (<a href="./references#CD002947-bbs2-0137" title="LawrenceRC , FelsonDT , HelmickCG , ArnoldLM , ChoiH , DeyoRA , et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis &amp; Rheumatism2008;58:26‐35. ">Lawrence 2008</a>) estimated that among US adults, nearly 27 million had clinical OA in 2005 (up from the estimate of 21 million for 1995). OA is characterized by degeneration of the joints. Any joint of the body can be affected, but the most prominent joints include the hips, knees, and hands. Women are affected with OA more often than men and the prevalence increases with increasing age. Overweight and heavy physical work may explain OA in some cases, but non‐mechanical factors and genetic disposition are involved as well (<a href="./references#CD002947-bbs2-0160" title="van denBergWB . Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis and Cartilage2011;19:338‐41. ">van den Berg 2011</a>; <a href="./references#CD002947-bbs2-0167" title="ZhangY , JordanJM . Epidemiology of osteoarthritis. Clinical Geriatric Medicine2010;26:355‐69. ">Zhang 2010a</a>). Primary OA has to be distinguished from secondary OA that is induced, for example, by traumatic events and endocrine or metabolic disorders. Both primary and secondary forms result in impaired quality of life due to pain and physical disability (<a href="./references#CD002947-bbs2-0151" title="SchmitzN , KrausVB , AignerT . Targets to tackle‐‐the pathophysiology of the disease. Current Drug Targets2010;11:521‐7. ">Schmitz 2010</a>). </p> </section> <section id="CD002947-sec-0054"> <h3 class="title" id="CD002947-sec-0054">Description of the intervention</h3> <p>For the purpose of this review we have adopted the WHO guidelines (<a href="http://www.who.int/medicines/areas/traditional/definitions/en/" target="_blank">www.who.int/medicines/areas/traditional/definitions/en/</a>) for the definition of medicinal plant products, that is, "Herbal medicines include herbs, herbal materials, herbal preparations and finished herbal products, that contain as active ingredients parts of plants, or other plant materials, or combinations. </p> <p> <ul id="CD002947-list-0001"> <li> <p>Herbs: crude plant material such as leaves, flowers, fruit, seed, stems, wood, bark, roots, rhizomes or other plant parts, which may be entire, fragmented or powdered. </p> </li> <li> <p>Herbal materials: in addition to herbs, fresh juices, gums, fixed oils, essential oils, resins and dry powders of herbs. In some countries, these materials may be processed by various local procedures, such as steaming, roasting, or stir‐baking with honey, alcoholic beverages or other materials. </p> </li> <li> <p>Herbal preparations: the basis for finished herbal products and may include comminuted or powdered herbal materials, or extracts, tinctures and fatty oils of herbal materials. They are produced by extraction, fractionation, purification, concentration, or other physical or biological processes. They also include preparations made by steeping or heating herbal materials in alcoholic beverages and/or honey, or in other materials. </p> </li> <li> <p>Finished herbal products: herbal preparations made from one or more herbs. If more than one herb is used, the term mixture herbal product can also be used. Finished herbal products and mixture herbal products may contain excipients in addition to the active ingredients. However, finished products or mixture products to which chemically defined active substances have been added, including synthetic compounds and/or isolated constituents from herbal materials, are not considered to be herbal." </p> </li> </ul> </p> <p>The WHO also notes that "in some traditions, materials of inorganic or animal origin may also be present", however, in this review we have applied the strict definition and excluded herbal products combined with non‐herbal materials (http://apps.who.int/medicinedocs/en/d/Jh2945e/4.html). </p> </section> <section id="CD002947-sec-0055"> <h3 class="title" id="CD002947-sec-0055">How the intervention might work</h3> <p>There is evidence that pro‐inflammatory cytokines play a significant role in the pathogenesis of OA, in which articular cartilage, subchondral bone, and synovial membrane are involved. Cytokines including interleukin‐1 (IL‐1), tumour necrosis factor α (TNFα), IL‐6, and members of the IL‐6 protein superfamily including adiponectin, oncostatin M, and pre‐B cell colony enhancing factor (also known as visfatin), IL‐7, IL‐17, and IL‐18 can promote articular cartilage extracellular matrix protein degradation or synergize with other cytokines to amplify and accelerate cartilage destruction. Attempts to modify the progression of human OA in well designed, controlled clinical trials with an IL‐1 receptor antagonist protein (IRAP) have not been successful (<a href="./references#CD002947-bbs2-0139" title="MalemudCJ . Anticytokine therapy for osteoarthritis: Evidence to date. Drugs &amp; Aging2010;27:95‐115. [DOI: 10.2165/11319950‐000000000‐00000] ">Malemud 2010</a>). Anabolic cytokines (also termed growth factors), including transforming growth factor‐beta (TGF‐β), insulin‐like growth factor‐1 (IGF‐1), and fibroblast growth factor‐2 (FGF‐2), have been characterized as potential chondroprotective agents (<a href="./references#CD002947-bbs2-0139" title="MalemudCJ . Anticytokine therapy for osteoarthritis: Evidence to date. Drugs &amp; Aging2010;27:95‐115. [DOI: 10.2165/11319950‐000000000‐00000] ">Malemud 2010</a>). Both aging and the OA process itself induce deranged TGF‐β receptor expression, causing a shift to dominant usage of activin receptor‐like kinase‐1 (ALK‐1) instead of ALK‐5, and resulting in a TGF‐β mediated catabolic pathway (<a href="./references#CD002947-bbs2-0160" title="van denBergWB . Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis and Cartilage2011;19:338‐41. ">van den Berg 2011</a>). </p> <p>Recently, other cytokines were also identified as being involved in the progressive breakdown of articular cartilage. Transcription factor hypoxia‐inducible factor‐2α (HIF‐2α), which is highly enhanced in OA cartilage, has been shown to activate catabolic metalloproteinases (MMP) including MMP‐13. In addition, HIF‐2α suppresses chondrocyte autophagy, promoting chondrocyte apoptosis. MMP‐13 production is also activated via the chondrocyte discoidin domain receptor (DDR‐2) through interaction with denatured collagen type II. The latter might occur in a proteoglycan depleted pericellular matrix where DDR‐2 expression is enhanced, such as in OA cartilage. A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS‐5) was identified to stimulate proteoglycan loss by interacting with transmembrane proteoglycan syndecan‐4. Furthermore, the alarmins (also know as myeloid‐related proteins), calcium binding proteins S100A8 and S100A9, were identified as catabolic mediators (<a href="./references#CD002947-bbs2-0160" title="van denBergWB . Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis and Cartilage2011;19:338‐41. ">van den Berg 2011</a>). An improved understanding of the balance between pro‐inflammatory, anabolic, and catabolic cytokines may eventually result in the commercial development of disease‐modifying OA drugs (<a href="./references#CD002947-bbs2-0139" title="MalemudCJ . Anticytokine therapy for osteoarthritis: Evidence to date. Drugs &amp; Aging2010;27:95‐115. [DOI: 10.2165/11319950‐000000000‐00000] ">Malemud 2010</a>).   </p> <p>Inflammation and imbalance in complex cytokine interactions cause morphological OA changes at the molecular level. Medicinal plant products may inhibit inflammatory mediators and interact with various cytokines, at least under experimental conditions (<a href="./references#CD002947-bbs2-0170" title="CameronM , GagnierJ , LittleC , ParsonsT , BlümleA , ChrubasikS . Evidence of the effectiveness of herbal medicinal products in the treatment of arthritis. Part A: Osteoathritis. Phytotherapy Research2009;23:1497‐515. [DOI: 10.1002/ptr.3007] ">Cameron 2009</a>). The mechanism of action of the oral herbal medicines is likely to be broader than that of non‐steroidal anti‐inflammatory drugs. Some studies in animals indicate a promising cartilage‐protective effect for some of the oral medicinal plant products, including Piascledine® containing ASU (<a href="./references#CD002947-bbs2-0140" title="MazieresB , TempestaC , TiechardM , VaguierG . Pathologic and biochemical effects of a lipidic avocado and soya extract on an experimental post‐contusive model of OA [Abstract]. Osteoarthritis and Cartilage1993;1:46. ">Mazieres 1993</a>), the <i>Harpagophytum</i> extract FB9195 (<a href="./references#CD002947-bbs2-0121" title="ChrubasikJE , LindhorstE , NeumannE , GerlachU , Faller‐MarquardtM , TordaT , Muller‐LadnerU , ChrubasikS . Potential molecular basis of the chondroprotective effect of Harpagophytum procumbens . Phytomedicine2006;13:598‐600. ">Chrubasik 2006</a>; <a href="./references#CD002947-bbs2-0130" title="HadzhiyskiH , LindhorstE , RaifW , TordaT , ChrubasikS . Impact of Harpagophytum procumbens on the urinary pyridinoline deoxypyridinoline ratio in experimental osteoarthritis [Abstract]. FACT: Focus on Alternative and Complementary Therapies2006;11:13. ">Hadhyiski 2006</a>), and a Chinese herbal mixture SKI306X® (<a href="./references#CD002947-bbs2-0111" title="ChoiJH , ChoiJH , KimDY , YoonJH , YounHY , YiJB , et al. Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase‐induced rabbit osteoarthritis model. Osteoarthritis and Cartilage2002;10:471‐8. ">Choi 2002</a>). In a later, long term confirmatory study in humans, Piascledine® showed no effect on joint space loss (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). It remains to be demonstrated whether the experimental observations of promising effects on surrogate markers of cartilage destruction by medicinal plant products are of clinical relevance. </p> </section> <section id="CD002947-sec-0056"> <h3 class="title" id="CD002947-sec-0056">Why it is important to do this review</h3> <p>Medicinal plant preparations are part of the armamentarium of traditional treatments for people with OA. This review is important to summarise the evidence of effectiveness of medicinal plant products used orally for OA, and to update the information on these products. We have undertaken this research to investigate the effectiveness and adverse side effects of these products so that people with OA and their healthcare providers may make more informed decisions about the usefulness of these interventions. </p> <p>In the previous Cochrane review on herbal medicines for OA, oral and topical herbal medicines were considered together. When the update of this review became particularly large, a separation of topical and oral medicinal plant products seemed advisable because: (a) only oral products are purported to have any effect on joint structure, (b) topical herbal medicines may act as counter‐irritants via the skin (for example nettle, peppermint, <i>Capsicum</i> ), and (c) some products cannot be administered orally due to systemic toxicity (<i>Arnica</i>, comfrey). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002947-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002947-sec-0057"></div> <p>To update an existing Cochrane systematic review to assess the benefits and harms of oral medicinal plant products in treating OA. Data were added from relevant randomised controlled trials published in the period from January 2000 to August 2013. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002947-sec-0058" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002947-sec-0058"></div> <section id="CD002947-sec-0059"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002947-sec-0060"> <h4 class="title">Types of studies</h4> <p>All randomised controlled (placebo or active control) parallel and crossover trials examining the effects of oral herbal interventions for treating OA. </p> </section> <section id="CD002947-sec-0061"> <h4 class="title">Types of participants</h4> <p>All persons diagnosed with OA according to the American College of Rheumatology (ACR) criteria (<a href="./references#CD002947-bbs2-0101" title="AltmanR , AschE , BlochD , BoleG , BorensteinD , BrandtK , et al. The American College of Rheumatology crtieria for the classification and reporting of osteoarthritis of the knee. Arthritis &amp; Rheumatism1986;29:1039‐49. ">Altman 1986</a>; <a href="./references#CD002947-bbs2-0102" title="AltmanR , AlarconG , AppelrouthD , BlochD , BorensteinD , BrandtK . The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis &amp; Rheumatism1990;33:1601‐10. ">Altman 1990</a>; <a href="./references#CD002947-bbs2-0103" title="AltmanR , AlarconG , AppelrouthD , BlochD , BorensteinD , BrandtK , et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis &amp; Rheumatism1991;34:505‐14. ">Altman 1991</a>) or the equivalent European League Against Rheumatism (EULAR) criteria (<a href="./references#CD002947-bbs2-0166" title="ZhangW , DohertyM , LeebBF , AlekseevaL , ArdenNK , BijlsmaJW , et al. EULAR evidence based recommendations for the diagnosis of hand osteoarthritis ‐ report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of Rheumatic Diseases2009;68:8‐17. ">Zhang 2009</a>; <a href="./references#CD002947-bbs2-0167" title="ZhangY , JordanJM . Epidemiology of osteoarthritis. Clinical Geriatric Medicine2010;26:355‐69. ">Zhang 2010a</a>; <a href="./references#CD002947-bbs2-0168" title="ZhangW , DohertyM , PeatG , Bierma‐ZeinstraMA , ArdenNK , BresnihanB , et al. EULAR evidence‐based recommendations for the diagnosis of knee osteoarthritis. Annals of Rheumatic Diseases2010;69(3):483‐9. ">Zhang 2010b</a>). Studies with samples defined according to vague descriptions (for example 'joint pain') were not considered. Studies with participant samples defined according to incomplete or partial ACR and EULAR criteria were included, and notes were provided to identify possible weaknesses in sample selection in these studies. </p> </section> <section id="CD002947-sec-0062"> <h4 class="title">Types of interventions</h4> <p>Any orally consumed herbal intervention compared with an inert (placebo) or active control was included. Herbal interventions included any plant preparation (whole, powder, extract, standardised mixture) but excluded homeopathy or aromatherapy products, or any preparation of synthetic origin. </p> <p>In the methods published for the original review, herbal therapies used in conjunction with other treatments or combined with a non‐herbal substance were also to be included if the effect of the non‐herbal intervention was consistent among all groups and quantifiable such that the effect of the herbal intervention could be determined. In this review, however, we have confined interventions to those that comply with the WHO definition of 'herbal' (<a href="http://www.who.int/medicines/areas/traditional/definitions/en/" target="_blank">www.who.int/medicines/areas/traditional/definitions/en/</a>). Accordingly, extracted single compounds, synthetic reproductions of naturally occurring compounds, and herbal therapies combined with non‐herbal substances are no longer herbal treatments. This definition is important because non‐herbal substances may interact with herbs and change their effects, potency, and safety profile. Even if the non‐herbal substance occurs in the same concentration in the placebo control (as is the case in one excluded study, <a href="./references#CD002947-bbs2-0077" title="ParkSH , KimSK , et al. Effects of AIF on knee osteoarthritis patients: Double‐blind, randomized, placebo‐controlled study. Korean Journal of Physiology and Pharmacology2009;13:33‐7. ">Park 2009</a>), the intervention‐control comparison is not valid because the non‐herbal substance may interact uniquely with the herbs (for example enhanced absorption of ingredients) and not with the placebo. </p> </section> <section id="CD002947-sec-0063"> <h4 class="title">Types of outcome measures</h4> <p>The main outcome measures considered were consistent with those used across Cochrane Musculoskeletal Group systematic reviews of interventions for OA: pain, function, adverse events, joint structure changes, and quality of life (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0024" target="_blank">Altman 1996</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0047" target="_blank">Pham 2004</a>). </p> <p>To assess the benefits of treatment:</p> <p> <ul id="CD002947-list-0002"> <li> <p>pain, measured on a visual analogue scale (VAS) (0 to 100), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (0 to 4, or VAS 0 to 100), numerical rating scale (0 to 3), or other pain scales; </p> </li> <li> <p>physical function, measured by a VAS (0 to 100), WOMAC function subscale (0 to 4, or VAS 0 to 100), algofunctional index (0 to 3), time to perform functional tasks, or other validated functional scales. </p> </li> </ul> </p> <p>To assess the safety of treatment:</p> <p> <ul id="CD002947-list-0003"> <li> <p>number of participants reporting any adverse event.</p> </li> </ul> </p> <p>Minor outcomes included:</p> <p> <ul id="CD002947-list-0004"> <li> <p>withdrawals due to adverse events;</p> </li> <li> <p>serious adverse events;</p> </li> <li> <p>radiographic joint changes measured as minimum joint space width;</p> </li> <li> <p>quality of life measured by the Short Form‐36 (SF‐36) or other validated scales.</p> </li> </ul> </p> <p>We extracted data from the last time point in each trial. Because most interventions were not purported to be structure modifying, we also extracted data from earlier time points in some studies to allow data pooling with trials of shorter duration. </p> <p>We included the following outcomes in the summary of findings tables, derived from the list of outcomes recommended by the Cochrane Musculoskeletal Group (CMSG) for inclusion in reviews of interventions for osteoarthritis: pain; function; number of participants experiencing any adverse event; withdrawals due to adverse events; serious adverse events; radiographic joint structure; and quality of life. </p> <p>We did not extract data for re‐analysis on any other outcome measures, such as swelling, use of rescue medications, or blood markers although these data were included in many of the included studies. </p> </section> </section> <section id="CD002947-sec-0064"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002947-sec-0065"> <h4 class="title">Electronic searches</h4> <p>For this review update we searched the following electronic databases from the date of the last search in the previously published version of the review (to November 2008) and updated the search again on 21 May 2009, 14 December 2010, 16 May 2011, 12 December 2011, 15 June 2012, 25 and 27 February 2013, 15 March 2013, 7 May 2013, and finally on 29 August 2013: </p> <p> <ol id="CD002947-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), part of <i>The Cochrane Library</i> (accessed 29 August 2013); </p> </li> <li> <p>DARE, part of <i>The Cochrane Library</i> (accessed 29 August 2013); </p> </li> <li> <p>MEDLINE (via Ovid) (2000 to 29 August 2013);</p> </li> <li> <p>MEDLINE  (Ovid MEDLINE® In‐Process &amp; Other Non‐Indexed Citations) (to 29 August 2013);</p> </li> <li> <p>EMBASE (via Ovid) (2000 to 29 August 2013);</p> </li> <li> <p>CINAHL (via Ovid) (2000 to Week 5 2008); via EBSCOhost (2008 to 29 August 2013);</p> </li> <li> <p>AMED (via Ovid) (1985 to 29 August 2013);</p> </li> <li> <p>ISI Web of Knowledge (2000 to 29 August 2013);</p> </li> <li> <p>Dissertation Abstracts, ProQuest (2000 to 29 August 2013);</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (apps.who.int/trialsearch) (accessed 29 August 2013). </p> </li> </ol> </p> <p>Thesaurus and free text searches appropriate to each database, which combined terms describing osteoarthritis and terms describing herbal medicine, were performed. No methodological filter was applied and the search was not limited by language. </p> <p>The full search strategies for each database are outlined in <a href="./appendices#CD002947-sec-0141">Appendix 1</a>. </p> </section> <section id="CD002947-sec-0066"> <h4 class="title">Searching other resources</h4> <p>We searched reference lists of included trials for any other potential studies. Unpublished research reports and theses (grey literature) were sought directly from pharmaceutical companies (Steigerwald Pharmaceuticals) (<a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>) and university libraries (<a href="./references#CD002947-bbs2-0063" title="GuyaderM . Herbal anti‐rheumatic therapies: A longitudinal, pharmacological and clinical study of the treatment of 50 osteoarthritic patients with Harpagophytum procumbens (Devil's Claw) following hospital intervention [Les plantes anti‐rhumatismales. Etude historique et pharmacologique, et etude clinique du nebulisat d'harpagophytum procumbens D.C. chez 50 patients arthrosiques suivis en service hospitalier]. Thesis for the award of the degree Doctor of Medicine.1984. ">Guyader 1984</a>). </p> </section> </section> <section id="CD002947-sec-0067"> <h3 class="title" id="CD002947-sec-0067">Data collection and analysis</h3> <section id="CD002947-sec-0068"> <h4 class="title">Selection of studies</h4> <p>This review was an update of a previous review. Two authors of the original review (CL, TP) and two other colleagues (JG, AB) made some contributions to this review and are acknowledged here as investigators. Because these investigators did not contribute to the totality of the review, they are identified in the <a href="#CD002947-sec-0138">Acknowledgements</a> rather than listed as authors of this review. </p> <p>All titles and abstracts identified from electronic databases and other searches were independently examined by three investigators (MC, SC, CL). The full manuscript was retrieved for each record that had the possibility of meeting the review criteria. </p> <p>Three review authors (MC, SC, CL) independently assessed the eligibility of retrieved studies for the review according to the inclusion criteria. </p> </section> <section id="CD002947-sec-0069"> <h4 class="title">Data extraction and management</h4> <p>Data were extracted from each eligible study by two review authors acting independently. Because of the length of time taken to complete this review and the associated review of topical medicinal plant products for OA, the large number of studies included in this update, and the inclusion of studies in languages other than English, five investigators (MC, SC, AB, JG, TP) contributed to the data extraction. </p> <p>Two review authors (MC, SC) independently extracted the following data from the included trials and entered the data in RevMan 5: </p> <p>1) trial characteristics including size and location of the trial, and source of funding;</p> <p>2) characteristics of the study population including age; and characteristics of the disease including diagnostic criteria and disease duration; </p> <p>3) characteristics of the therapy in all trial arms including type and dose of therapy;</p> <p>4) risk of bias domains as outlined in 'Assessment of risk of bias in included studies', below; </p> <p>5) outcome measures, as the mean and standard deviation for continuous outcomes, and number of events for dichotomous outcomes (as outlined in <a href="http://archie.cochrane.org/sections/documents/#CRIT_OUTCOMES" target="_blank">Types of outcome measures</a>). </p> <p>If data on more than one pain scale were provided for a trial, we referred to a previously described hierarchy of pain‐related outcomes (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0039" target="_blank">Juni 2006</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007320.pub2/full#CD007320-bbs2-0049" target="_blank">Reichenbach 2007</a>) and extracted data on the pain scale that was highest on the following list: </p> <p> <ol id="CD002947-list-0006"> <li> <p>global pain; </p> </li> <li> <p>pain on walking; </p> </li> <li> <p>WOMAC pain subscore; </p> </li> <li> <p>composite pain scores other than WOMAC;</p> </li> <li> <p>pain with activities other than walking;</p> </li> <li> <p>rest pain or pain during the night;</p> </li> <li> <p>WOMAC global algofunctional score; </p> </li> <li> <p>Lequesne osteoarthritis index global score; </p> </li> <li> <p>other algofunctional scale;</p> </li> <li> <p>patient's global assessment; </p> </li> <li> <p>physician's global assessment.</p> </li> </ol> </p> <p>If data on more than one function scale were provided for a trial, we extracted data according to the hierarchy: </p> <p> <ol id="CD002947-list-0007"> <li> <p>global disability score; </p> </li> <li> <p>walking disability; </p> </li> <li> <p>WOMAC disability subscore; </p> </li> <li> <p>composite disability scores other than WOMAC; </p> </li> <li> <p>disability other than walking; </p> </li> <li> <p>WOMAC global scale; </p> </li> <li> <p>Lequesne osteoarthritis index global score; </p> </li> <li> <p>other algofunctional scale; </p> </li> <li> <p>patient’s global assessment; </p> </li> <li> <p>physician’s global assessment.</p> </li> </ol> </p> <p>If data on more than one quality of life scale were provided for a trial, we extracted data according to the hierarchy: </p> <p> <ol id="CD002947-list-0008"> <li> <p>SF‐36;</p> </li> <li> <p>EuroQoL;</p> </li> <li> <p>Sickness Impact Profile (SIP);</p> </li> <li> <p>Nottingham Health Profile (NHP).</p> </li> </ol> </p> <p>To avoid multiple outcome reporting in the review, we adopted the following rules to extract data. </p> <p> <ul id="CD002947-list-0009"> <li> <p>Where outcomes were reported at several time points, we extracted the measure at the end of the intervention as the main outcome. Studies of similar duration were analysed using end of intervention data only. We also extracted data at interim time points and reported these data for completeness but did not include them in meta‐analyses. </p> </li> <li> <p>Where trial authors reported both final values and change from baseline values for the same outcome, we extracted the final values. </p> </li> <li> <p>Where trial authors reported data analysed based on the intention‐to‐treat (ITT) sample and another sample (e.g. per protocol, as‐treated), we extracted ITT‐analysed data. </p> </li> <li> <p>For crossover trials, data were extracted only up to the point of crossover given the potential for carry‐over effects of these particular interventions and to bias the treatment effect following crossover. </p> </li> </ul> </p> <p>Adverse events were measured as the number of patients experiencing any adverse event, patients who were withdrawn or dropped out because of adverse events, and patients experiencing any serious adverse events. Serious adverse events were defined as events resulting in in‐patient hospitalisation, prolongation of hospitalisation, persistent or significant disability, congenital abnormality or birth defect of offspring, life‐threatening events, or death. </p> <p>If additional data were required, we contacted the trial authors to obtain these data. Some data were converted to normalised scales prior to extraction and reporting. Where data were imputed or calculated (for example standard deviations calculated from standard errors, P values, or confidence intervals; imputed from graphs; or from the standard deviations in other trials) we reported these adjustments (see <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>). Any disagreements were resolved by consensus. </p> </section> <section id="CD002947-sec-0070"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review investigators (MC, SC) independently assessed the risk of bias of each included trial against the key criteria: random sequence generation; allocation concealment; blinding of participants, personnel and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias in accordance with methods recommended by The Cochrane Collaboration (<a href="./references#CD002947-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies.. Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). Each of these criteria were explicitly judged as: (a) low, (b) unclear (either lack of information or uncertainty over the potential for bias), or (c) high risk of bias. Potential disagreements were discussed and resolved by referring to the original protocol and, if necessary, arbitration by member(s) of the editorial group. </p> </section> <section id="CD002947-sec-0071"> <h4 class="title">Measures of treatment effect</h4> <p>When possible, the analyses were based on ITT data (outcomes provided for every randomised participant) from the individual trials. For each trial, we presented outcome data as point estimates with the mean and standard deviation for continuous outcomes and risk ratio (RR) with corresponding 95% confidence interval for dichotomous outcomes. Where possible, for continuous outcomes we extracted the end of treatment scores rather than change from baseline scores. For continuous data, results were presented as mean differences (MD) and 95% confidence intervals (CI). We had planned that when different scales were used to measure the same outcome or concept, standardised mean difference (SMD) would be used. This was applicable to one analysis (ASU 300 mg versus placebo) for function. Outcomes pooled using SMD were re‐expressed as a mean difference by multiplying the SMD by a representative control group baseline standard deviation from one trial using a familiar instrument. </p> </section> <section id="CD002947-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <p>Where a study was defined as a crossover trial, data were extracted only up to the point of crossover, given the potential for carry‐over effects of these particular interventions to bias the treatment effect following crossover. </p> </section> <section id="CD002947-sec-0073"> <h4 class="title">Dealing with missing data</h4> <p>For dichotomous outcomes we used the number randomised as the denominator, making the assumption that any participants missing at the end of treatment did not have a positive outcome. For continuous outcomes with no standard deviation reported, we calculated standard deviations (SD), if possible, from standard errors (SEM), P values, or CIs. For four studies we converted the VAS data from a 10 cm scale to a 100 mm scale (<a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>), and for three studies we converted SEM to SD (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>). </p> <p>If no measures of variance were reported and the SD could not be calculated, we had planned to impute SDs from other studies in the same meta‐analysis, using the average of the other SDs that were available, provided only a small proportion of studies comprising the meta‐analysis had missing data. This imputation of missing data was not required for any of the meta‐analyses. </p> <p>We contacted trial authors to obtain details of methods that were missing from the trial reports. Details of author responses, as well as data conversion and imputation, are explained in characteristics of included studies and the associated table (see table <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>). </p> </section> <section id="CD002947-sec-0074"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed included trials for clinical homogeneity in terms of participants, interventions, and comparators. For studies judged as clinically homogenous, we quantified the possible magnitude of inconsistency (that is heterogeneity) across studies using the I<sup>2</sup> statistic with a rough guide to interpretation as follows: 0% to 40% might not be important; 30% to 60% might represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; 75% to 100% considerable heterogeneity (<a href="./references#CD002947-bbs2-0123" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD002947-sec-0075"> <h4 class="title">Assessment of reporting biases</h4> <p>To examine the possibility of publication bias, we planned to construct funnel plots if at least 10 studies were available for the meta analysis of a primary outcome, however we identified too few trials for this analysis. </p> <p>We planned to assess the presence of small study bias in the overall meta‐analysis by checking if the random‐effects model estimate of the intervention effect was more beneficial than the fixed‐effect model estimate, but again there were too few trials for this analysis. </p> </section> <section id="CD002947-sec-0076"> <h4 class="title">Data synthesis</h4> <p>As far as data extraction was possible, descriptive results were reported for all included studies. We pooled data from clinically homogenous trials; that is with the same interventions, doses, comparators, and outcomes. Where we could not combine data, we have summarised the effect estimates and 95% CIs of each trial narratively. Meta‐analyses are reported for multiple studies of ASU and <i>Boswellia serrata</i> only, using the random‐effects model, based on the assumption that clinical and methodological heterogeneity was likely. </p> <section id="CD002947-sec-0077"> <h5 class="title">Summary of findings</h5> <p>See: 'Summary of findings' tables.</p> <p>The main results (pain, function, joint structure, adverse events, withdrawals due to adverse events, serious adverse events, quality of life) of the review are presented in summary of findings tables (<a href="./references#CD002947-bbs2-0153" title="SchunemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011. ">Schunemann 2011a</a>; <a href="./references#CD002947-bbs2-0154" title="SchunemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011. ">Schunemann 2011b</a>). The overall grading of the evidence using the GRADE approach, classifying the evidence for each herbal intervention as: (a) high, (b) moderate, (c) low, or (d) very low, is included as an indication of our confidence in the results of the studies. </p> <p>Continuous outcomes pooled using SMDs were re‐expressed as MD by multiplying the SMD by a representative control group baseline SD from a trial using a familiar instrument (<a href="./references#CD002947-bbs2-0154" title="SchunemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011. ">Schunemann 2011b</a>). </p> <p>In the comments column of the summary of findings table we reported the absolute per cent difference, the relative per cent change from baseline, and the number needed to treat (NNT); NNT was reported only when the outcome showed a statistically significant difference). </p> <p>For dichotomous outcomes, such as adverse events, the NNT was calculated from the control group event rate and the relative risk (RR) using the Visual Rx NNT calculator (<a href="./references#CD002947-bbs2-0110" title="CatesCD . Visual Rx NNT Calculator. Dr Chris Cates EBM website. Available from http://www.nntonline.net/, 2008. ">Cates 2008</a>). The NNT for continuous measures was calculated using the Wells calculator (available at the CMSG Editorial office, <a href="http://musculoskeletal.cochrane.org/" target="_blank">http://musculoskeletal.cochrane.org/</a>). </p> <p>For dichotomous outcomes, the absolute risk difference was calculated from the risk difference statistic in RevMan and the result expressed as a percentage. For continuous outcomes, the absolute benefit or change was calculated as the improvement in the intervention group minus the improvement in the control group, in the original units. </p> <p>The relative per cent change for dichotomous data was calculated as the RR ‐ 1 and expressed as a percentage. For continuous outcomes, the relative difference in the change from baseline was calculated as the absolute benefit divided by the baseline mean of the control group. </p> </section> </section> <section id="CD002947-sec-0078"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In order to explain the heterogeneity between the results of the included studies, we have included some subgroup analyses by type and length of intervention. </p> <p>Data from studies of ASU compared with placebo have been subgrouped according to dose (300 mg or 600 mg) and length of intervention (three, six, or 36 months) (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>), or in the case of one study planned over two years but not reported the data available after 12 months of intervention (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). </p> <p>Data from studies of <i>Boswellia serrata</i> extracts have been subgrouped by proprietary product because although these products all contain <i>Boswellia serrata</i> extract we cannot be certain that the active principles are identical (<a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>). </p> <p>There were insufficient data available on most oral herbal products to justify subgroup analyses. </p> </section> <section id="CD002947-sec-0079"> <h4 class="title">Sensitivity analysis</h4> <p>We planned a sensitivity analysis to investigate the robustness of the treatment effect on pain and function relative to allocation concealment and participant blinding, by removing the trials that reported inadequate or unclear allocation concealment and lack of participant blinding from the meta‐analysis to see if this changed the overall treatment effect. There were insufficient data to perform these analyses. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002947-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002947-sec-0080"></div> <section id="CD002947-sec-0081"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>. </p> <p>See: <a href="./references#CD002947-sec-0157" title="">Characteristics of excluded studies</a>. </p> <p>Note: proprietary names underlined; botanical names are set in italics.</p> <p>Forty‐nine randomised controlled studies involving 5980 patients with OA met the inclusion criteria for this review (45 studies were identified for this review update and four studies were included in the original review). </p> <p>Most of the studies were of parallel design, with two groups comparing a herbal intervention to a placebo (inert) control only (n = 28). A further seven studies compared herbal interventions to both active and placebo controls in three (or more) arm designs (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>; <a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>). One study included a non‐intervention control in a third arm comparison against a herbal intervention and placebo (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>). Thirteen studies were head‐to‐head comparisons between herbal products and active controls (<a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>). </p> <p>All studies including active controls used a non‐inferiority design, however in five of these studies we queried the activity of the comparator agent (<a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>). </p> <p>Only seven studies used true crossover designs (<a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>), versus placebo, and one of these studies included a third arm against an active control (<a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>). One study was described as a crossover trial but the methodology and reported results indicated that this study was conducted as a parallel trial (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>), and in this review this study was classified as a parallel design. </p> <p>Eighteen studies were of confirmatory design (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>), that is effect size was estimated a priori, statistical power and alpha level were set, and sample size recruitment undertaken according to these calculations. The remaining 32 studies were of exploratory design and were generally of poorer methodological quality. </p> <section id="CD002947-sec-0082"> <h4 class="title">Results of the search</h4> <p>This review was formed from the division of a broader review of herbal therapies for the treatment of OA. In the original review both topical and oral medicinal plant products were considered. The search strategy for this updated review was structured from the protocol used in the original review. The searches for this review update have been repeated several times since 2005. It is not possible, therefore, to give a precise account of the search results as the number of records identified from all searches. </p> <p>A full search was completed before the current review was divided into two parts (December 2011). In that full search of all databases we identified, after the removal of duplicates, 288 abstracts on topical or oral herbal medicines in the treatment of OA. </p> <p>In recent repeat searches (June 2012, February 2013, May 2013, August 2013) we identified approximately 2500 citations, reduced to 309 citations after removal of duplicates from previous searches, and from these titles and abstracts we sought 99 items in full. Three studies published as abstracts only were excluded because they were identified as duplicate publications of full text manuscripts already included in this review. A further seven studies currently obtained only in abstract form are awaiting classification should full text reports become available. See <a href="#CD002947-fig-0001">Figure 1</a> for our best estimate of results from the searches. </p> <div class="figure" id="CD002947-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002947-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>A total of 45 new studies, including four studies published between 1988 and 1997 that had been overlooked in the previous review (<a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>), were identified for inclusion in the updated review (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>; <a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>; <a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). These new studies were added to the four studies of oral herbal products included in the original review (<a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a>). </p> </section> <section id="CD002947-sec-0083"> <h4 class="title">Included studies</h4> <p>See: <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>. </p> <p>Thirty‐three different medicinal plant products were tested in the included studies. Products were compared with placebo, active, and non‐intervention controls. Due to differing study protocols and different herbal interventions, meta‐analyses were restricted to data from multiple studies of proprietary products from avocado‐soyabean unsaponifiables (ASU) and <i>Boswellia serrata</i>. </p> <p>Monoherbal products studied were medicinal plant products derived from <i>Boswellia serrata</i> (gum resin extracts), <i>Curcuma domestica</i> (ethanolic root extract), the Malay jewel vine (<i>Derris scandens</i> ) (ethanolic stem extract), <i>Garcinia kola</i> (crude seed), devil's claw (<i>Harpagophytum procumbens</i> ) (aqueous or etholic extractions or crude powdered plant material), <i>Petiveria alliacea</i> (tipi tea) (aqueous extract), <i>Pinus pinaster</i> (polyphenol concentrate from pine bark), <i>Rosa canina lito</i> (crude plant material from fruit and seed), <i>Salix pupurea</i> +<i>daphnoides</i> (ethanolic bark extract), <i>Uncaria guianensis</i> (aqueous bark extract), <i>Vitellaria paradoxa</i> (patented seed extract), and <i>Zingiber officinale</i> (acetone or carbon dioxide extracts). </p> <p>Mixtures of two herbal preparations included medicinal products from <i>Boswellia carteri</i> (gum resin extract) and <i>Curcuma longa</i> (root extract), <i>Persea gratissma</i> (unsaponifiables) and <i>Glycine max</i> (unsaponifiables), <i>Phellondenron amurense</i> (bark extract) and <i>Citrus sinensis</i> (peel extract), <i>Uncaria guianensis</i> and<i>Lepidium meyenii</i> (aqueous bark extracts), and a combination of root extracts of two ginger species (<i>Zingiber officinalis</i> and <i>Alpinia galanga</i> (also known as Thai ginger)). </p> <p>Polyherbal preparations included two European mixtures, Phytodolor N® and Reumalex®; a Korean mixture SKI306X®; 10 Ayurvedic formulae: RA‐11®, Antarth, shunthi‐guduchi (SGC), shunthi‐guduchi with guggal (SGCG), and five formulae known only as A, B, C, D, or E; two Chinese herbal mixtures: Duhuo Jisheng Wan and blood‐nourishing, hard‐softening (BNHS); and a Japanese herbal mixture called Boiogito. </p> <p>See <a href="#CD002947-tbl-0009">Table 1</a> for preparation details of all products. </p> <div class="table" id="CD002947-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Herbal medicinal products used for the treatment of OA</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>PLANT</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>MEDICINAL PRODUCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DOSE</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>MARKER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Botanical name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Part/s</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tradename</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preparation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug:Extract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constituent marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quantity of marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from single plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Boswellia serrata</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>gum resin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CapWokvel<sup>TM</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>extraction solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>boswellic acid</p> <p>(total organic acids 65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>, <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐Loxin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 or 250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKBA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a> </p> <p><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflapin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKBA + non‐volatile oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a> </p> <p><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Curcuma domestica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>curcumoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Derris scandens</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (50%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>genistein derivatve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Garcinia kola</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Harpagophytum procumbens</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthrotabs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5‐2.5:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>harpagoside<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flexiloges</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (60%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5‐5.5:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>, <a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Harpadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cryoground powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Petiveria alliacea</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tipi tea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9g / 600 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Pinus pinaster</i> (synonym <i>Pinus maritima</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Pycnogenol®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>polyphenol concentrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>proanthocyanidins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Ricinus officinalis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ricinoleic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Rosa canina lito</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rose hip and seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyben Vital or Litozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>galactolipid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a><a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a> </p> <p><a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix daphnoides</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (70%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐14:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix pupurea x daphnoides</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (70%) extract<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Uncaria guianensis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Vitellaria paradoxa </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patented extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>triterpenes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EV.EXT 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acetone extract<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zintona EC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO2 extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gingerol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from two plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Boswellia carteri</i> + <i>Curcuma longa</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gum + root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>boswellic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Persea gratissma</i> (P) + <i>Glycine max</i> (G) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oils</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Piascledine 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unsaponifiable fraction 1/3 P;2/3 G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 or 600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>, <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>, <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Phellondenron amurense</i> + <i>Citrus sinensis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> <p>peel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NP 06‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370 mixture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>berberine</p> <p>polymethoxylated flavones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Uncaria guianensis + Lepidium meyenii</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reparagen®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500</p> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i> + <i>Alpinia galanga</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EV.EXT 77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acetone extract<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from three or more plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Clematis mandshurica</i> + <i>Prunella vulgaris</i> + <i>Trichosanthes kirilowii</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root, flower, root; 1:1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanol 30% extracts, thereafter butanol extraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600‐1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oleanolic acid 4%, rosmarinic acids 0.2%, ursolic acids 0.5%, hydroxybenzoic acid 0.03%,<br/> hydroxymethoxybenzoic acid 0.03%, trans‐cinnamic<br/> acid 0.05% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>, <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><i>Fraxinus excelsior</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Phytodolor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>fresh plant ethanolic (45,6%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>3:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>5‐8 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total flavonoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 ‐ 0.56 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>, <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>, <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicyl alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 ‐ 0.8 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Solidago virgaurea</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>isofraxidin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 ‐ 1.1 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Populus tremula</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark and leaf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 ‐ 8 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix alba</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Reumalex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐80mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Guaiacun officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>resin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cimicifuga racemosa</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Smilax</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Populus</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese mixture<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duhuo Jisheng Wan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Paeoniae alba</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Chinese mixture:</p> <p>Blood nourishing, hard softening (BNHS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>paconiflorin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Gentiana macrophylla</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gentianine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Glycyrrhiza</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Auryvedic formaulae<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>total gingerols</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rhizome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A, B, C, D, and E</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tinospora cordifolia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A, B, C, D, and E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tinosporosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Withania somnifera</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae B and E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total withanolides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Emblica officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fruit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tannins</p> <p>galic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tribulus terrestris</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fruit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A and B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total saponins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antarth<sup>3</sup> (for sandhigata vata) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RA‐11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese mixture<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boiogito</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>1. Harpagoside content estimated indirectly and approximately from iridoid glycoside content in daily dose of raw material (<a href="./references#CD002947-bbs2-0156" title="SporerF , ChrubasikS . Preparations from Devil's claw (Harpagophytum procumbens) [Präparate aus der Teufelskralle (Harpagophytum procumbens)]. Zeitschrift für Phytotherapie1999;20:235‐6. ">Sporer 1999</a>). </p> <p>2. Ethanolic extract stated in unpublished thesis but not in published paper (<a href="./references#CD002947-bbs2-0150" title="SchmidB . Treatment of hip and knee osteoarthritis with willow bark extract [Behandlung von Cox‐ und Gonarthrosen mit einem Weidenrindenextrakt]. Dissertation Universität Tübingen1998. ">Schmid 1998b</a>). </p> <p>3. Information provided by manufacturer but not reported in paper.</p> <p>4. Chinese herbal medicine contains 7.75% each of: radix angelicae pubescentiis, radix gentianae macrophyllae, cortex eucommiae, radix achyranthis bidentatae, radix angelicae sinensis, herba taxilli, radix rehmanniae preparata, rhizoma chuanxiong, cortex cinnamomi, radix ledebouriellae. 5% each of: radix paeoniae alba, radix codonopis, radix glycyrrhizae, poria. 2.5% herba asari. </p> <p>5. All Ayurvedic formulae A‐E contain <i>Zingiber officinale</i> (dried rhizome powder, total gingerols as marker), and <i>Tinospora cordifolia</i> (dried stem aqueous extract, marker tinosporosides). Some formulae also included <i>Emblica officinale</i> , <i>Withania somnifera</i> , or <i>Tribulus terrestris</i>. Drug:extract ratio and marker content not stated. </p> <p>6. Ayurvedic phytomedicine Antarth contains <i>Boswellia serrata, Commiphora mukul, Curcuma longa</i> and <i>Vitex negundo, Alpinia galangal, Withania somnifera, Tribulus terrestris,</i>  and <i>Tinospora cordifolia</i>. </p> <p>7. Japanese herbal medicine Boiogito contains <i>Sinomenium acutum</i> , <i>Astragalus</i> (species not stated) root, <i>Atractylodes lancea</i> rhizome, Jujube (probably <i>Ziziphus zizyphus</i> ), <i>Glycyrrhiza</i> (species not stated), and ginger (species not stated, probably <i>Zingiber officinale</i>). </p> </div> </div> <p>A wide range of outcome measures were used and the reporting of measures differed among studies, limiting the utility of some studies for meta‐analysis. All VAS were 100 mm lines with anchor points identified as 0 (nil symptom) and 100 (worst possible symptom), but in four studies the VAS scores were reported on a centimetre scale in the range 0 to 10 cm (<a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>). For ease of comparison between trials we converted all VAS data to the 0 to 100 mm scale. </p> <p>Several studies used the WOMAC, but this index may be used with two possible scoring methods: a battery of 0 to 4 Likert scales, or a battery of 100 mm VAS. Typically the Likert scale scores are presented as aggregate scores (sums) for each of the three subscales (pain subscore range 0 to 20, stiffness subscore range 0 to 8, physical function subscore range 0 to 68), whereas the VAS may be aggregated (pain subscore range 0 to 500, stiffness subscore range 0 to 200, physical function subscore range 0 to 1700) or converted to normalised units (means) for each subscale (all subscales scored 0 to 100). Although both scoring systems are acceptable for clinical and research use, there is no agreed conversion ratio between them so studies using the differing systems are not comparable. Also, in a few studies although standardised measures such as the WOMAC were used the data were reported in atypical forms that required some conversion or estimation before they could be included in these analyses. Specific details of all data conversions are included in the <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>. </p> </section> <section id="CD002947-sec-0084"> <h4 class="title">Excluded studies</h4> <p>See: <a href="./references#CD002947-sec-0157" title="">Characteristics of excluded studies</a>. </p> <p>Reasons for excluding studies were: (a) not a randomised controlled trial (<a href="./references#CD002947-bbs2-0062" title="GrahameR , RobinsonBV . Devil's claw (Harpagophytum procumbens): Pharmacological and clinical studies. Annals of the Rheumatic Diseases1981;40:632. ">Grahame 1981</a>; <a href="./references#CD002947-bbs2-0063" title="GuyaderM . Herbal anti‐rheumatic therapies: A longitudinal, pharmacological and clinical study of the treatment of 50 osteoarthritic patients with Harpagophytum procumbens (Devil's Claw) following hospital intervention [Les plantes anti‐rhumatismales. Etude historique et pharmacologique, et etude clinique du nebulisat d'harpagophytum procumbens D.C. chez 50 patients arthrosiques suivis en service hospitalier]. Thesis for the award of the degree Doctor of Medicine.1984. ">Guyader 1984</a>; <a href="./references#CD002947-bbs2-0066" title="KogureT , TatsumiT , ShigetaT , FujinagaH , SatoT , NiizawaA . Effect of Kampo medicine on pain and range of motion of osteoarthritis of the hip accompanied by acetabular dysplasia: Case report and literature review. Integrative Medicine Highlights2011;6:13‐7. [DOI: 10.4137/IMI.S7884] ">Kagore 2011</a>; <a href="./references#CD002947-bbs2-0071" title="LinshengW . Treatment of bony arthritis with herbal medicine and by massotherapy ‐ analysis of 121 cases. Journal of Traditional Chinese Medicine1997;17(1):32‐6. ">Linsheng 1997</a>; <a href="./references#CD002947-bbs2-0072" title="LoewD , SchusterO , MollerfeldJ . Stability and biopharmaceutical quality. A postulate for bioavailability and effectiveness of Harpagophytum procumbens [Stabilitat und biopharmazeutische Qualitat. Voraussetzung fur Bioverfugbarkeit und Wirksamkeit von Harpagophytum procumbens]. In: LoewD , RietcrockN editor(s). Phytopharmaka II. Forschung und klinische Anwendung. Darmstadt: Steinkopf‐Verlag, 1996:83‐93. ">Loew 1996</a>; <a href="./references#CD002947-bbs2-0075" title="MishraLC , SinghBB , VinjamurySP . The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study. Althernative Therapies in Health and Medicine2003;9:74‐9. ">Mishra and Singh 2003</a>; <a href="./references#CD002947-bbs2-0076" title="MyersS , O'ConnorJ , FittonJH , BrooksL , RolfeM , ConnellanP , et al. A combined phase I and phase II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. Biologics: Targets &amp; Therapy2010;4:33‐44. ">Myers 2010</a>; <a href="./references#CD002947-bbs2-0082" title="SaleySR , TilakMN , DeshmukhSS . Amavata ‐ a clinical study of 41 cases. Rheumatism1987;22(2):46‐50. ">Saley 1987</a>; <a href="./references#CD002947-bbs2-0086" title="SrivastavaKC , MustafaT . Ginger (Zingiber officinale) and rheumatic disorders. Medical Hypotheses1989;29:25‐8. ">Srivastava 1989</a>; <a href="./references#CD002947-bbs2-0087" title="WangZM , ChangJY , et al. A report on 310 cases of articular rheumatism treated with Feng Shi Han Tong tablet. Chung Hsi I Chieh Ho Tsa Chih1985;5(5):284‐5, 260. ">Wang 1985</a>; <a href="./references#CD002947-bbs2-0088" title="WegenerT , LupkeNP . Treatment of patients with arthrosis of hip or knee with an aqueous extract of Devil's claw (Harpagophytum procumbens DC). Phytotherapy Research2003;17(10):1165‐72. ">Wegener 2003</a>; <a href="./references#CD002947-bbs2-0090" title="XuJ‐W , DingJ‐X . An analysis on the clinical therapeutic effect of the manipulation matched with Chinese medical herb washing for treatment of osteoarthritis of the knee. Journal of Beijing Teachers College of Physical Education2005;1:9. ">Xu 2005</a>; <a href="./references#CD002947-bbs2-0091" title="YuelongC , HongshengZ , JianP , FeiyueL , ShaojianX , JinghuaG , et al. Individually integrated traditional Chinese medicine approach in the management of knee osteoarthritis: study protocol for a randomized controlled trial. Trials2011;12:160. [DOI: 10.1186/1745‐6215‐12‐160] ">Yuelong 2011</a>; <a href="./references#CD002947-bbs2-0092" title="ZellJ , EckerR , BatzH , VestweberAM . Mistletoe for hip and knee arthrosis: Segment ‐ or immunotherapy? [Misteltherapie bei Gon‐ und Coxarthrose: Segment ‐ oder Immuntherapie? Eine Pilotstudie]. Heilkunst1993;106(9):23‐6. ">Zell 1993</a>), (b) review or discussion paper (<a href="./references#CD002947-bbs2-0050" title="Anonymous . The garlic treatment: detoxifying with garlic. [Die knoblauchkur: entschlackung durch knoblauch]. Natur &amp; Heilen1993;70(10):520‐1. ">Anonymous 1993</a>; <a href="./references#CD002947-bbs2-0054" title="BrienS , LewithGT , McGregorG . Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: A review of safety and efficacy. The Journal of Alternative and Complementary Medicine2006;12:981‐93. ">Brien 2006</a>; <a href="./references#CD002947-bbs2-0056" title="ChrubasikS , WinkM . Traditional herbal therapy for the treatment of rheumatic pain: Preparations from Devil's claw and stinging nettle. Pain Digest1998;8:94‐101. ">Chrubasik 1998</a>; <a href="./references#CD002947-bbs2-0057" title="DharmanandaS . Chinese herbal therapies for chronic joint pain. The American Chiropractor1985;January:38‐42. ">Dharmananda 1985</a>; <a href="./references#CD002947-bbs2-0059" title="FalchVB . Ginger ‐ not only a spice. Review of its effect and efficacy profile [Ingwer ‐ nicht nur ein Gewurz. Untersuchungen zu Wirkungen und Wirksamkeit]. Deutsche Apotheker Zeitung1997;137:47‐52, 55‐60. ">Falch 1997</a>; <a href="./references#CD002947-bbs2-0061" title="GendoU . Chronische Polyarthritis in view of traditional Chinese medicine (TCM) [Die chronische Polyarthritis aus der Sicht der traditionellen Chinesischen Medizin (TCM)]. Naturamed1997;12(10):37‐40. ">Gendo 1997</a>; <a href="./references#CD002947-bbs2-0067" title="KielczynskiW . Osteoarthritis ‐ clinical outcomes after uniform, long‐term herbal treatment. The European Journal of Herbal Medicine1997;3(2):29‐35. ">Kielczynski 1997</a>; <a href="./references#CD002947-bbs2-0073" title="LongL , SoekenK , ErnstE . Herbal medicines for the treatment of osteoarthritis: A systematic review. Rheumatology2001;40:779‐93. ">Long 2001</a>; <a href="./references#CD002947-bbs2-0079" title="RuessD . Echinacin in the treatment of primary chronic polyarthritis [Echinacin in der Therapie der primar‐chronischen Polyarthritis]. ZFA ‐ Stuttgart1981;57(11):865. ">Reuss 1981</a>), (c) not a herbal intervention (<a href="./references#CD002947-bbs2-0051" title="BelcaroG , CesaroneMR , DugallM , PellegriniL , LeddaA , GrossiMG , et al. Efficacy and safety of Meriva®, a curcumin‐phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Medicine Review2010;15(4):337‐44. ">Belcaro 2010</a>; <a href="./references#CD002947-bbs2-0070" title="LevyRM , SaikovskyR , ShmidtE , KhokhlovA , BurnettBP . Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short‐term randomized, double‐blind pilot study. Nutrition Research2009;29:298‐304. ">Levy 2009</a>; <a href="./references#CD002947-bbs2-0077" title="ParkSH , KimSK , et al. Effects of AIF on knee osteoarthritis patients: Double‐blind, randomized, placebo‐controlled study. Korean Journal of Physiology and Pharmacology2009;13:33‐7. ">Park 2009</a>), (d) unable to identify the herbal components of the intervention (<a href="./references#CD002947-bbs2-0065" title="JacquetA , GirodetP , ParienteA , ForestK , Mallet , MooreN . Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double‐blind placebo‐controlled clinical trial. Arthritis Research &amp; Therapy2009;11:R192. [DOI: 10.1186/ar2891] ">Jacquet 2009</a>; <a href="./references#CD002947-bbs2-0068" title="KulkarniRR , PatkiPS , JogVP , GandageSG , PatwardhanB . Treatment of osteoarthritis with a herbomineral formulation: A double‐blind, placebo‐controlled, cross‐over study. Journal of Ethnopharmacology1991;33:91‐5. ">Kulkarni 1991</a>), (e) individualised treatments thus not a standardised herbal intervention (<a href="./references#CD002947-bbs2-0060" title="FangR , MengQ‐C , DengY‐J , SongG , BaiY‐P . Effects of Bu Shen Tong Luo decoction on matrix metalloproteinase‐1, matrix metalloproteinase‐3, tissue inhibitor of matrix metalloprotease‐1 and interleukin‐1beta content in the synovial fluid and serum of patients with knee osteoarthritis. Journal of Clinical Rehabilitative Tissue Engineering Research2008;12:5581‐5. ">Fang 2008</a>; <a href="./references#CD002947-bbs2-0064" title="HamblinL , LairdA , ParkesE , WalkerAF . Improved arthritic knee health in a pilot RCT of phytotherapy. The Journal of the Royal Society for the Promotion of Health2008;128(5):255‐62. [CENTRAL: 00651201] ">Hamblin 2008</a>), (f) mixed sample and unable to extract data for participants with OA only (<a href="./references#CD002947-bbs2-0053" title="BiswasNR , BiswasK , PandeyM , PandyRM . Treatment of osteoarthritis, rheumatoid arthritis and non‐specific arthritis with a herbal drug: a double‐blind, active drug controlled parallel study. JK Practitioner1998;5(2):129‐32. ">Biswas 1998</a>; <a href="./references#CD002947-bbs2-0058" title="DuT‐X , HanX‐F , GaoS‐T . Effect of hanshibi granule on rheumatism due to blockage of cold and damp. Chinese Journal of Clinical Rehabilitation2006;10:148‐50. ">Du 2006</a>; <a href="./references#CD002947-bbs2-0069" title="LechnerM , SteirerI , BrinkhausB , ChenY , Krist‐DunglC , KoschierA , et al. Efficacy of individualized Chinese herbal medication in osteoarthrosis of hip and knee: a double‐blind, randomized‐controlled clinical study. Journal of Alternative and Complementary Medicine2011;17(6):539‐47. ">Lechner 2011</a>; <a href="./references#CD002947-bbs2-0083" title="SchaffnerW . Willow bark ‐ an antirheumatic in modern phytotherapy? [Weidenrinde ‐ Ein Antirheumatikum der modernen Phytotherapie?]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verglag, 1997:125‐7. ">Schaffner 1997</a>), (g) duplicate publication or part thereof (<a href="./references#CD002947-bbs2-0055" title="ChantreP , CappelaereA , LeblanD , GuedonD , VandermanderJ , FournieB . Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine2000;7(3):177‐83. ">Chantre 2000</a>; <a href="./references#CD002947-bbs2-0074" title="LungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week, randomized, double‐blind trial of the efficacy and safety of SKI306X: a herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. The American Journal of Chinese Medicine2004;32:291‐301. ">Lung 2004</a>; <a href="./references#CD002947-bbs2-0078" title="ReinE , KharazmiA , ThamsborgG , WintherK . A herbal remedy, made from a subspecies of rose‐hip Rosa canina, reduces symptoms of knee and hip osteoarthritis. Osteoarthritis and Cartilage2004;12 Suppl 2:S80. ">Rein 2004b</a>; <a href="./references#CD002947-bbs2-0085" title="SchmidB , LüdtkeR , SelbmannH‐K , KötterI , TschirdewahnB , SchaffnerW , HeideL . Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial. Phytotherapy Research2001;15:344‐50. [DOI: 10.1002/ptr.981] ">Schmid 2001</a>; <a href="./references#CD002947-bbs2-0089" title="WintherK , KharazmiA , ReinE . A powder made from a subspecies of rosehip (Rosa canina) reduces WOMAC symptoms scores as well as cholesterol levels in patients suffering from osteoarthritis. Osteoarthritis and Cartilage2004;13 Suppl A:S93. ">Winther 2004</a>), (h) abstract publication only (<a href="./references#CD002947-bbs2-0052" title="BiswasNR , BiswasA , PandeyRM . EASE ‐ a herbal preparation for rheumatoid arthritis, non specific arthritis and osteoarthritis. FACT: Focus on Alternative and Complementary Therapies. Proceedings of 4th Annual Symposium on Complementary Health Care. Exeter (UK), 1997; Vol. 2, issue 4:186‐7. ">Biswas 1997</a>; <a href="./references#CD002947-bbs2-0084" title="SchmidB , TschirdewahnB , KotterI , GunaydinI , LudtkeR , SelbmannHK , et al. Analgesic effects of willow bark extract in osteoarthritis: results of a clinical double‐blind trial. FACT:Focus on Alternative and Complementary Therapies1998;3(4):186. ">Schmid 1998a</a>), or (i) did not include functional or clinical outcomes (<a href="./references#CD002947-bbs2-0093" title="ZengY‐R , FanY‐G , WuF , LiX‐P , FanH‐J . Effects of compound herb of invigorating kidney and promoting blood flow on serum matrix metalloproteinases‐3, tumor necrosis factor alpha, interleukin‐1, hyaluronic acid, lipid peroxidation levels and superoxide dismutase activity in patients with knee osteoarthritis. Journal of Clinical Rehabilitative Tissue Engineering Research2008;12:5436‐9. ">Zeng 2008</a>). Subanalyses of two studies (<a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>) were identified in other publications (<a href="./references#CD002947-bbs2-0074" title="LungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week, randomized, double‐blind trial of the efficacy and safety of SKI306X: a herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. The American Journal of Chinese Medicine2004;32:291‐301. ">Lung 2004</a>; <a href="./references#CD002947-bbs2-0078" title="ReinE , KharazmiA , ThamsborgG , WintherK . A herbal remedy, made from a subspecies of rose‐hip Rosa canina, reduces symptoms of knee and hip osteoarthritis. Osteoarthritis and Cartilage2004;12 Suppl 2:S80. ">Rein 2004b</a>; <a href="./references#CD002947-bbs2-0089" title="WintherK , KharazmiA , ReinE . A powder made from a subspecies of rosehip (Rosa canina) reduces WOMAC symptoms scores as well as cholesterol levels in patients suffering from osteoarthritis. Osteoarthritis and Cartilage2004;13 Suppl A:S93. ">Winther 2004</a>) and were excluded from this review to avoid repetition of data. In the original review, one study was classified as pending assessment subject to full translation of the texts (<a href="./references#CD002947-bbs2-0072" title="LoewD , SchusterO , MollerfeldJ . Stability and biopharmaceutical quality. A postulate for bioavailability and effectiveness of Harpagophytum procumbens [Stabilitat und biopharmazeutische Qualitat. Voraussetzung fur Bioverfugbarkeit und Wirksamkeit von Harpagophytum procumbens]. In: LoewD , RietcrockN editor(s). Phytopharmaka II. Forschung und klinische Anwendung. Darmstadt: Steinkopf‐Verlag, 1996:83‐93. ">Loew 1996</a>), but in this update language was no barrier to inclusion and this study was excluded on other grounds. </p> </section> </section> <section id="CD002947-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <p>See: <a href="./references#CD002947-sec-0156" title="">Characteristics of included studies</a>, 'Risk of bias' tables. </p> <p>The risk of bias of each study was assessed independently by two review authors according to the criteria described in the methods (<a href="./references#CD002947-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies.. Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>; <a href="./references#CD002947-bbs2-0153" title="SchunemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, updated March 2011. ">Schunemann 2011a</a>). Quality of the included studies was variable and should be taken into account when interpreting results. See <a href="#CD002947-fig-0002">Figure 2</a> for a summary of the risk of bias assessment. Only three studies adequately met all six validity criteria and thus were at minimal risk of bias (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>). </p> <div class="figure" id="CD002947-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002947-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Although not directly measures of bias, we considered if authors reported that they had obtained ethics committee approval, clinical trials registration, or complied with the Declaration of Helsinki and International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals in Human Use Good Clinical Practice (ICH GCP) guidelines. Further, we considered that risk of bias could be assumed to be low if these oversights implied that a risk of bias was reduced. For example, the ICH GCP guidelines were recommended in Germany, France, Great Britain, and Scandanavia from 1986 onwards, therefore we have assumed that Human Research Ethics committee approvals granted for studies after this time, in these countries, necessitated compliance with the guidelines regarding randomisation, allocation concealment, and blinding of participants and assessors. In 1989, these guidelines were recommended across the European Community (EC) as it was then constituted. Again, we have assumed that from this date studies with ethics committee approval, conducted in EC countries, have complied with these guidelines. In 1996, compliance with the ICH CGP guidelines was required under German law governing clinical trials. </p> <p>The ICH GCP guidelines are now adopted by the WHO and most countries, including many developing countries, are listed as following these guidelines. Formally constituted human research ethics committees are charged with ensuring that clinical trials are conducted in compliance with these guidelines and associated regional legislation. Six studies reported some form of board approval or review but did not specify that the board was a formally constituted human research ethics committee nor reported compliance with relevant guidelines or legislation (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>). Nine studies did not report any form of ethical oversight or compliance with research design guidelines (ICH GCP guidelines or Declaration of Helsinki) (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>). </p> <section id="CD002947-sec-0086"> <h4 class="title">Allocation</h4> <p>We attributed low risk of bias to 28 studies that fully described an appropriate process of generating a randomisation schedule (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). We also attributed low risk of bias to two studies that reported compliance with the ICH GCP guidelines but did not fully describe the randomisation processes because in these studies adequate randomisation processes could be inferred (see <a href="#CD002947-sec-0090">Other potential sources of bias</a>) (<a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>). </p> <p>A further 13 studies were described as randomised but the method of randomisation was not reported (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>; <a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>; <a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>). In another two studies randomisation was reported in insufficient detail to allow replication of the method (<a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>), and in a further two studies the methods could be more accurately described as quasi‐randomisation (<a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a>). We classified each of these studies as having unclear risk of bias due to randomisation procedures. One study was not randomised (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>) and has been classified as having high risk of bias. </p> <p>Allocation concealment was poorly described in most studies. Allocation concealment was assessed according to the Cochrane format, as described in the methods (<a href="./references#CD002947-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies.. Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). We attributed low risk of bias to three studies (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>) in which allocation concealment was explicitly reported, and the 20 studies in which it could reasonably be inferred from the description of methods (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). One study reported that allocation was not concealed, neither from participants nor the research assistant (<a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>). This study has been classified as having a high risk of bias. </p> <p>Allocation concealment could not be determined in any other study; neither could failure to conceal allocation be determined. These studies have been classified as having unclear risk of bias for this domain. </p> </section> <section id="CD002947-sec-0087"> <h4 class="title">Blinding</h4> <p>Low risk of bias has been attributed to 33 studies in which the herbal products and placebo or active controls could not be distinguished by colour, size, smell, shape, packaging, or treatment regimen (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). </p> <p>In a small number of studies (n = 9), the method of blinding was inadequately described and no reference to governing guidelines made (see <a href="#CD002947-sec-0090">Other potential sources of bias</a>). Although we considered it highly likely that these studies were sufficiently blinded, we downgraded the risk of blinding to unclear (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>). Risk of bias has been downgraded to high in studies that were open label, single blinded, or where interventions could be clearly distinguished (<a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>). </p> <p>In some studies where allocation concealment was inadequately described (see <a href="#CD002947-sec-0086">Allocation (selection bias)</a>) it was unclear whether clinical examiners were blinded to treatment (detection bias). We have classified these studies as having unclear risk of bias in the blinding domain. </p> </section> <section id="CD002947-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Low risk of bias has been assigned to 28 studies in which participant withdrawals were fully reported and analyses conducted according to an ITT model. in these studies methods for replacing missing data were fully reported (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>; <a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>; <a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>; <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>; <a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>; <a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). Unclear risk of attrition bias has been attributed to 17 studies in which withdrawals were reported but not considered in the analyses (per protocol analysis only) (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>; <a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>). Studies that neither reported participant withdrawals nor applied any method for replacement of missing data were ascribed a high risk of attrition bias. </p> </section> <section id="CD002947-sec-0089"> <h4 class="title">Selective reporting</h4> <p>Some studies adopted validated measures but outcome data were reported as non‐standardised scores (VAS 0 to 10 instead of 0 to 100, paracetamol in tablets rather than milligrams). We converted these data to standardised forms prior to re‐analysis and have noted these data conversions in this section of the risk of bias tables but not attributed any increased risk. </p> <p>In three studies we identified errors in data during conversion and have downgraded these studies to unclear risk (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>). </p> <p>We have downgraded to unclear risk of bias 12 studies in which data were insufficiently reported to allow extraction for re‐analysis (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>; <a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>; <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a>; <a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>). </p> <p>Examples of selective reporting included providing mean scores only (omission of SDs) at some or all time points, or reporting data spread as standard errors of measure (SEM) rather than SDs. Similarly, data reported only as group change scores, percentages, or raw scores without measures of data spread, and data presented in graphical form only, were inadequate for re‐analysis. In some cases we were able to calculate the unreported data (for example convert SEM to SD), however we considered that the classification of unclear risk of bias should still be applied to this selective reporting (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>; <a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>). </p> <p>A few studies were particularly poorly reported and have been classified as having high risk of bias for this criterion. Examples of very poor reporting included omission of key demographic data (for example age, gender, concomitant disease) and failure to report reasons for withdrawals or adverse events (that is a safety concern). In one study that was described as a crossover design with three arms (intervention, placebo control, and non‐intervention control) data were reported from the intervention and placebo control groups only, and no data were reported after the apparent crossover (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>). We cannot be certain whether the reporting bias in this study occurred in the description of the research design or reporting of the results. We have treated this study as a two group parallel design and classified it as having a high risk of reporting bias. </p> <p>In some studies reporting bias was difficult to identify. Omission of details may not be apparent if consistent throughout the report. For example, in one study of pine bark extract the outcome data were reported at 90 days only (<a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>) whereas in the other two studies of this product the outcome data were reported at more frequent intervals (<a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>; <a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>). We considered it unlikely that the former study was planned as a simple pre‐post analysis over such a wide treatment period and questioned whether mid‐point data may have been omitted from the report. </p> </section> <section id="CD002947-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>Selection bias due to diagnostic criteria (see <a href="#CD002947-sec-0086">Allocation (selection bias)</a>) is reported under the heading of 'other bias' in the risk of bias tables. </p> <p>We attributed low risk of bias to studies that recruited and assessed participants consistently with the ACR and EULAR criteria, obtained ethics committee approval, had clinical trials registration, used validated outcome measures, and reported compliance with the Declaration of Helsinki and ICH GCP guidelines. Further, we considered that risk of bias could be assumed to be low if satisfying one of these conditions implied the satisfaction of another. For example, the ICH GCP guidelines were recommended in Germany, France, Great Britain, and Scandanavia from 1986 onwards, therefore we have assumed that Human Research Ethics committee approvals granted after this time for studies in these countries necessitated compliance with the guidelines. In 1989, these guidelines were recommended across the European Community (EC) as it was then constituted. Again, we have assumed that from this date studies with ethics committee approval and conducted in EC countries have complied with these guidelines regarding randomisation, allocation concealment, and blinding of participants and assessors. </p> <p>In 1996, compliance with the ICH CGP guidelines was required under German law governing clinical trials. The ICH GCP guidelines are now adopted by the WHO and most countries, including many developing countries, are listed as following these guidelines. Formally constituted human research ethics committees are charged with ensuring that clinical trials are conducted in compliance with these guidelines and associated regional legislation. We have classified as low risk all studies that reported either compliance with ICH GCP guidelines or ethics committee approval, or both. </p> <p>Unclear risk of bias has been attributed to six studies that reported some form of board approval or review but did not specify that the board was a formally constituted human research ethics committee nor reported compliance with relevant guidelines or legislation (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a>; <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>; <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>). High risk of bias has been attributed to the nine studies that did not report any form of ethical oversight or compliance with research design guidelines (ICH GCP guidelines or Declaration of Helsinki) (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>). </p> </section> </section> <section id="CD002947-sec-0091"> <h3 class="title" id="CD002947-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD002947-tbl-0001"><b>Summary of findings for the main comparison</b><i>Boswellia serrata</i> for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0002"><b>Summary of findings 2</b><i>Boswellia serrata</i> (enriched) 100 mg for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0003"><b>Summary of findings 3</b><i>Boswellia serrata</i> (enriched) 250 mg for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0004"><b>Summary of findings 4</b><i>Boswellia serrata</i> (enriched) plus non‐volatile oil for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0005"><b>Summary of findings 5</b><i>Boswellia serrata</i> compared to valdecoxib for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0006"><b>Summary of findings 6</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0007"><b>Summary of findings 7</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) for treating osteoarthritis</a>; <a href="./full#CD002947-tbl-0008"><b>Summary of findings 8</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</a> </p> <p>See: 'Additional tables', <a href="#CD002947-tbl-0009">Table 1</a>: Herbal medicinal products used for the treatment of OA. </p> <p>Results are listed below, grouped by the intervention in alphabetical order. Medicinal products from single plants are listed first, by botanical name, followed by products formed from two plants, followed by herbal mixtures from three or more plants. For consistency and ease of reading this same order of presentation was used in <a href="#CD002947-tbl-0009">Table 1</a>: Herbal medicinal products used for the treatment of OA. </p> <section id="CD002947-sec-0092"> <h4 class="title">Medicinal products from single plants</h4> <section id="CD002947-sec-0093"> <h5 class="title"><i>Boswellia serrata</i> versus placebo </h5> <p><i>Boswellia serrata</i> extracts have been subgrouped by proprietary products because we cannot be certain that the active principle in each product is identical. </p> <p>One study investigated the proprietary Boswellia product CapWokvel®. The extract of <i>Boswellia serrata</i> was compared with placebo in 30 participants with OA in a crossover trial of two periods of eight weeks intervention separated by a three week washout period (<a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>). In this review, data have been extracted for the first arm of the trial only and may be considered as from an eight week parallel group trial. Pain and function (loss of movement) were rated using a 0 to 3 scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe), and statistically significant improvements in favour of the <i>Boswellia serrata</i> group were reported over the eight weeks of intervention (pain: MD ‐2.45, 95% CI ‐2.85 to ‐2.23, P &lt; 0.01; <a href="./references#CD002947-fig-0003" title="">Analysis 1.1</a>; function: MD ‐2.16, 95% CI ‐2.56 to ‐1.76, P &lt; 0.01; <a href="./references#CD002947-fig-0004" title="">Analysis 1.2</a>). </p> <p>Two studies investigated the proprietary <i>Boswellia serrata</i> product 5‐Loxin®. Both studies were undertaken by the same author team and were of similar design, suitable for pooling. Both studies involved three parallel groups, two intervention groups and one placebo control, over 12 weeks. The earlier study by <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a> was a dose‐finding study comparing high (250 mg/day) and low (100 mg/day) doses. Participants who took 250 mg of 5‐Loxin reported less pain (<a href="./references#CD002947-fig-0009" title="">Analysis 3.1</a>) and better function (<a href="./references#CD002947-fig-0010" title="">Analysis 3.2</a>) than participants who took the placebo. The risk of adverse events did not meaningfully differ between groups (5‐Loxin 27/57 events, placebo 30/57 events; RR 0.90, 95% CI 0.62 to 1.30). The higher dose of 5‐Loxin did not produce significantly greater clinical outcomes than the 100 mg dose. </p> <p>In the subsequent study (<a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>), 100 mg of 5‐Loxin® was compared with 100 mg/day of an alternative <i>Boswellia serrata</i> product. Meta‐analysis of the data from the two 100 mg 5‐Loxin® groups in both studies showed that 90 days treatment with this product produced improvements over placebo in pain (MD ‐16.94, 95% CI ‐22.39 to ‐11.50; <a href="./references#CD002947-fig-0006" title="">Analysis 2.1</a>) and function (MD ‐9.62, 95% CI ‐11.35 to ‐7.89; <a href="./references#CD002947-fig-0007" title="">Analysis 2.2</a>). Also, the risk of adverse events appeared lower in the 5‐Loxin group than in the placebo group (5‐Loxin 18/48 events, placebo 30/48 events; RR 0.60, 95% CI 0.39 to 0.92; <a href="./references#CD002947-fig-0008" title="">Analysis 2.3</a>). </p> <p>Two studies investigated the proprietary <i>Boswellia serrata</i> product Aflapin® (<a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>; <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>). In the three way comparison of Aflapin® and 5‐Loxin® against placebo in 60 patients over 90 days, both treatment groups reported significantly greater improvements in pain (<a href="./references#CD002947-fig-0012" title="">Analysis 4.1</a>) and function (<a href="./references#CD002947-fig-0013" title="">Analysis 4.2</a>) than did the placebo group, and Aflapin® consistently outperformed 5‐Loxin® (<a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>). This study was conducted using an ANOVA model and results of the three groups were presented as a series of student's t‐tests; multivariate analysis would be required to confidently account for any chance effect from multiple two group comparisons. Data were extracted from the Aflapin® group in this study and subgrouped but not meta‐analysed with data from an additional study (<a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>), a two parallel group test against placebo in patients with OA over 30 days, because of the substantial difference in length of intervention between these studies (30 days, <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>; 90 days, <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>). Viewing these studies together, trends of effectiveness of Aflapin® to reduce pain (30 days: MD ‐14.80, 95% CI ‐20.29 to ‐9.31; 90 days: MD ‐18.10, CI ‐24.95 to ‐11.25; <a href="./references#CD002947-fig-0012" title="">Analysis 4.1</a>) and increase function (30 days: MD ‐14.30, 95% CI ‐20.70 to ‐8.53; 90 days: MD ‐15.80, 95% CI ‐21.92 to ‐9.68; <a href="./references#CD002947-fig-0013" title="">Analysis 4.2</a>). The risk of participants reporting adverse events did not differ between Aflapin® and the placebo groups after 30 or 90 days of intervention (30 days: Aflapin® 1/30, placebo 1/29; RR 0.97, 95% CI 0.06 to 14.74; 90 days: Aflapin® 1/19, placebo 1/19; RR 1.00, 95% CI 0.07 to 14.85; <a href="./references#CD002947-fig-0014" title="">Analysis 4.3</a>). </p> </section> <section id="CD002947-sec-0094"> <h5 class="title"><i>Boswellia serrata</i> versus cyclo‐oxygenase‐II (COX‐II) inhibitor anti‐inflammatory drugs </h5> <p>A single study compared the<i>Boswellia serrata</i> extract Cap Wovkel against the COX‐II inhibitor anti‐inflammatory drug valdecoxib in 66 participants over six months. Although follow‐up was continued for an additional month, we extracted all data at the end of the intervention period. Although the authors reported that results favoured the intervention, re‐analysis of the data indicated that results slightly favoured the intervention for WOMAC pain subscale scores only (<a href="./references#CD002947-fig-0015" title="">Analysis 5.1</a>). Results favoured control on all other outcomes, including function (<a href="./references#CD002947-fig-0016" title="">Analysis 5.2</a>). Fewer participants in the valdecoxib group reported adverse events, thus the risk of adverse events appeared greater in the <i>Boswellia serrata</i> group (Cap Wovkel 4/33, valdecoxib 2/33; RR 2.00, 95% CI 0.39 to 10.18; <a href="./references#CD002947-fig-0017" title="">Analysis 5.3</a>). </p> </section> <section id="CD002947-sec-0095"> <h5 class="title"><i>Curcuma domestica</i> versus NSAIDs </h5> <p>A single study (107 participants recruited) compared six weeks intervention with an ethanolic root extract from <i>Curcuma domestica</i> against ibuprofen in a randomised, active control, parallel trial. Particpants within both groups showed statistically significant mean improvements in all outcomes over time at all time points (two, four, and six weeks). Between‐group differences were not significant (<a href="./references#CD002947-fig-0019" title="">Analysis 6.1</a>; <a href="./references#CD002947-fig-0020" title="">Analysis 6.2</a>) suggesting that <i>Curcuma domestica</i> has comparable efficacy to ibuprofen in the treatment of osteoarthritic pain and pain‐related functional impairments. </p> </section> <section id="CD002947-sec-0096"> <h5 class="title"><i>Derris scandens</i> versus NSAIDs </h5> <p>An ethanolic extract from the stem of <i>Derris scandens</i> was tested in a head‐to‐head comparison with naproxen in a two group parallel trial over four weeks in people with OA of the knee (<a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a>). Outcomes were reported using the WOMAC‐VAS, but on a 10 cm scale. We extracted these data and converted them to normalised scores (range 0 to 100), and in so doing identified an error in one of the CIs. We contacted the authors who confirmed our correction. Our re‐analysis supported the authors' conclusions that the effectiveness of <i>Derris scandens</i> was not significantly different from naproxen in improving OA pain (MD 5.00, 95% CI ‐1.84 to 11.84; <a href="./references#CD002947-fig-0022" title="">Analysis 7.1</a>) and physical function (MD 5.11, 95% CI ‐0.13 to 10.33; <a href="./references#CD002947-fig-0023" title="">Analysis 7.2</a>), but that the mean differences and CIs may be larger than originally reported. Also, of particular importance in comparisons against non‐steroidal anti‐inflammatory drugs (NSAIDs) <i>Derris scandens</i> showed a favourable adverse events profile: fewer participants in the <i>Derris scandens</i> group reported adverse events (<i>Derris scandens</i> 22/63, naproxen 29/62) and the risk of an adverse event occurring in that group was markedly lower than in the naproxen group (RR 0.75, 95% CI 0.49 to 1.15; <a href="./references#CD002947-fig-0024" title="">Analysis 7.3</a>). </p> </section> <section id="CD002947-sec-0097"> <h5 class="title"><i>Garcinia kola</i> </h5> <p>The crude seed of <i>Garcinia kola</i> was compared over six weeks to two NSAIDs, naproxen and celecoxib, as well as a placebo control in a four group parallel trial of 143 patients with OA of the knee (<a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a>). Results favoured all active interventions over placebo for reductions in pain and function. These outcomes appeared to have been measured using two independent WOMAC subscales with differing reporting and scoring formats: pain was measured using the WOMAC‐VAS, and function using the WOMAC 0 to 4. Data were reported as change scores, percentages, CIs, and P values, insufficient for extraction in this review. Comparing efficacy of the active agents, pain relief appeared to have been most rapid and persistent in the celecoxib group, and most delayed and least persistent in the <i>Garcinia kola</i> group. </p> </section> <section id="CD002947-sec-0098"> <h5 class="title"><i>Harpagophytum procumbens</i> (Devil's claw) </h5> <p>Four studies investigated three different products from the roots of <i>Harpagophytum procumbens.</i> Three studies compared two different extracts to placebo in trials completed by 174 participants (<a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>). One study (92 participants) compared cryoground root powder to the weak NSAID diacerhein (<a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>). </p> <p>In the studies using the ethanolic <i>Harpagophytum</i> extract Flexiloges®, no improvement in WOMAC pain scores was found (<a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>; <a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>). These authors provided post hoc definitions of improvement that favoured the intervention. 'Responders' to treatment were defined as participants whose WOMAC pain scores did not increase by more than 20%, either with (<a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>) or without (<a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>) additional rescue medication (up to 4000 mg ibuprofen) in weeks 17 to 20 of the study. These definitions of response were inconsistent with the American College of Rheumatology (ACR) criteria for response, and data derived from these measures have not been reproduced in this review. </p> <p>In contrast, the aqueous <i>Harpagophytum</i> extract Arthrotabs® showed favourable effects on OA pain measured using a 0 to 4 categorical rating scale, but these data were also insufficiently reported (<a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>). </p> <p>The <i>Harpagophytum</i> powder Harpadol® was not inferior to diacerhein in reducing pain, as measured using a 100 mm VAS (<a href="./references#CD002947-fig-0003" title="">Analysis 1.1</a>) (<a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>). This study constituted moderate evidence that four months daily use of 2610 mg of <i>Harpagophytum procumbens</i> powder was not significantly different from 100 mg diacerhein, producing comparable improvements in pain. In this same study participants in the <i>Harpagophytum</i> group used fewer NSAIDS (diclofenac) and analgesics (acetominophen supplemented by caffeine) at all time points (30, 60, and 120 days) than did participants in the diacerhein group. Due to differences in the protocols and outcome measures these studies were not suitable for data pooling. </p> </section> <section id="CD002947-sec-0099"> <h5 class="title"><i>Petiveria alliacea</i> (tipi tea) </h5> <p>Overall, the study of tipi tea (<a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>) was inadequately reported, although it should be noted that the study was published only in the form of a letter. Attempts to obtain a report of the study in greater detail were not successful. Data reported in this study were not adequate for re‐analysis but were reported descriptively for the sake of completeness. Participants receiving tipi tea and participants receiving placebo tea both showed some improvement although no significant differences were found between the two groups. The study was small (n = 20, crossover design) and provided little detail with regard to inclusion criteria. Pain scales against which the outcomes were quantified were not disclosed. Five participants, three during use of the placebo tea and two during use of the tipi tea, reported mild adverse effects. Two participants failed to complete the trial but the reasons for their withdrawal were not explained. </p> </section> <section id="CD002947-sec-0100"> <h5 class="title"><i>Pinus pinaster</i> (synonym<i>Pinus maritima</i>) </h5> <p>Although the pine bark extract Pycnogenol® was investigated in three studies (293 participants) the data could not be pooled despite all studies returning results that favoured the intervention over placebo. The two smaller, earlier studies used identical doses of Pycnogenol® (150 mg daily) over the same intervention period (three months) but the content of the marker substance in the daily dose differed considerably. Moreover, the reported pain and physical function data used two different forms of outcome measure, the VAS 0 to 100 mm items of the WOMAC (<a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>) and the 0 to 4 grading (<a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>). Unlike another Cochrane review exclusively on this product, in which results of these two studies were pooled (<a href="./references#CD002947-bbs2-0152" title="SchooneesA , VisserJ , MusekiwaA , VolminkJ . Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008294.pub4] ">Schoonees 2012</a>), we have reported data from these studies independently. Data in one study were reported graphically (<a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>), which was insufficient to allow extraction for re‐analysis without a considerable margin for error. Results from the other study demonstrated improvements in pain (<a href="./references#CD002947-fig-0029" title="">Analysis 10.1</a>) and physical function (<a href="./references#CD002947-fig-0030" title="">Analysis 10.2</a>) for the Pycnogenol® group over the placebo, but the small sample size (n = 37) of this study was noted as caution against generalisation of these results. </p> <p>The more recent, larger study used a confirmatory design and reported outcome data using the WOMAC 0 to 4 (<a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a>). Despite positive outcomes from this study the data could not be pooled with the earlier studies because a smaller dose of pine bark extract (100 mg daily) with an undeclared content of marker substance in the daily dose was used in the confirmatory study. Results from this study also favoured pine bark extract over placebo for improvements in pain (<a href="./references#CD002947-fig-0032" title="">Analysis 11.1</a>) and physical function (<a href="./references#CD002947-fig-0033" title="">Analysis 11.2</a>). Observed together, these three studies provided modest evidence that pine bark extract was effective in reducing pain and improving physical function in people with OA even at daily doses as low as 100 mg. </p> </section> <section id="CD002947-sec-0101"> <h5 class="title"><i>Ricinus officinalis</i> (castor oil) </h5> <p>Castor seed oil was compared to diclofenac (NSAID) in 110 patients with probable OA of the knee in a parallel trial over four weeks (<a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>). Pain was reported on a 100 mm VAS. Results of this exploratory study were insufficiently reported to allow extraction and re‐analysis. Results favoured diclofenac over <i>Rinicus officinalis</i> for improvement in pain, although pain decreased in both the intervention and active control groups over time. The adverse event profile markedly favoured castor oil over placebo (<a href="./references#CD002947-fig-0034" title="">Analysis 12.1</a>), however it was unclear whether pain (possibly due to untreated OA) was included among the adverse events reported in the placebo group. </p> </section> <section id="CD002947-sec-0102"> <h5 class="title"><i>Rosa canina lito</i> (rose hip) </h5> <p>Three studies (306 participants) compared daily doses of 5 g of a rose hip and seed powder (<i>Rosae caninae</i> pseudofructus cum fructibus powder) to placebo. Two studies reported reductions in OA pain on a standardised five point scale (0 to 4: 0 = no relief, 4 = almost total relief) (<a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>) and the third used the WOMAC‐VAS (<a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). Although the WOMAC‐VAS included a pain subscale, these pain data were not pooled. The data in one study were insufficiently reported to allow extraction for re‐analysis (<a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>) and the remaining two studies used differing outcome measures to report pain (<a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>). Also, the periods of intervention differed between studies: three months (<a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>), and four months (<a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>). </p> <p>Previously it has been suggested that it was likely that some participants may have been in common between the <a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a> and <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a> reports such that pooling data from these studies would double count some individuals (<a href="./references#CD002947-bbs2-0162" title="VlachojannisJE , DukeRK , TranVH , DukeCC , ChrubasikS . Anti‐inflammatory herbal medicines for the control of pain. In: CarpinellaM C , RaiM editor(s). Novel Therapeutic Agents from Plants. Enfield, NH, USA: Science Publisher, 2009:339‐67. ">Vlachojannis 2009</a>), but correspondence with the study authors confirmed that the data were not transferred between these studies (Winther, personal communication, 21 September 2011). In this review we have treated these reports as independent studies. </p> <p>These studies constituted modest and somewhat conflicting evidence that daily consumption of 5 g of <i>Rosa canina lito</i> powder produced improvements in OA pain superior to placebo (<a href="./references#CD002947-fig-0035" title="">Analysis 13.1</a>). </p> </section> <section id="CD002947-sec-0103"> <h5 class="title"><i>Salix daphnoides</i> or <i>Salix pupurea x daphnoides</i> (willow) </h5> <p>Two studies (205 participants recruited) of willow bark preparations returned differing results (<a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>; <a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>). One study compared an ethanolic bark extract of <i>Salix daphnoides</i>, equivalent to 240 mg salicin, to placebo and active (100 mg diclofenac) controls in parallel groups over six weeks to determine that although slightly more effective than placebo, willow bark was less effective than diclofenac in reducing OA pain measured using the WOMAC pain scale (<a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>). In this study similar numbers and severities of adverse events were reported for both the willow bark and ibuprofen interventions. </p> <p>Another study compared the same daily dose of <i>Salix purpurea</i> x <i>daphnoides</i> ethanolic bark extract to placebo and reported improvements in WOMAC pain scores after two weeks of intervention (<a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>). </p> <p>Although these products have different names, both are drawn from the subspecies daphnoides (subspecies of <i>Salix purpurea</i>) and may be considered together, however data from these studies were not suitable for meta‐analysis because the authors did not report measures of variance (SD) for mean scores at the 14 day time point. In this review mean WOMAC pain and function scores were reported for a descriptive comparison (<a href="./references#CD002947-fig-0039" title="">Analysis 14.1</a>; <a href="./references#CD002947-fig-0040" title="">Analysis 14.2</a>; <a href="./references#CD002947-fig-0042" title="">Analysis 15.1</a>; <a href="./references#CD002947-fig-0043" title="">Analysis 15.2</a>). </p> <p>The risk of participants reporting adverse events was not significantly different between <i>Salix</i> extract and placebo (<i>Salix</i> 19/43, placebo 20/41; RR 0.91, 95% CI 0.57 to 1.43; <a href="./references#CD002947-fig-0041" title="">Analysis 14.3</a>), but when compared against diclofenac the adverse events profile of <i>Salix daphnoides</i> was favourable (<i>Salix</i> 19/43, diclofenac 30/43; RR 0.63, 95% CI 0.43 to 0.93; <a href="./references#CD002947-fig-0044" title="">Analysis 15.3</a>). </p> </section> <section id="CD002947-sec-0104"> <h5 class="title"><i>Uncaria guianensis</i> (cat's claw) </h5> <p>In a 4 week, parallel group trial comparing aqueous bark extract of <i>Uncaria guianensis</i> with placebo (<a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>) participants using cat's claw reported a statistically significant reduction in pain with activity within the first week of treatment (P &lt; 0.01). The same pattern of improvements were seen in physicians' and patients' global assessments of disease activity. These improvements were maintained throughout the four week trial, but data from these measures were not reported in sufficient detail to allow re‐analysis in this review. In contrast, reduction in night pain (MD ‐11.10, 95% CI ‐26.4 to 4.24, <a href="./references#CD002947-fig-0045" title="">Analysis 16.1</a>) was not statistically significant although changes on this measure somewhat favoured cat's claw over placebo. </p> </section> <section id="CD002947-sec-0105"> <h5 class="title"><i>Vitellaria paradoxa </i>(shea) </h5> <p>A patented seed extract of <i>Vitellaria paradoxa</i>, the African shea tree, was tested against placebo in a single centre, two group parallel trial for 89 patients with OA of the hip or knee (<a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a>). Clinical outcomes were measured using the WOMAC and the Comprehensive Osteoarthritis Test (COAT). Results were equivocal on all clinical outcomes, and none of these data were reported in sufficient detail to allow extraction. The authors focused their report on improvements in biomarkers, which were not of importance in this review. </p> </section> <section id="CD002947-sec-0106"> <h5 class="title"><i>Zingiber officinale</i> (ginger) </h5> <p>Data from three studies of ginger could not be pooled because the ginger preparations were dissimilar, including acetone extract (<a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>), carbon dioxide extract (<a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>), and a mixture of two ginger species (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>). </p> <p>A crossover trial of Zintona EC, a standardised carbon dioxide extract containing <i>Zingiber officinale</i> (also known as Chinese ginger), with placebo reported results in favour of the intervention on measures of pain on movement and function (handicap), using the 100 mm VAS for these domains from the Hebrew version of the WOMAC (<a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a>) (<a href="./references#CD002947-fig-0047" title="">Analysis 17.1</a>; <a href="./references#CD002947-fig-0048" title="">Analysis 17.2</a>). The first arm of the crossover included 24 participants; one participant in the ginger group reported an adverse effect with the intervention (heartburn) (ginger 1/12, placebo 0/12; RR 3.05, 95% CI 0.16 to 78.19; <a href="./references#CD002947-fig-0049" title="">Analysis 17.3</a>). </p> <p>Another study compared a 510 mg daily dose of standardised acetone extract of <i>Zingiber officinale</i> (EV.EXT 33) with 1200 mg ibuprofen and both tablet and capsule placebos in a crossover trial in 67 participants (56 completed) and reported results in favour of ibuprofen for measures of pain (100 mm VAS), Lequesne algofunctional index, and use of NSAIDS (<a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>). Data reporting in this study was insufficient to allow extraction for re‐analysis. </p> </section> </section> <section id="CD002947-sec-0107"> <h4 class="title">Medicinal products from two plants</h4> <section id="CD002947-sec-0108"> <h5 class="title"><i>Boswellia carteri</i> and<i>Curcuma longa</i> </h5> <p>Although the authors described this study as a crossover trial, their reporting of the research method was consistent with a two group parallel trial of a <i>Boswellia‐curcuma</i> mixture compared with placebo over three months of intervention among people with OA (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>). Minutes of pain free walking time, considered in this review as a measure of function, were recorded in each group after one, two, and three months of intervention. At each time point the placebo group reported a shorter mean pain free walking time, and at two and three months the differences between the placebo and intervention groups on this measure were statistically significant (one month: MD 2.5, 95% CI ‐0.07 to 5.07, P = 0.06; two months: MD 4.00, 95% CI 1.31 to 6.69, P = 0.004; 3 months: MD 3.5, 95% CI 0.65 to 6.35, P = 0.02; <a href="./references#CD002947-fig-0050" title="">Analysis 18.1</a>), but none of these measures were adjusted for baseline scores. </p> <p>For measures of pain on passive movement and pain on active movement, group means and mean changes from baseline were calculated from frequency tables reported in the paper (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>). No measures of data spread were reported and SDs could not be calculated from the data provided. </p> </section> <section id="CD002947-sec-0109"> <h5 class="title"><i>Persea gratissma</i> and <i>Glycine max</i> (avocado‐soyabean unsaponifiables (ASUs)) versus placebo </h5> <p>The avocado‐soyabean unsaponifiable (ASU) product Piascledine® was investigated in six studies; in five studies ASU was compared with placebo (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>) and in a sixth study ASU was tested head‐to‐head against a 1200 mg daily dose of chondroitin sulphate (<a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>). When compared against chondroitin sulphate, ASU was not inferior on any outcome (<a href="./references#CD002947-fig-0065" title="">Analysis 21.1</a>; <a href="./references#CD002947-fig-0066" title="">Analysis 21.2</a>; <a href="./references#CD002947-fig-0067" title="">Analysis 21.3</a>). </p> <p>On the basis of two studies (<a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>) the original review concluded that the evidence for ASU in the treatment of OA was convincing (Little 2000). A further study supported this conclusion (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>). Another study of Piascledine® over two years did not reveal any differences between groups, neither in the primary outcome measure of joint space width nor in clinical parameters including pain, function, and NSAID consumption (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). A further study over three years (36 months) showed no differences between the ASU and placebo groups on any clinical or functional outcomes, but radiological assessment of joint space width revealed that 20% fewer participants in the ASU group showed progressive narrowing of joint space width (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). </p> <p>Each of the five placebo‐controlled studies used a daily dose of 300 mg Piascledine®, and one study included an additional group that received 600 mg daily (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>). A total of 1008 participants with OA completed these trials. In one study a subgroup of patients with OA of the hip and of the knee were identified and analysed independently (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>). Pooling of results for NSAID consumption measured as diclofenac equivalents, pain measured using a 100 mm VAS, and Lequesne functional index indicated that these studies were highly hetergeneous, returning an I<sup>2</sup> of approximately 80% for the meta‐analysis of each of these outcome measures. Although the longer trials returned results that conflicted with the shorter trials, they were designed to investigate structural joint changes as the primary outcome and clinical outcomes were of secondary importance (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). Lequesne and colleagues reported that they were surprised by the lack of symptomatic improvements among participants in the Piascledine® group and were unable to explain why this trial was markedly different to those of other well designed trials of Piascledine® in patients with OA (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). Rather than present a single meta‐analysis, we subgrouped these studies according to the dose of Piascledine® and the length of the intervention period. </p> <section id="CD002947-sec-0110"> <h6 class="title">Pain</h6> <p>In two studies (326 participants) pain was measured on a 100 mm VAS after three months of 300 mg Piascledine® daily (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>). Using a random‐effects model the pooled results were a MD of ‐11.90 (95% CI ‐23.95 to 0.15; <a href="./references#CD002947-fig-0051" title="">Analysis 19.1</a>). Results after six months of treatment with 300 mg daily also favoured Piascledine® (MD ‐10.40, 95% CI ‐17.20 to ‐3.60) (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>) but after 12 months the results indicated no superior performance compared with placebo (MD 1.00, 95% CI ‐6.58 to 8.58) (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). </p> <p>Results from the one study (156 participants) that included a 600 mg daily dose were consistent in favour of Piascledine® (MD ‐14.20, 95% CI ‐20.82 to ‐7.58; <a href="./references#CD002947-fig-0062" title="">Analysis 20.1</a>) (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>). </p> <p>Results after 36 months of treatment were reported as changes from baseline rather than absolute scores (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). Because of the considerable difference in length of intervention, these results have not been meta‐analysed with the results from shorter duration studies. In this study of 399 participants there was no significant difference in pain reduction between the ASU and placebo groups (MD ‐0.66, 95% CI ‐7.39 to 6.07; <a href="./references#CD002947-fig-0052" title="">Analysis 19.2</a>). </p> <p>Results also differed somewhat according to pain location. <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a> reported greater improvement amongst participants with OA of the hip (MD ‐13.80, 95% CI ‐25.22 to ‐2.38) compared with those with OA of the knee (MD ‐7.10, 95% CI ‐14.45 to 0.25; <a href="./references#CD002947-fig-0053" title="">Analysis 19.3</a>), but in both subgroup analyses the CIs overlapped the midline indicating inconclusive results. </p> </section> <section id="CD002947-sec-0111"> <h6 class="title">Physical function</h6> <p>The Lequesne algofunctional index was used as a measure of overall physical function in all studies, but these data were extracted from three studies only (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>) because the other studies also reported function using outcome measures prioritised over Lequesne by the Cochrane Musculoskeletal Review Group. Again, results differed according to the length of intervention. Results after three months of treatment with either 300 mg or 600 mg Piascledine® daily favoured use of this intervention for improvements in function (300 mg: MD ‐1.80, 95% CI ‐2.68 to ‐0.92; <a href="./references#CD002947-fig-0056" title="">Analysis 19.6</a>; 600 mg: MD ‐1.30, 95% CI ‐2.38 to ‐0.22; <a href="./references#CD002947-fig-0063" title="">Analysis 20.2</a>). After 12 months of treatment with the 300 mg dose the MD for function was 0.10 (95% CI ‐0.78 to 0.98; <a href="./references#CD002947-fig-0056" title="">Analysis 19.6</a>). In one study functional disability was also measured with a 100 mm VAS; participants taking 300 mg Piascledine® daily reported improvement compared with participants taking placebo after six months of treatment (MD ‐13.20, 95% CI ‐20.00 to ‐6.40; <a href="./references#CD002947-fig-0054" title="">Analysis 19.4</a>) (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>). In another study the WOMAC functional scale was used as a key outcome after 36 months of treatment (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). Results in this study showed a MD of ‐1.00 (95% CI ‐7.14 to 5.14; <a href="./references#CD002947-fig-0055" title="">Analysis 19.5</a>). </p> <p>For the four studies that measured function at the end of treatment ASU 300 mg improved function (SMD ‐0.42, 95% CI ‐0.73 to ‐0.11; I<sup>2</sup> = 74%; <a href="./references#CD002947-fig-0057" title="">Analysis 19.7</a>). Re‐expressed, this translates to a mean reduction in functional disability of 7 mm (‐5 mm to ‐12 mm) on a 0 to 100 mm VAS disability scale (0 is best score). The high heterogeneity was accounted for by the result from <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>, the 12 month study which showed no effect of ASU 300 mg compared with placebo. </p> <p>Overall there was moderate evidence that three or six months of daily use of 300 mg of Piascledine® afforded statistically significant improvements in pain (100 mm VAS) and physical function (Lequesne algofunctional index) but these improvements did not persist in longer studies. Despite multiple studies with adequate sample sizes, the evidence was graded as moderate because allocation concealment was unreported (unclear) in each of the studies showing these improvements. In all other ways, these studies were well designed, and the consistent results across three studies were convincing. </p> </section> <section id="CD002947-sec-0112"> <h6 class="title">Joint space width</h6> <p>Joint space width was reported in only two of the six studies of ASU (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). In a study of 108 participants over 24 months between group differences were identified only when the participants were subgrouped into those with below median and above median joint space width (JSW) scores at baseline (<a href="./references#CD002947-fig-0061" title="">Analysis 19.11</a>). The below median JSW subgroup who consumed ASU showed significantly less reduction in joint space width (that is preservation of joint space) compared with participants who consumed placebo (MD ‐0.43, 95% CI ‐0.73 to ‐0.13), but changes in JSW from baseline were not significantly different between the placebo and intervention groups in the above median JSW subgroup (MD 0.16, 95% CI ‐0.31 to 0.63) (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>). After 36 months there was no significant difference in changes in JSW from baseline between the ASU and placebo groups (MD ‐0.03, 95% CI ‐0.22 to 0.16). </p> <p>In the longest term study participants were identified as 'progressors' if they showed a JSW reduction of greater than or equal to 0.5 mm over three years (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). In the ASU group 40.4% of participants were identified as progressors compared with 50.3% of participants in the placebo group. These data were insufficiently reported for extraction and re‐analysis. </p> </section> <section id="CD002947-sec-0113"> <h6 class="title">Adverse events</h6> <p>The number of participants who reported adverse events was reported per group in each study. In two studies more participants in the placebo groups reported adverse events (<a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>), and in the other two studies more participants in the 300 mg ASU groups reported adverse events (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>). When these data were meta‐analysed for the 300 mg dose of ASU there was a negligible difference in the odds of a participant in either the placebo or intervention group reporting an adverse event (ASU 267/521, placebo 270/529; RR 1.04, 95% CI 0.97 to 1.12; <a href="./references#CD002947-fig-0058" title="">Analysis 19.8</a>). These studies together constituted high level evidence that participants taking 300 mg of ASU daily experienced no greater odds of adverse events than did participants taking a placebo preparation. </p> </section> </section> <section id="CD002947-sec-0114"> <h5 class="title"><i>Phellondendron amurense</i> and <i>Citrus sinensis</i> (NP 06‐1) </h5> <p>The medicinal plant product NP 06‐1 is a mixture of <i>Phellondenron amurense</i> bark extract and <i>Citrus sinensis</i> peel extract. <a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a> and colleagues tested this product against placebo in a four group parallel study of 80 patients with OA of the knee over eight weeks. Two groups (one intervention and one control) included participants of normal body weight; the other two groups included overweight participants. Results in both the normal weight and overweight participants favoured NP 06‐1 over placebo for improvement of knee function as measured using the Lequesne algofunctional index (MD ‐3.82, 95% CI ‐7.05 to ‐0.59; <a href="./references#CD002947-fig-0069" title="">Analysis 22.1</a>). NP 06‐1 contains berberine, which may have contributed to weight loss in the overweight participants. </p> </section> <section id="CD002947-sec-0115"> <h5 class="title"><i>Uncaria guianensis</i> and <i>Lepidium meyenii</i> (Reparagen®) </h5> <p>Reparagen® is a mixture of aqueous bark extracts of <i>Uncaria guianensis</i> and <i>Lepidium meyenii.</i> It was tested against glucosamine sulphate in a two group parallel trial in 95 patients with OA of the knee (<a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>). Results from this trial suggested that Reparagen® was not significantly different from glucosamine sulphate for the remediation of OA pain. These results were insufficiently reported to allow data extraction for re‐analysis. The adverse event profile of Reparagen® appeared favourable (<a href="./references#CD002947-fig-0070" title="">Analysis 23.1</a>). </p> </section> <section id="CD002947-sec-0116"> <h5 class="title"><i>Zingiber officinale</i> and <i>Alpinia galanga</i> </h5> <p>A standardised extract (EV.EXT 77) of ginger (<i>Zingiber officinale)</i> and galangal (<i>Alpina officinale</i>, also known as Thai ginger) was compared with placebo in 261 people with OA of the knee (<a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a>). Significant improvements in favour of ginger were reported for pain (100 mm VAS) after walking 50 feet (MD ‐9.60, 95% CI ‐16.81 to ‐2.39, P = 0.009; <a href="./references#CD002947-fig-0071" title="">Analysis 24.1</a>). Also, improvements in all components of the WOMAC score were reported in favour of the ginger group over placebo. These improvements were statistically significant for the WOMAC stiffness score and the WOMAC total score but not for the pain and function domains of the WOMAC that were considered in this review. </p> </section> </section> <section id="CD002947-sec-0117"> <h4 class="title">Medicinal products from three or more plants</h4> <section id="CD002947-sec-0118"> <h5 class="title">Korean herbal mixture: SKI306X®</h5> <p>Two studies compared the Korean herbal preparation SKI306X® to placebo (<a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>) or diclofenac controls (<a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>). The earlier study (139 participants) was undertaken to determine the dose and safety profile of the intervention. The latter study (249 participants) was conducted to determine clinical efficacy. In the earlier study, daily doses of 200 mg, 400 mg, and 600 mg were compared with placebo and outcomes measured using a pain VAS and Lesquesne index. Meta‐analyses of these results (pooling doses) demonstrated consistent effects in favour of SKI306X® for reducing pain (MD ‐17.36, 95% CI ‐22.57 to ‐12.15; <a href="./references#CD002947-fig-0074" title="">Analysis 25.1</a>) and improving physical function (MD ‐2.73, 95% CI ‐3.71 to ‐1.74; <a href="./references#CD002947-fig-0075" title="">Analysis 25.2</a>). Effect sizes for these outcomes did not show a consistent linear relationship to dose. There was moderate evidence that, regardless of dose (600 mg, 1200 mg, 1800 mg), four weeks daily use of SKI306X® produced statistically significant improvements in the pain VAS and Lequesne algofunctional index compared to placebo. </p> <p>The number of participants who reported adverse events was reported per group, and more participants receiving 400 mg SKI306X® reported adverse events than did participants in any other group. When each of the intervention subgroups was compared with the placebo group the risk ratios (RR) differed between comparisons, but for each subgroup the risk of participants reporting adverse events was not clearly greater in the placebo or intervention groups. When these data were meta‐analysed, there was negligible difference in the risk of a participant in either the placebo or SKI306X group reporting an adverse event (overall SKI306X 14/70, placebo 15/69; RR 0.93, 95% CI 0.49 to 1.79; <a href="./references#CD002947-fig-0076" title="">Analysis 25.3</a>). </p> <p>In a follow‐up study, a daily dose of 600 mg SKI306X® was compared with 100 mg diclofenac. Results favoured diclofenac for the same outcome measures of 100 mm VAS for pain (MD 1.31, 95% CI ‐2.78 to 5.40; <a href="./references#CD002947-fig-0077" title="">Analysis 26.1</a>) and Lequesne's algofunctional index (MD 0.77, 95% CI 0.10 to 1.44; <a href="./references#CD002947-fig-0078" title="">Analysis 26.2</a>). Statistically significant changes in these measures were seen within both groups over time. Between‐group differences in physical function were statistically significant (P = 0.02) but differences in self‐reported pain were not (P = 0.53). This study constituted moderate evidence that daily use of 600 mg of SKI306X over four weeks produced improvements in pain (100 mm VAS) that were not statistically significantly different from 100 mg diclofenac. When compared against diclofenac, 600 mg SKI306X appeared to have a favourable adverse event risk profile (SKI306X 22/125, diclofenac 36/124; RR 0.61, 95% CI 0.38 to 0.97; <a href="./references#CD002947-fig-0079" title="">Analysis 26.3</a>). </p> </section> <section id="CD002947-sec-0119"> <h5 class="title">Phytodolor®N</h5> <p>Three studies compared Phytodolor®N (prepared from ash bark, aspen leaf, aspen bark, golden rod herb; for details see table) to placebo or active control (piroxicam) in 176 participants and reported results in favour of Phytodolor®N for reduced use of NSAIDs (diclofenac) and improvement in range of motion as measured by finger to ground distance in lumbar flexion (<a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>). Finger to ground distance is one of the methods used to quantify the Schober test (lumbar spine flexion in standing) and is a measure of physical function that is more commonly used in the assessment of people with low back pain than with OA. It is probably a meaningful measure of physical function in participants with OA of the lumbar spine but none of these studies were limited to participants with spinal OA. </p> <p>These studies could be viewed with some skepticism because they were undertaken by the manufacturer (Steigerwald Pharmaceuticals). One of these studies was a crossover design with intervention periods of seven days duration and used a dose of Phytodolor®N 33% greater than that used in the two other studies (<a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>). The other two studies were of parallel design, one of three weeks intervention with measures at weekly intervals (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>) and the other of four weeks intervention with measures at baseline and weeks one, two, and four (<a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>). Because doses of Phytodolor®N and some of the measures differed among trials, and because most of the data from these studies were reported as composite statistics (Chi<sup>2</sup>, P values), data could not be pooled for meta‐analyses. In this review all available mean data were reported for descriptive comparison (<a href="./references#CD002947-fig-0080" title="">Analysis 27.1</a>; <a href="./references#CD002947-fig-0081" title="">Analysis 27.2</a>; <a href="./references#CD002947-fig-0082" title="">Analysis 27.3</a>). For one study, group means and mean changes from baseline were calculated from frequency tables reported in the paper (<a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>). SDs could not be calculated from the data provided. </p> </section> <section id="CD002947-sec-0120"> <h5 class="title">Reumalex®</h5> <p>A self‐prescribed dose ("2 tablets at a time") of the herbal mixture Reumalex® was compared with placebo over two months of treatment. Both patients with rheumatoid arthritis and OA were recruited for this study. Separate data for the OA subgroup were provided for the primary outcomes of the AIMS 2 pain score and modified Ritchie index (<a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a>). At the end of the treatment period the mean reduction in AIMS 2 pain score was greater in the Reumalex® group (MD ‐0.89, 95% CI ‐1.73 to ‐0.05; <a href="./references#CD002947-fig-0083" title="">Analysis 28.1</a>). </p> <p>Four participants withdrew from each of the placebo and intervention groups due to side effects, and a further five (Reumalex® n = 2, placebo n = 3) complained of exacerbation of symptoms, but it was unclear how many of these participants were people with OA (RR 1.08, 95% CI 0.40 to 2.91; <a href="./references#CD002947-fig-0084" title="">Analysis 28.2</a>). </p> </section> <section id="CD002947-sec-0121"> <h5 class="title">Chinese herbal mixture: Duhuo Jisheng Wan</h5> <p>The Chinese herbal mixture Duhuo Jisheng Wan (DJW) was tested in a head‐to‐head comparison against diclofenac sodium over four weeks intervention (following one week run‐in) in patients with unilateral or bilateral OA of the knee (<a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>). Pain and stiffness across a range of conditions were measured using a battery of VAS. The Lequesne algofunctional index was used to capture joint function data. DJW appeared to be as effective as diclofenac in reducing joint pain (<a href="./references#CD002947-fig-0085" title="">Analysis 29.1</a>) and improving function (<a href="./references#CD002947-fig-0086" title="">Analysis 29.2</a>). Unfortunately, the risk of adverse events associated with DJW were also comparable to diclofenac (DJW 28/100, diclofenac 27/100; RR 1.04, 95% CI 0.66 to 1.63; <a href="./references#CD002947-fig-0087" title="">Analysis 29.3</a>). This toxicity profile, combined with the fact that DJW was administered as an 18 capsule per day dose, meant that it was unlikely to gain credence as a viable alternative to NSAIDs. </p> </section> <section id="CD002947-sec-0122"> <h5 class="title">Chinese herbal mixture: blood‐nourishing, hard‐softening</h5> <p>The Chinese mixture for blood‐nourishing and hard‐softening (BNHS) is an extract from the root of <i>Paeoniae alba, Gentiana macrophylla,</i> and <i>Glycyrrhiza</i> (species not stated, possibly <i>uralensis</i>). This product was tested against two active controls (western medicine control: glucosamine sulphate, Chinese medicine control: counter osteophyte herbal mixture) although the activity of the controls was not demonstrated in the paper and may be questionable. Although Cao and colleagues reported this investigation as one study it was really two distinct clinical trials run simultaneously over four weeks in different hospitals (<a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>). Sixty participants (30 at each site) were randomised to receive BNHS capsules and 30 participants were randomised to receive one of the two active control drugs. Data from the two trials were presented independently. </p> <p>When compared with glucosamine sulphate, BNHS capsules produced slightly superior improvements in VAS measures of pain on walking (MD ‐2.00, 95% CI ‐6.81 to 2.81; <a href="./references#CD002947-fig-0091" title="">Analysis 31.1</a>) but no mean improvements in WOMAC function (MD 0.00, 95% CI ‐2.53 to 2.53; <a href="./references#CD002947-fig-0092" title="">Analysis 31.2</a>). No adverse events were reported in this trial. </p> <p>In comparison with the alternate Chinese herbal mixture counter osteophytes, BNHS capsules produced a slight mean increase in pain on walking (MD 2.00, 95% CI ‐7.12 to 11.12; <a href="./references#CD002947-fig-0088" title="">Analysis 30.1</a>) and slight improvement in physical function (MD ‐2.00, 95% CI ‐7.57 to 3.57; <a href="./references#CD002947-fig-0089" title="">Analysis 30.2</a>). Four participants in this trial reported adverse events with use of BNHS. No participants reported adverse events associated with use of the alternative Chinese mixture. Because the sample size was small, and all adverse events occurred in one group, the risk of adverse events associated with BNHS appeared considerable in this trial (RNHS 4/30, Chinese control 0/30; RR 9.00, 95% CI 0.51 to 160.17; <a href="./references#CD002947-fig-0090" title="">Analysis 30.3</a>) but this result may be viewed with some skepticism considering that no participants in the other trial reported any adverse events with BNHS capsule use. </p> </section> <section id="CD002947-sec-0123"> <h5 class="title">Ayurvedic formulae</h5> <p>Three studies investigated seven Ayurvedic formulae. Two studies investigated formulae available as proprietary products: Antarth® (<a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>) and RA‐II® (<a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>). The third study compared five Ayurvedic formulae formed from combinations of five plant extracts (<a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>) (for details see table). Because none of the Ayurvedic formulae were the same these studies were not suitable for pooling and are described independently. </p> <section id="CD002947-sec-0124"> <h6 class="title">Ayurvedic formulae: A, B, C, D and E</h6> <p>Five Ayurvedic formulae formed from five herbal ingredients in varying combinations were tested against each other and against placebo in a six group trial over 16 weeks in 245 patients with OA of the knee (<a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a>). Pain was measured on a 0 to 10 VAS and physical function was measured using the Indian version of the WOMAC 0 to 4. Results of this exploratory study were not reported in full detail to allow extraction and re‐analysis. Generally results were equivocal on most outcomes. This study may have been underpowered to detect changes in a six group comparison (35 participants per group). The adverse event profile was noteworthy: participants who received formula D showed markedly greater odds of reporting adverse events (<a href="./references#CD002947-fig-0094" title="">Analysis 32.1</a>). </p> </section> <section id="CD002947-sec-0125"> <h6 class="title">Ayurvedic formula: Antarth</h6> <p>Antarth was compared against placebo in a two group parallel trial over 12 weeks in 90 patients with OA of the knee (<a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a>). Pain was measured on a 0 to 10 cm VAS, which we converted to a 0 to 100 mm scale during data extraction. Results slightly favoured Antarth over placebo for the reduction of pain in OA (<a href="./references#CD002947-fig-0095" title="">Analysis 33.1</a>) but should be interpreted with caution because this exploratory study may have been underpowdered to detect clinical effects of Antarth. </p> </section> <section id="CD002947-sec-0126"> <h6 class="title">Ayurvedic formula: RA‐11</h6> <p>RA‐11 was tested against placebo in a two group parallel trial over 32 weeks in 90 people with OA of the knee (<a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a>). Pain, stiffness, and physical function were measured using the Indian modification of the WOMAC 0 to 4. Because the study was fully powered, with 45 participants in each group, and rescue medication was not permitted this study was well designed to capture data on the pain reducing effects of RA‐11. An ITT model was applied to the analyses and missing data were replaced by the last observation carried forward method. Three participants were removed from the trial by the investigators due to "efficacy failure". Forcibly withdrawing participants with worsening pain and carrying forward data from the last observation of these participants may have somewhat exaggerated the effects of of RA‐11 on pain. Results favoured RA‐11 over placebo for improvements in pain (<a href="./references#CD002947-fig-0096" title="">Analysis 34.1</a>) and function (<a href="./references#CD002947-fig-0097" title="">Analysis 34.2</a>). </p> </section> <section id="CD002947-sec-0127"> <h6 class="title">Ayurvedic formulae: SGC and SGCG</h6> <p>Ayurvedic formulae SGC and SGCG were tested against glucosamine sulphate and celecoxib in a four parallel group trial over 24 weeks (<a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>). On measures of pain (VAS 0 to 100), function (WOMAC function), and with regard to participants reporting adverse events, both Auryvedic formulae were comparable to both glucosamine sulphate and celecoxib. </p> </section> </section> <section id="CD002947-sec-0128"> <h5 class="title">Japanese herbal mixture: Boiogito</h5> <p>The Japanese herbal mixture Boiogito was compared head‐to‐head with loxoprofen for the management of knee pain and effusion in a small (n = 50) exploratory study over 12 weeks. Participants who took Boiogito reported slightly better Knee Society Rating System knee scores, including less joint effusion, than participants who took loxoprofen, but the results did not differ significantly between groups (MD ‐1.30, 95% CI ‐8.90 to 6.30; <a href="./references#CD002947-fig-0111" title="">Analysis 39.1</a>). On the other hand participants who took loxoprofen reported slightly greater functional capacity on the stair climbing component of the Knee Society Rating System (MD 3.60, 95% CI 0.51 to 6.69; <a href="./references#CD002947-fig-0112" title="">Analysis 39.2</a>) and no adverse events. One participant using Boiogito reported an adverse event (Boiogito 1/24, loxoprofen 0/23; RR 2.88, 95% CI 0.12 to 67.29; <a href="./references#CD002947-fig-0113" title="">Analysis 39.3</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002947-sec-0129" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002947-sec-0129"></div> <section id="CD002947-sec-0130"> <h3 class="title" id="CD002947-sec-0130">Summary of main results</h3> <p>Thirty‐one medicinal plant products from single plant parts (<i>Boswellia serrata</i> , <i>Curcuma domestica Derris scandens</i> , <i>Garcinia kola</i> , <i>Harpagophytum procumbens</i> , <i>Petiveria alliacea</i> , <i>Pinus pinaster</i> , <i>Rosa canina lito</i> , <i>Salix pupurea+daphnoides, Uncaria guianensis</i> , <i>Vitellaria paradoxa</i> and <i>Zingiber officinale</i> ); five mixtures of two herbal preparations (<i>Boswellia carteri</i> and <i>Curcuma longa</i> , <i>Persea gratissma</i> and <i>Glycine max</i> , <i>Phellondenron amurense</i> and <i>Citrus sinensis</i> , <i>Uncaria guianensis</i> and<i>Lepidium meyenii</i> , and <i>Zingiber officinalis</i> and <i>Alpinia galanga</i> ) and the polyherbal preparations Phytodolor®N, Reumalex®, SKI306X®, Chinese herbal mixtures Duhuo Jisheng Wan and blood‐nourishing, hard‐softening, Ayurvedic formulae RA‐11, A, B, C, D, E, and Antarth, and Japanese herbal mixture Boiogito were compared in 47 studies against placebo (n = 38), active control (n = 19), and no intervention (n = 1). Due to the differing study protocols (different outcome measures and times of outcome assessments) and medicinal plant products employed, pooling of data was only possible for the proprietary products avocado‐soybean unsaponifiables (ASU) and <i>Boswellia serrata</i>. </p> <p>Despite the great number of clinical trials carried out, reliable data could only be achieved for the ASU product Piascledine®. The pooled data of three studies with a confirmatory study design showed OA improvements, but another definitive study over two years failed to demonstrate effectiveness except in a subgroup of people with less severe complaints. The most recent comparison of Piascledine® and chondroitin sulphate showed that the ASU product was not inferior to the slow‐acting anti‐arthritic substance for which effectiveness within six months is controversial (<a href="./references#CD002947-bbs2-0138" title="LeeYH , WooJH , ChoiSJ , JiJD , SongGG . Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30(3):357‐63. ">Lee 2010</a>; <a href="./references#CD002947-bbs2-0148" title="ReichenbachS , SterchiR , SchererM , TrelleS , BürgiE , BürgiU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146(8):580‐90. ">Reichenbach 2007</a>; <a href="./references#CD002947-bbs2-0164" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , ReichenbachS , TrelleS . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ2010;341:c4675. [DOI: 10.1136/bmj.c4675] ">Wandel 2010</a>). Also, the most recent placebo‐controlled study lasting three years failed to show any benefit for ASU in clinical outcome measures including the WOMAC index. The study was planned to confirm slower radiographic progression in symptomatic hip OA (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>) but only 20% fewer progressors were identified in the post hoc analysis, with progressors defined as patients with joint width space loss &gt; ‐0.5 mm. </p> <p>Of the five studies that investigated three different extracts from <i>Boswellia serrata</i> gum resin, pooled data from two studies indicated OA improvement for the <i>Boswellia</i> product 5‐Loxin®. The remaining 38 studies showed unproven benefit in the alleviation of OA for the herbal medicinal products investigated, which originated from Africa, Asia, Europe, India, and the Americas. Serious adverse events were not reported for any of the medicinal plant products. </p> </section> <section id="CD002947-sec-0131"> <h3 class="title" id="CD002947-sec-0131">Overall completeness and applicability of evidence</h3> <p>Evidence from studies that recruited patients with diagnoses of OA confirmed according to ACR or EULAR criteria may be directly applied to clinical practice. In some studies diagnostic criteria applied at recruitment were not labelled as ACR or EULAR criteria but were described in sufficient detail to be confident that they were fully consistent with the recommendations of these authorities. In six studies, however, ACR and EULAR criteria were not fully considered and these studies have been downgraded to unclear risk of selection bias (<a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>; <a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>; <a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a>; <a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a>; <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>; <a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>). The applicability of evidence from these studies to clinical practice is also unclear. In another five studies selection was so broad as to almost certainly have included recruitment of participants with conditions other than OA (<a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a>; <a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>; <a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a>; <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>; <a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>). These studies are classified as having high risk of bias and evidence from these studies may be of questionable use in clinical practice. </p> <p>The WHO recommends that the manufacturing procedure of medicinal plant products should be described in detail (for example if other substances are added during manufacture in order to adjust the plant preparation to a certain level of active or characteristic constituents or for any other purpose). A method for identification and, where possible, assay of the plant preparation should be added. If identification of the active principle is not possible it should be sufficient to identify a characteristic ingredient or mixture of ingredients (for example the 'chromatographic fingerprint') to ensure consistent quality of the preparation in order to be able to re‐do the study with an essentially similar product (having a comparable active principle, see below). </p> <p>The active principle of a medicinal plant product is the sum of all ingredients that produce the medicinal action. The active principle has not been fully been identified for any of the anti‐inflammatory acting herbal medicinal products. Co‐active ingredients include flavonoids (<i>Acacia catechu, Citrus sinensis</i> , <i>Curcuma</i> species,<i>Derris scandens, Garcinia kola</i> ,<i>Harpagophytum procumbens</i> , <i>Petiveria alliacea</i> , Phytodolor®N<i>, Rosa canina</i> , <i>Salix</i> species, <i>Scutellaria baicalensis</i> ,<i>Zingiber</i> species), unsaturated fatty acids (Piascledine®, <i>Ricinus officinalis</i> , <i>Rosa canina</i> , SKI306X®, <i>Vitellaria paradoxa</i> ), alkaloids (<i>Acacia catechu</i> (tryptamine derivatives), <i>Garcinia kola</i> ,<i>Lepidium meyenii</i> (lepidiline), <i>Phellondenron amurense</i> (berberine), <i>Symphytum officinale, Uncaria</i> species) and in particular polyphenols (<i>Acacia catechu</i> , <i>Citrus sinensis</i> ,<i>Pines pinaster</i> ,<i>Rosa canina</i> ), iridoid glycosides calculated as harpagoside (<i>Harpagophytum procumbens</i> ), gingerols (<i>Zingiber</i> species), boswellic acids (<i>Boswellia</i> species), curcurminoids (<i>Curcuma</i> longa), or mustard glycosides (<i>Lepidium meyenii</i>). Mixtures of two or more herbal preparations form a new entity with their characteristic active principle being different from that of the single medicinal plant products, as are the actions and adverse events. If herbal extracts are combined the superiority of the mixture over the individual herbal preparation has to be established in vitro, in animal experiments, and in human pharmacological studies in order to demonstrate the superior effect and the safety. </p> <p>The minimum information given for a medicinal plant product in an article should include the plant part, the brand name (if the preparation has not been solely prepared for the study), the excipient added in the case of extracts and the drug extract ratio if no crude plant material is used. The daily dosage of the 'native' plant preparation should be stated otherwise the extract dose may also contain additives (<a href="./references#CD002947-bbs2-0114" title="ChrubasikS ,  SporerF ,  WinkM . Active ingredients in medicines from Harpagophytum procumbens [Zum Wirkstoffgehalt in Arzneimitteln aus Harpagophytum procumbens]. Forschende Komplementarmedizin1996;3:57‐63. ">Chrubasik 1996</a>). Although not requested by regulatory authorities, it is desirable to know the content of at least one characteristic marker substance (if possibly a co‐active ingredient). Only few studies provided all this information (<a href="#CD002947-tbl-0009">Table 1</a>). The results of studies with insufficient declared characteristics are only attributable to the particular product used in the study and cannot be transferred to other medicinal products from this plant material unless bioequivalence of the products has been demonstrated (<a href="./references#CD002947-bbs2-0119" title="ChrubasikS , RoufogalisB . Bioequivalence of herbal medicines. New Zealand Journal of Pharmacy2003;53:39‐44. ">Chrubasik 2003</a>). </p> <p>Salicin, the characteristic ingredient of <i>Salix</i> species, is an ineffective pro‐drug. However, during absorption salicin is metabolized into co‐active salicylic acid derivatives. Surprisingly, the amount of salicylic acid produced from a daily dose of <i>Salix</i> bark extract containing 240 mg of salicin corresponds to an aspirin dose of only 100 mg, a cardioprotective rather than an anti‐inflammatory dose (<a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>). This <i>Salix</i> extract dose, however, cannot be used to replace aspirin as a blood thinner because it has been shown not to have a major impact on blood clotting (<a href="./references#CD002947-bbs2-0136" title="KrivoyN , PavlotzkyE , ChrubasikS , EisenbergE , BrooksG . Effect of Salicis cortex extract on human platelet aggregation. Planta Medica2001;67:209‐13. ">Krivoy 2001</a>). It is implausible that the regulatory authority EMA has restricted the use of willow bark preparations to four weeks (<a href="./references#CD002947-bbs2-0163" title="VlachojannisC , MagoraF , ChrubasikS . Pro and contra duration restriction of willow bark treatment. Phytotherapy Research2014;28(1):148‐9. ">Vlachojannis 2013</a>) in light of the fact that NSAIDs in current use, with a higher risk benefit ratio than willow extract, are used for longer treatment durations, for example up to 138 weeks (<a href="./references#CD002947-bbs2-0147" title="ReginsterJY , MalmstromK , MehtaA , BergmanG , KoAT , CurtisSP , ReicinAS . Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138‐week randomised studies of patients with osteoarthritis. Annals of the Rheumatic Diseases2007;66:945‐51. ">Reginister 2007</a>). Acute toxicity studies in rats could not determine a lethal dose of willow bark extract even in doses 200 times the experimental level (<a href="./references#CD002947-bbs2-0128" title="GlinkoA . Pharmacological properties of a standardized extract from Willow Bark (Cortex salicis) [treatise]. Chair of Pharmacology and Toxicology. Pomeranian Academy of Medicine. Szczecin, 1998. ">Glinko 1998</a>). Data on chronic toxicity are still lacking (<a href="./references#CD002947-bbs2-0124" title="European Medicines Agency (EMA). Assessment report on salicis cortex (willow bark) and herbal preparation(s) thereof with well‐established use and traditional use. EMA, London, 20092009. ">EMA 2009</a>; <a href="./references#CD002947-bbs2-0125" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003. ">ESCOP 2003</a>;). Possible interactions with natural or synthetic blood thinners need to be elucidated, especially if higher doses of willow bark extract (with 360 mg or 480 mg salicin per day) are employed. A life‐threatening anaphylactic reaction was observed in a patient with a history of allergy to salicylates (<a href="./references#CD002947-bbs2-0107" title="BoullataJI , McDonnellPJ , OlivaCD . Anaphylactic reaction to a dietary supplement containing willow bark. Annals of Pharmacotherapy2003;37:832‐5. ">Boullata 2003</a>). Known salicylate allergy is therefore a contra‐indication for the use of willow bark preparations. </p> <p>The clinical studies investigating medicinal products from <i>Harpagophytum procumbens</i> included a cryoground powder, an aqueous and an ethanolic extract. The extracts contained only half the amount of harpagoside in the daily dosage than what would be expected after complete extraction and if no additives were added. The ethanolic extracts were incompletely extracted (<a href="./references#CD002947-bbs2-0156" title="SporerF , ChrubasikS . Preparations from Devil's claw (Harpagophytum procumbens) [Präparate aus der Teufelskralle (Harpagophytum procumbens)]. Zeitschrift für Phytotherapie1999;20:235‐6. ">Sporer 1999</a>) and the aqueous extract contained additives (<a href="./references#CD002947-bbs2-0114" title="ChrubasikS ,  SporerF ,  WinkM . Active ingredients in medicines from Harpagophytum procumbens [Zum Wirkstoffgehalt in Arzneimitteln aus Harpagophytum procumbens]. Forschende Komplementarmedizin1996;3:57‐63. ">Chrubasik 1996</a>). According to the European Pharmacopoeia it is required that the starting material for <i>Harpagophytum</i> products contains a minimum of 1.2% of harpagoside. Since the daily dose of extracts should be prepared from 4.5 to 9 g of crude plant material, the daily dosage would provide 50 to 100 mg of harpagoside or more (European Medicines Agency (EMA) monographs). Thus, of the four studies investigating <i>Harpagophytum</i> products only one has used an appropriate dose. </p> <p>In general, the daily dosages of medicinal products are based on information from monographs or textbooks and are not the result of dose‐finding studies. It seems likely that an increase in dose might improve the clinical effect. This was shown for aqueous <i>Harpagophytum</i> and ethanolic <i>Salix</i> extracts in a patient population suffering from acute exacerbations of chronic low back pain (<a href="./references#CD002947-bbs2-0115" title="ChrubasikS , JunckH , BreitschwerdtH , ConradtC , ZappeH . Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: A randomized, placebo‐controlled, double‐blind study. European Journal of Anaesthesiology1999;16:118‐29. ">Chrubasik 1999</a>; <a href="./references#CD002947-bbs2-0116" title="ChrubasikS , EisenbergE , BalanE , WeinbergerT , LuzzatiR , ConradtC . Treatment of low back pain exacerbations with willow bark extract: A randomized double‐blind study. American Journal of Medicine2000;109:9‐14. ">Chrubasik 2000</a>). However, for some medicinal products a ceiling effect was demonstrated. For example, a 600 mg dose of Piascledine® per day was not more effective than a half dose (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>), and 600 mg or 400 mg of the herbal mixture SKI306X® was not more effective than 200 mg per day (<a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>), or 250 mg of the proprietary <i>Boswellia serrata</i> extract 5‐Loxin® was not more effective than 100 mg per day (<a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>). The first medical report on the use of dried and powdered willow bark dates back to 1763 (<a href="./references#CD002947-bbs2-0158" title="StoneE . An account of the success of the bark of the willow in the cure of agues. Philosophy. Trans: Royal Society London1763;53:195‐200. ">Stone 1763</a>). The empirically chosen daily dose (up to 24 g) might have contained up to 1000 mg of salicin as the crude plant material generally contains about 4% salicin. Higher doses than that used in the study by <a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a> may reliably improve OA complaints. Future studies are required to identify the optimum daily doses of medicinal products. </p> <p>Unsaturated fatty acids contribute to the anti‐inflammatory effect of some medicinal plant products (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>; <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>; <a href="./references#CD002947-bbs2-0108" title="CameronM , GagnierJJ , ChrubasikS . Herbal therapy for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD002948] ">Cameron 2011</a>; <a href="./references#CD002947-bbs2-0133" title="JägerAK , EldeenIM , vanStadenJ . COX‐1 and ‐2 activity of rose hip. Phytotherapy Research2007;21(12):1251‐2. ">Jäger 2007</a>; <a href="./references#CD002947-bbs2-0134" title="JägerAK , PetersenKN , ThomasenG , ChristensenSB . Isolation of linoleic and alpha‐linolenic acids as COX‐1 and ‐2 inhibitors in rose hip. Phytotherapy Research2008;22(7):982‐4. ">Jäger 2008</a>; <a href="./references#CD002947-bbs2-0165" title="WenzigEM , WidowitzU , KunertO , ChrubasikS , BucarF , KnauderE , BauerR . Phytochemical composition and in vitro pharmacological activity of two rose hip (Rosa canina L.) preparations. Phytomedicine2008;15(10):826‐35. ">Wenzig 2008</a>). It seems likely that castor seed oil may improve OA complaints. Because a dose‐finding study has not been undertaken, and high doses of castor oil produce unpleasant laxative effects, we question whether higher doses of castor oil are likely to be tolerated by people with OA. </p> <p>The net benefit of an intervention may be defined as the magnitude of benefit minus the magnitude of harm (<a href="./references#CD002947-bbs2-0132" title="ICH . International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Synopsis of ICH guidelines and topics. Geneva, Switzerland: Author, 2004. ">ICH 2004</a>). Benefit and harm are not always measurable in standardised effect size units, complicating the calculation of net effect. However, the point remains that for each of the herbal medicines where clinical benefit is reported, clinical harm (adverse events, toxicity) must be considered in making an overall judgement of the usefulness of the intervention. Among the non‐herbal medications commonly used to treat OA, NSAIDs in particular are associated with frequent and sometimes severe side effects (<a href="./references#CD002947-bbs2-0127" title="GabrielSE , JaakkimainenL , BombardierC . Risk for serious gastrointestinal complications related to use of nonsteroidal anti‐inflammatory drugs. A meta‐analysis. Annals of Internal Medicine1991;115:787‐96. ">Gabriel 1991</a>), particularly gastrointestinal complications including dyspepsia, perforations, ulcers, and bleeds (<a href="./references#CD002947-bbs2-0142" title="OfmanJJ , MacLeanCH , StrausWL , MortonSC , BergerML , RothEA , ShekelleP . A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. Journal of Rheumatology2002;29:804‐12. ">Ofman 2002</a>; <a href="./references#CD002947-bbs2-0143" title="OfmanJJ , MacleanCH , StrausWL , MortonSC , BergerML , RothEA , ShekellePG . Meta‐analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis &amp; Rheumatism2003;49:508‐18. ">Ofman 2003</a>), which add considerable cost to the usual care of people with OA (<a href="./references#CD002947-bbs2-0155" title="SmalleyWE , GriffinMR , FoughtRL , RayWA . Excess costs from gastrointestinal disease associated with nonsteroidal anti‐inflammatory drugs. Journal of General Internal Medicine1996;11:461‐9. ">Smalley 1996</a>). In theory, ginger and <i>Curcuma</i> products might go along with an increased risk of stomach bleeding, however this has not been sufficiently evaluated (www.ema.europa.eu/docs/en_GB/document_library/Herbal_‐_Community_herbal_monograph/2011/09/WC500112680.pdf'; www.ema.europa.eu/docs/en_GB/document_library/Herbal_‐_Community_herbal_monograph/2010/02/WC500070703.pdf). In fact, no serious adverse events were reported with any herbal intervention in the included studies. It appears that the benefit risk ratio of medicinal plant products is superior to that of NSAIDs. A recent pharmacovigilance analysis revealed 117 reported adverse events, mostly cutaneous, hepatic and gastrointestinal disorders, associated with the intake of Piascledine®. Although the incidence of adverse events seems to be 'very rare', in light of the fact that the product is widely prescribed in France there is concern regarding possible under‐reporting of adverse events (<a href="./references#CD002947-bbs2-0144" title="OlivierP , MontastrucJL . Réseau français des centres régionaux de pharmacovigilance [Post‐marketing safety profile of avocado‐soybean unsaponifiables]. Presse Medicale2010;39(10):e211‐6. ">Olivier 2010</a>) (www.drugcite.com/?q=PIASCLEDINE&amp;s=&amp;a=). </p> <p>A systematic review of adverse events is available for <i>Harpagophytum procumbens</i> that includes 28 clinical studies (mostly observational) reporting on 6892 patients who consumed <i>Harpagophytum</i> extract for up to one year. In none of the double blind studies was the incidence of adverse events higher during treatment with <i>Harpagophytum</i> than during placebo treatment. Minor adverse events (AE) were described across 20 studies in 138 of 4274 <i>Harpagophytum</i> consumers. This corresponds to an overall adverse event rate of around 3% for <i>Harpagophytum</i> preparations with a maximum of 100 mg harpagoside as the daily dosage (<a href="./references#CD002947-bbs2-0161" title="VlachojannisJE , RoufogalisBD , ChrubasikS . Systematic review on the safety of Harpagophytum preparations for osteoarthritic and low back pain. Phytotherapy Research2008;22(2):149‐52. [DOI: 10.1002/ptr.2314] ">Vlachojannis 2008</a>). Some of the adverse events, particularly minor gastrointestinal complaints and allergies, were probably related to <i>Harpagophytum</i>. Three studies on preclinical toxicity indicated very low acute toxicity (<a href="./references#CD002947-bbs2-0125" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003. ">ESCOP 2003</a>). Data on chronic toxicity, including mutagenicity, carcinogenicity, teratogenicity, and embryogenicity, were not found (<a href="./references#CD002947-bbs2-0125" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003. ">ESCOP 2003</a>). For most medicinal plant products preclinical data are not available, and only some of them report on their AE profiles (<a href="./references#CD002947-bbs2-0104" title="BaschE , BoonH , Davies‐HeeremaT , FoppoI , HashmiS , HasskarlJ , et al. Boswellia: an evidence‐based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy2004;4(3):63‐83. ">Basch 2004</a>; <a href="./references#CD002947-bbs2-0120" title="ChrubasikS , PittlerMH , RoufogalisBD . Zingiberis rhizoma: a comprehensive review on the ginger effect and efficacy profiles. Phytomedicine2005;12(9):684‐701. ">Chrubasik 2005</a>; <a href="./references#CD002947-bbs2-0125" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. New York: Thieme‐Verlag Stuttgart, 2003. ">ESCOP 2003</a>; <a href="./references#CD002947-bbs2-0126" title="European Scientific Cooperative on Phytotherapy (Eds). ESCOP Monographs. Vol. Supplement, Stuttgart, New York: Thieme Press, 2009. ">ESCOP 2009</a>; <a href="./references#CD002947-bbs2-0135" title="KrishnarajuAV , SundararajuD , VamsikrishnaU , SuryachandraR , MachirajuG , SenguptaK , TrimurtuluG . Safety and toxicological evaluation of Aflapin: a novel Boswellia‐derived anti‐inflammatory product. Toxicology Mechanisms and Methods2010;20(9):556‐63. ">Krishnaraju 2010</a>; <a href="./references#CD002947-bbs2-0152" title="SchooneesA , VisserJ , MusekiwaA , VolminkJ . Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008294.pub4] ">Schoonees 2012</a>; <a href="./references#CD002947-bbs2-0157" title="StohsSJ , PreussHG , SharaM . The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p‐synephrine. Phytotherapy Research2011;25(10):1421‐8. [DOI: 10.1002/ptr.3490] ">Stohs 2011</a>; <a href="./references#CD002947-bbs2-0159" title="ValerioLGJr , GonzalesGF . Toxicological aspects of the South American herbs cat's claw (Uncaria tomentosa) and Maca (Lepidium meyenii) : a critical synopsis. Toxicology Review2005;24(1):11‐35. ">Valerio 2005</a>; www.herbal‐ahp.org, http://apps.who.int/medicinedocs/en/d/Js2200e/). It is thus recommended to do safety pharmacological studies according to published guidelines (www.fda.gov/cder/guidance/index.htm, www.emea.europa.eu/pdfs/human/ich/030095en.pdf) for the individual medicinal plant products. If a carcinogenic effect is assumed, carcinogenicity studies are also mandatory (www.ich.org/LOB/media/MEDIA489.pdf). If the guidelines of good manufacturing practice including those for the starting material (www.api‐conference.org/pa4.cgi?src=eca_news_data.htm&amp;nr=488&amp;show=daten/news/GMP_News_488.htm&amp;id=S11510781142) are considered, contamination of medicinal products with other herbal medicines, pesticides, heavy metals, or drugs can be ruled out. </p> <p>The adverse effect quota and profile for Phytodolor®N appear to be better than for NSAIDs. Gastrointestinal complaints were most frequently reported (2.6%), and occasionally allergic skin reactions have occurred. Some adverse effects are partly due to the alcohol content of Phytodolor®N (45.6% vol, 0.7 g per 40 drops), which poses a health risk to children and to adults with liver disease, alcoholism, epilepsy, or brain damage. Caution is advised during pregnancy or lactation and for drivers and individuals who operate machines, even though no impairment of consciousness or reactivity is expected to occur with 0.7 g of alcohol per dose. Studies on mutagenicity, teratogenicity, and toxicity in the parent animals and their progeny gave no evidence for any toxic effects arising from the intake of the combination during pregnancy and the lactation period (<a href="./references#CD002947-bbs2-0129" title="GundermannKJ . Phytodolor solution. Clinical expert report. Darmstadt, Germany: Steigerwald, 2001. ">Gundermann 2001</a>). </p> </section> <section id="CD002947-sec-0132"> <h3 class="title" id="CD002947-sec-0132">Quality of the evidence</h3> <p>Generally the studies included in this review are of lower quality than desired, but we stress that these studies represent the current best quality evidence for the effectiveness of oral medicinal plant interventions in the treatment of OA. Poorer quality studies with non‐randomised, uncontrolled designs were excluded (for example <a href="./references#CD002947-bbs2-0063" title="GuyaderM . Herbal anti‐rheumatic therapies: A longitudinal, pharmacological and clinical study of the treatment of 50 osteoarthritic patients with Harpagophytum procumbens (Devil's Claw) following hospital intervention [Les plantes anti‐rhumatismales. Etude historique et pharmacologique, et etude clinique du nebulisat d'harpagophytum procumbens D.C. chez 50 patients arthrosiques suivis en service hospitalier]. Thesis for the award of the degree Doctor of Medicine.1984. ">Guyader 1984</a>; <a href="./references#CD002947-bbs2-0076" title="MyersS , O'ConnorJ , FittonJH , BrooksL , RolfeM , ConnellanP , et al. A combined phase I and phase II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. Biologics: Targets &amp; Therapy2010;4:33‐44. ">Myers 2010</a>; <a href="./references#CD002947-bbs2-0080" title="RosenPD , LiakeasGP , SadigimE , BiedAM . A pilot study assessing the short term use of Tanacetum parthenium for treatment of osteoarthritis. Integrative Medicine2013;12(3):31‐6. ">Rosen 2013</a>). We excluded clinical trials of products that are not strictly herbal so as to avoid misinterpretation of the results of these studies in herbal medicine practice (for example <a href="./references#CD002947-bbs2-0051" title="BelcaroG , CesaroneMR , DugallM , PellegriniL , LeddaA , GrossiMG , et al. Efficacy and safety of Meriva®, a curcumin‐phosphatidylcholine complex, during extended administration in osteoarthritis patients. Alternative Medicine Review2010;15(4):337‐44. ">Belcaro 2010</a>; <a href="./references#CD002947-bbs2-0065" title="JacquetA , GirodetP , ParienteA , ForestK , Mallet , MooreN . Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double‐blind placebo‐controlled clinical trial. Arthritis Research &amp; Therapy2009;11:R192. [DOI: 10.1186/ar2891] ">Jacquet 2009</a>; <a href="./references#CD002947-bbs2-0068" title="KulkarniRR , PatkiPS , JogVP , GandageSG , PatwardhanB . Treatment of osteoarthritis with a herbomineral formulation: A double‐blind, placebo‐controlled, cross‐over study. Journal of Ethnopharmacology1991;33:91‐5. ">Kulkarni 1991</a>; <a href="./references#CD002947-bbs2-0070" title="LevyRM , SaikovskyR , ShmidtE , KhokhlovA , BurnettBP . Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short‐term randomized, double‐blind pilot study. Nutrition Research2009;29:298‐304. ">Levy 2009</a>). We note that more recent studies typically have higher quality reporting than older studies, and commend researchers in this field for the improvement of research design and reporting. </p> <p>There is moderate‐quality evidence that in people with OA, <i>Boswellia serrata</i> slightly improved pain and function. The evidence was downgraded to moderate as there is a potential for imprecision due to the small number of participants contributing to these outcomes. There is moderate‐quality evidence that avocado‐soybean unsaponifiables (ASU) probably improved pain and function slightly but may not preserve joint space. Evidence was downgraded due to inconsistency across results, or imprecision. Further research may change our estimates of the size of effects, and the precision around estimates. </p> <p>We are uncertain whether other oral herbal products improve OA pain or function, or slow progression of joint structure damage because the evidence available is limited to single studies only, or studies providing data that cannot be pooled. Some of these studies are of low to very low quality, and some important outcome measures (eg: quality of life, joint space width) were omitted. </p> </section> <section id="CD002947-sec-0133"> <h3 class="title" id="CD002947-sec-0133">Potential biases in the review process</h3> <p>Incomplete reporting in some studies may have led us to undervalue the evidence of effectiveness, because we made strict judgements of methodological quality on the basis of reporting. On the other hand, incomplete reporting may be indicative of bias in studies such that incompletely reported trials may overestimate the treatment effects, thus we stand by our strict, conservative judgements (<a href="./references#CD002947-bbs2-0131" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies.. Higgins JPT, Green S (editors). The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). For example, in countries in which the ICH guidelines are implemented in law, Human Research Ethics Committees would approve a clinical trial protocol only if it accords with the ICH good clinical practice consolidated guidelines (<a href="./references#CD002947-bbs2-0132" title="ICH . International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Synopsis of ICH guidelines and topics. Geneva, Switzerland: Author, 2004. ">ICH 2004</a>). Randomisation, blinding, masking of outcome assessment, and allocation concealment will probably have been adequately conducted even if the study was simply reported as "randomised and double‐blind". To allow full and accurate assessment of future studies, we recommend that authors conform to the Consolidated Standards of Reporting Trials (CONSORT) (<a href="./references#CD002947-bbs2-0105" title="BeggC , ChoM , EastwoodS , HoretonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials. The CONSORT Statement. JAMA1996;276(8):637‐9. ">Begg 1996</a>; <a href="./references#CD002947-bbs2-0141" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: Revised recommendations for improving the quality of reports of parallel‐group randomized trials. Annals of Internal Medicine2001;134:657‐62. ">Moher 2001</a>).         </p> <p>Studies fail for a variety of reasons and, although venturing into conjecture, we consider that groups may have differed at baseline according to some parameters that were not measured, but may have influenced the primary outcome measures. For example, baseline data in the <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a> study did not include details of the quantity of NSAIDs consumed or use of opioids for pain. Neither was anything reported about the mood state of the participants, which may also have influenced pain measures. Joint space loss was significantly reduced in patients with mild OA possibly indicating that early use of ASU may act preventively, but this suggestion needs to be confirmed in a follow‐up study. Concerns regarding baseline differences between groups are amplified for studies with inadequate or unclear methods of randomisation and allocation concealment. </p> <p>Many studies, although well designed, were probably underpowered and the lack of evidence of effect may be due to Type II error. Trends to effectiveness may be suggested from underpowered studies if improvements can be calculated and reported as effect sizes. </p> <p>Glucosamine sulphate and chondroitin sulphate were used as active controls in some studies (<a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a>; <a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a>; <a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a>; <a href="./references#CD002947-bbs2-0036" title="PavelkaK , CosteP , GéherP , KrejciG . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659‐70. [DOI: 10.1007/s10067‐010‐1384‐8] ">Pavelka 2010</a>) but we question this assumption. Several recent systematic reviews suggest that chondroitin sulphate has negligible effect on OA pain (<a href="./references#CD002947-bbs2-0148" title="ReichenbachS , SterchiR , SchererM , TrelleS , BürgiE , BürgiU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146(8):580‐90. ">Reichenbach 2007</a>; <a href="./references#CD002947-bbs2-0164" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , ReichenbachS , TrelleS . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ2010;341:c4675. [DOI: 10.1136/bmj.c4675] ">Wandel 2010</a>) and a small but significant protective effect against joint space narrowing (<a href="./references#CD002947-bbs2-0138" title="LeeYH , WooJH , ChoiSJ , JiJD , SongGG . Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30(3):357‐63. ">Lee 2010</a>). Glucosamine sulphate does not act on pain pathways or mediators. Glucosamine is an amino acid that may enhance cartilage repair and, due to this reparative process, pain may reduce in people with OA but typically these changes take six to 12 weeks to occur and effect sizes are not large (<a href="./references#CD002947-bbs2-0138" title="LeeYH , WooJH , ChoiSJ , JiJD , SongGG . Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30(3):357‐63. ">Lee 2010</a>; <a href="./references#CD002947-bbs2-0148" title="ReichenbachS , SterchiR , SchererM , TrelleS , BürgiE , BürgiU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146(8):580‐90. ">Reichenbach 2007</a>). In a meta‐analysis of 10 large randomised controlled trials of glucosamine, chondroitin, or the two in combination on joint pain and on radiological progression of disease in OA of the hip or knee Wandel and colleagues determined that glucosamine use produced a mean reduction in pain of 4 mm on a 100 mm VAS, an effect that did not exceed a minimum clinically important difference (<a href="./references#CD002947-bbs2-0164" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , ReichenbachS , TrelleS . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ2010;341:c4675. [DOI: 10.1136/bmj.c4675] ">Wandel 2010</a>). </p> <p>We attempted to minimise bias in this review through transparent and thorough methods. We adopted a broad search strategy without language restrictions. We attempted to include grey literature by seeking manufacturers' reports, theses and unpublished reports as well as searching electronic databases. We removed duplicate publications from our analysis and reported fully our reasons for excluding or not assessing any trials. We conducted independent data extraction, in duplicate, of all included studies. Despite these strategies the review may be subject to some bias, particularly our personal biases due to our clinical practice experiences in arthritis care (MC) and herbal medicine (SC). </p> </section> <section id="CD002947-sec-0134"> <h3 class="title" id="CD002947-sec-0134">Agreements and disagreements with other studies or reviews</h3> <p>This review is the update of a Cochrane review (Little 2000), which we divided into two parts. For completeness, the updated review of topical herbal medicines for the treatment of OA (<a href="./references#CD002947-bbs2-0109" title="CameronM , ChrubasikS . Topical herbal therapies for treating osteoarthritis. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD010538] ">Cameron 2013</a>) should be read in conjunction with this updated review. </p> <p>The results of this review are largely consistent with the findings of earlier reviews that included meta‐analyses of trials of ASU (<a href="./references#CD002947-bbs2-0169" title="CameronM , ChrubasikS , ParsonsT , GagnierJ , BlümleA , LittleC . Herbal therapy for treating osteoarthritis: Update of a Cochrane review. Annals of the Rheumatic Diseases2007;66 Supp II:494. ">Cameron 2007</a>; <a href="./references#CD002947-bbs2-0170" title="CameronM , GagnierJ , LittleC , ParsonsT , BlümleA , ChrubasikS . Evidence of the effectiveness of herbal medicinal products in the treatment of arthritis. Part A: Osteoathritis. Phytotherapy Research2009;23:1497‐515. [DOI: 10.1002/ptr.3007] ">Cameron 2009</a>; <a href="./references#CD002947-bbs2-0112" title="ChristensenR , BartelsEM , AstrupA , BliddalH . Symptomatic efficacy of avocado‐soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta‐analysis of randomized controlled trials.. Osteoarthritis and Cartilage2008;16:399‐408. ">Christensen 2008a</a>; Little 2000), which showed that this combination of two herbs shows benefits for OA pain and function in the short term. The addition of larger and longer term studies to these meta‐analyses suggests that the effects of ASU on pain and function are not sustained over longer periods of two to three years, and that the effects of ASU on joint structure are small at best (<a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>; <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>). </p> <p>In people with low back pain the ethanolic <i>Salix</i> bark extract in two doses demonstrated a dose‐dependent effect superior to placebo (<a href="./references#CD002947-bbs2-0116" title="ChrubasikS , EisenbergE , BalanE , WeinbergerT , LuzzatiR , ConradtC . Treatment of low back pain exacerbations with willow bark extract: A randomized double‐blind study. American Journal of Medicine2000;109:9‐14. ">Chrubasik 2000</a>), and was not inferior to the synthetic rofecoxib (<a href="./references#CD002947-bbs2-0117" title="ChrubasikS , KünzelO , ModelA , ConradtC , BlackA . Treatment of low back pain with a herbal or syntheticantirheumatic: a randomized controlled study. Rheumatology2001;40:1388‐93. ">Chrubasik 2001</a>). In one of the two studies included in this review, a comparable dose of <i>Salix</i> extract failed to produce a significant effect in patients with OA, while the control group responded favourably to treatment with diclofenac (<a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>). It may well be that a higher <i>Salix</i> extract dose might have relieved OA patients' pain; empirically, higher willow bark extract doses have been used for the treatment of pain since the middle ages (<a href="./references#CD002947-bbs2-0162" title="VlachojannisJE , DukeRK , TranVH , DukeCC , ChrubasikS . Anti‐inflammatory herbal medicines for the control of pain. In: CarpinellaM C , RaiM editor(s). Novel Therapeutic Agents from Plants. Enfield, NH, USA: Science Publisher, 2009:339‐67. ">Vlachojannis 2009</a>). </p> <p>This review is also largely consistent with a previous systematic review and meta‐analysis of randomised controlled trials of <i>Rosa canina</i> for OA (<a href="./references#CD002947-bbs2-0113" title="ChristensenR , BartelsEM , AltmanRD , AstrupA , BliddalH . Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? A meta‐analysis of randomized controlled trials. Osteoarthritis and Cartilage2008;16:965‐72. ">Christensen 2008b</a>). The same three studies are included in both reviews. Unlike Christensen and colleagues we did not pool pain scores for meta‐analysis because different outcome measures were used across two of the three trials (<a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a>; <a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a>), and in the third study pain data were reported insufficiently for data extraction and re‐analysis (<a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a>). We concur with Christensen and colleagues that <i>Rosa canina</i> probably reduces pain in OA but we recommend that this purported effect be thoroughly tested in a sufficiently powered randomised controlled trial using standardised outcome measures. </p> <p>This review differs somewhat from an earlier Cochrane review exclusively on pine bark extract (<a href="./references#CD002947-bbs2-0152" title="SchooneesA , VisserJ , MusekiwaA , VolminkJ . Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008294.pub4] ">Schoonees 2012</a>). We identified and included the studies from the Schoonees and colleagues' review but we have reported data from these studies independently rather than pooling them for meta‐analysis because different outcome measures (WOMAC‐VAS (<a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a>) and WOMAC 0 to 4 (<a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>)) were used across the studies, and data in one study were reported graphically (<a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a>), insufficient to allow extraction for re‐analysis. </p> <p>This review is compromised by many poorly designed clinical trials that were underpowered and inadequately blinded. Herbal medicine is not a field known for the widespread adoption of evidence‐based practice, however, in light of the low quality body of evidence in oral herbal treatment for OA, practitioners might continue to ignore the research and do what they 'have always done'. Even small effect sizes may represent clinically meaningful improvements, particularly if these small effects represent improvements in a common condition with a substantial population burden of disease (for example OA). In light of the fact that serious adverse events related to any of the medicinal plant products were not observed, physicians and patients should not be discouraged in using herbal medicines at all. In this section, therefore, we have chosen to address some of the common biases in herbal medicine as well as in this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002947-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002947-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002947-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Boswellia serrata 999 mg versus placebo, Outcome 1 Pain (0 to 3)." data-id="CD002947-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 <i>Boswellia serrata</i> 999 mg versus placebo, Outcome 1 Pain (0 to 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Boswellia serrata 999 mg versus placebo, Outcome 2 Function: loss of function (0 to 3)." data-id="CD002947-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 <i>Boswellia serrata</i> 999 mg versus placebo, Outcome 2 Function: loss of function (0 to 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Boswellia serrata 999 mg versus placebo, Outcome 3 Participants (n) reported adverse effects." data-id="CD002947-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 <i>Boswellia serrata</i> 999 mg versus placebo, Outcome 3 Participants (n) reported adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Boswellia serrata (enriched) 100 mg versus placebo, Outcome 1 Pain VAS 0‐100 at 90 days." data-id="CD002947-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 <i>Boswellia serrata</i> (enriched) 100 mg versus placebo, Outcome 1 Pain VAS 0‐100 at 90 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Boswellia serrata (enriched) 100 mg versus placebo, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 <i>Boswellia serrata</i> (enriched) 100 mg versus placebo, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Boswellia serrata (enriched) 100 mg versus placebo, Outcome 3 Adverse event episodes (n) reported." data-id="CD002947-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 <i>Boswellia serrata</i> (enriched) 100 mg versus placebo, Outcome 3 Adverse event episodes (n) reported. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Boswellia serrata (enriched) 250 mg versus placebo, Outcome 1 Pain VAS 0‐100 at 90 days." data-id="CD002947-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 <i>Boswellia serrata</i> (enriched) 250 mg versus placebo, Outcome 1 Pain VAS 0‐100 at 90 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Boswellia serrata (enriched) 250 mg versus placebo, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 <i>Boswellia serrata</i> (enriched) 250 mg versus placebo, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Boswellia serrata (enriched) 250 mg versus placebo, Outcome 3 Adverse event episodes (n) reported." data-id="CD002947-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 <i>Boswellia serrata</i> (enriched) 250 mg versus placebo, Outcome 3 Adverse event episodes (n) reported. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Boswellia serrata (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 1 Pain VAS 0‐100." data-id="CD002947-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 <i>Boswellia serrata</i> (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 1 Pain VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Boswellia serrata (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 <i>Boswellia serrata</i> (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Boswellia serrata (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 <i>Boswellia serrata</i> (enriched) 100 mg plus non‐volatile oil versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 1 WOMAC‐VAS (Pain)." data-id="CD002947-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 <i>Boswellia serrata</i> 999 mg versus valdecoxib, Outcome 1 WOMAC‐VAS (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 <i>Boswellia serrata</i> 999 mg versus valdecoxib, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 <i>Boswellia serrata</i> 999 mg versus valdecoxib, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Boswellia serrata 999 mg versus valdecoxib, Outcome 4 Participants (n) withdrew due to adverse events." data-id="CD002947-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 <i>Boswellia serrata</i> 999 mg versus valdecoxib, Outcome 4 Participants (n) withdrew due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Curcuma domestica versus ibuprofen, Outcome 1 Pain on walking NRS 0‐10." data-id="CD002947-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 <i>Curcuma domestica</i> versus ibuprofen, Outcome 1 Pain on walking NRS 0‐10. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Curcuma domestica versus ibuprofen, Outcome 2 Function: 100m walk time (seconds)." data-id="CD002947-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 <i>Curcuma domestica</i> versus ibuprofen, Outcome 2 Function: 100m walk time (seconds). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Curcuma domestica versus ibuprofen, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 <i>Curcuma domestica</i> versus ibuprofen, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Derris scandens versus naproxen, Outcome 1 WOMAC‐VAS (Pain) change from baseline." data-id="CD002947-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 <i>Derris scandens</i> versus naproxen, Outcome 1 WOMAC‐VAS (Pain) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Derris scandens versus naproxen, Outcome 2 WOMAC‐VAS (Function) change from baseline." data-id="CD002947-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 <i>Derris scandens</i> versus naproxen, Outcome 2 WOMAC‐VAS (Function) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Derris scandens versus naproxen, Outcome 3 Participants (n) reported adverse events.." data-id="CD002947-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 <i>Derris scandens</i> versus naproxen, Outcome 3 Participants (n) reported adverse events.. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Harpagophytum procumbens versus diacerhein, Outcome 1 Pain VAS 0‐100 change from baseline at 120 days." data-id="CD002947-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 <i>Harpagophytum procumbens</i> versus diacerhein, Outcome 1 Pain VAS 0‐100 change from baseline at 120 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Harpagophytum procumbens versus diacerhein, Outcome 2 Participants (n) reported adverse events." data-id="CD002947-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 <i>Harpagophytum procumbens</i> versus diacerhein, Outcome 2 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Petiveria alliacea versus placebo, Outcome 1 Pain (scale unknown) with mvt change from baseline." data-id="CD002947-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 <i>Petiveria alliacea</i> versus placebo, Outcome 1 Pain (scale unknown) with mvt change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Petiveria alliacea versus placebo, Outcome 2 Participants (n) reported adverse events." data-id="CD002947-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 <i>Petiveria alliacea</i> versus placebo, Outcome 2 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Pinus pinaster (Pycnogenol® 150 mg) versus placebo, Outcome 1 WOMAC‐VAS (Pain)." data-id="CD002947-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 <i>Pinus pinaster</i> (Pycnogenol® 150 mg) versus placebo, Outcome 1 WOMAC‐VAS (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Pinus pinaster (Pycnogenol® 150 mg) versus placebo, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 <i>Pinus pinaster</i> (Pycnogenol® 150 mg) versus placebo, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Pinus pinaster (Pycnogenol® 150 mg) versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 <i>Pinus pinaster</i> (Pycnogenol® 150 mg) versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Pinus pinaster (Pycnogenol® 100 mg) versus placebo, Outcome 1 WOMAC 0‐4 (Pain)." data-id="CD002947-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 <i>Pinus pinaster</i> (Pycnogenol® 100 mg) versus placebo, Outcome 1 WOMAC 0‐4 (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Pinus pinaster (Pycnogenol® 100 mg) versus placebo, Outcome 2 WOMAC 0‐4 (Function)." data-id="CD002947-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 <i>Pinus pinaster</i> (Pycnogenol® 100 mg) versus placebo, Outcome 2 WOMAC 0‐4 (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Ricinus officinale versus placebo, Outcome 1 Participants (n) reported adverse events." data-id="CD002947-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 <i>Ricinus officinale</i> versus placebo, Outcome 1 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Rosa canina versus placebo, Outcome 1 Relief of pain (0 to 4) at 3 months." data-id="CD002947-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 <i>Rosa canina</i> versus placebo, Outcome 1 Relief of pain (0 to 4) at 3 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Rosa canina versus placebo, Outcome 2 WOMAC‐VAS (Pain)." data-id="CD002947-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 <i>Rosa canina</i> versus placebo, Outcome 2 WOMAC‐VAS (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Rosa canina versus placebo, Outcome 3 WOMAC‐VAS (Function)." data-id="CD002947-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 <i>Rosa canina</i> versus placebo, Outcome 3 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Rosa canina versus placebo, Outcome 4 Participants (n) reported adverse events." data-id="CD002947-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 <i>Rosa canina</i> versus placebo, Outcome 4 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Salix purpurea x daphnoides versus placebo, Outcome 1 Pain VAS 0‐100 at 14 days." data-id="CD002947-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 <i>Salix purpurea x daphnoides</i> versus placebo, Outcome 1 Pain VAS 0‐100 at 14 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Salix purpurea x daphnoides versus placebo, Outcome 2 Function VAS 0‐100 at 14 days." data-id="CD002947-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 <i>Salix purpurea x daphnoides</i> versus placebo, Outcome 2 Function VAS 0‐100 at 14 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Salix purpurea x daphnoides versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 <i>Salix purpurea x daphnoides</i> versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Salix purpurea x daphnoides versus diclofenac, Outcome 1 WOMAC‐VAS (Pain)." data-id="CD002947-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 <i>Salix purpurea x daphnoides</i> versus diclofenac, Outcome 1 WOMAC‐VAS (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Salix purpurea x daphnoides versus diclofenac, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 <i>Salix purpurea x daphnoides</i> versus diclofenac, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Salix purpurea x daphnoides versus diclofenac, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 <i>Salix purpurea x daphnoides</i> versus diclofenac, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Uncaria guianensis versus placebo, Outcome 1 Pain VAS 0‐100 (night)." data-id="CD002947-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 <i>Uncaria guianensis</i> versus placebo, Outcome 1 Pain VAS 0‐100 (night). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Uncaria guianensis versus placebo, Outcome 2 Participants (n) reported adverse events." data-id="CD002947-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 <i>Uncaria guianensis</i> versus placebo, Outcome 2 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Zingiber officinale (Zintona EC) versus placebo, Outcome 1 Pain VAS 0‐100 (movement)." data-id="CD002947-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 <i>Zingiber officinale</i> (Zintona EC) versus placebo, Outcome 1 Pain VAS 0‐100 (movement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Zingiber officinale (Zintona EC) versus placebo, Outcome 2 Function (handicap) VAS 0‐100." data-id="CD002947-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 <i>Zingiber officinale</i> (Zintona EC) versus placebo, Outcome 2 Function (handicap) VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Zingiber officinale (Zintona EC) versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 <i>Zingiber officinale</i> (Zintona EC) versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Boswellia carteri + Curcuma longa versus placebo, Outcome 1 Function: pain free walking time (minutes)." data-id="CD002947-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 <i>Boswellia carteri</i> + <i>Curcuma longa</i> versus placebo, Outcome 1 Function: pain free walking time (minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 1 Pain VAS 0‐100." data-id="CD002947-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 1 Pain VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 2 Pain VAS 0‐100 change from baseline at 36 months." data-id="CD002947-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 2 Pain VAS 0‐100 change from baseline at 36 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 3 Pain VAS 0‐100 grouped by joint." data-id="CD002947-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 3 Pain VAS 0‐100 grouped by joint. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 4 Function: disability VAS 0‐100." data-id="CD002947-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 4 Function: disability VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 5 WOMAC‐VAS (Function) change from baseline at 36 months." data-id="CD002947-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 5 WOMAC‐VAS (Function) change from baseline at 36 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 6 Lequesne algofunctional index." data-id="CD002947-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.6</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 6 Lequesne algofunctional index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 7 Function (various tools)." data-id="CD002947-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.7</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 7 Function (various tools). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 8 Participants (n) reported adverse events." data-id="CD002947-fig-0058" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.8</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 8 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 9 Participants (n) withdrew due to adverse events." data-id="CD002947-fig-0059" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.9</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 9 Participants (n) withdrew due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 10 Particpants (n) reported serious adverse events." data-id="CD002947-fig-0060" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.10</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 10 Particpants (n) reported serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-019-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-019-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Persea gratissma + Glycine max (ASU 300 mg) versus placebo, Outcome 11 JSW change from baseline." data-id="CD002947-fig-0061" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.11</div> <div class="figure-caption"> <p>Comparison 19 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus placebo, Outcome 11 JSW change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-019-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Persea gratissma + Glycine max (ASU 600 mg) versus placebo, Outcome 1 Pain VAS 0‐100." data-id="CD002947-fig-0062" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) versus placebo, Outcome 1 Pain VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Persea gratissma + Glycine max (ASU 600 mg) versus placebo, Outcome 2 Lequesne algofunctional index." data-id="CD002947-fig-0063" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) versus placebo, Outcome 2 Lequesne algofunctional index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-020-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-020-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Persea gratissma + Glycine max (ASU 600 mg) versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0064" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-020-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate, Outcome 1 WOMAC‐VAS (Pain)." data-id="CD002947-fig-0065" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus chondroitin sulphate, Outcome 1 WOMAC‐VAS (Pain). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0066" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus chondroitin sulphate, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-021-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-021-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0067" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus chondroitin sulphate, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-021-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-021-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate, Outcome 4 Paricipants (n) reported serious adverse events." data-id="CD002947-fig-0068" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21 <i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) versus chondroitin sulphate, Outcome 4 Paricipants (n) reported serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-021-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Phellondendron amurense + Citrus sinensis (NP 06‐1) versus placebo, Outcome 1 Lequesne algofunctional index." data-id="CD002947-fig-0069" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 <i>Phellondendron amurense</i> + <i>Citrus sinensis</i> (NP 06‐1) versus placebo, Outcome 1 Lequesne algofunctional index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Uncaria guianensis + Lepidium meyenii versus glucosamine sulphate, Outcome 1 Participants (n) reported adverse events." data-id="CD002947-fig-0070" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 <i>Uncaria guianensis + Lepidium meyenii</i> versus glucosamine sulphate, Outcome 1 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Zingiber officinale + Alpinia galanga (EV.EXT77) versus placebo, Outcome 1 Pain immediately after walking 50 feet VAS 0‐100." data-id="CD002947-fig-0071" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 <i>Zingiber officinale</i> + <i>Alpinia galanga</i> (EV.EXT77) versus placebo, Outcome 1 Pain immediately after walking 50 feet VAS 0‐100. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Zingiber officinale + Alpinia galanga (EV.EXT77) versus placebo, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0072" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 <i>Zingiber officinale</i> + <i>Alpinia galanga</i> (EV.EXT77) versus placebo, Outcome 2 WOMAC‐VAS (Function). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-024-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-024-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Zingiber officinale + Alpinia galanga (EV.EXT77) versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0073" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.3</div> <div class="figure-caption"> <p>Comparison 24 <i>Zingiber officinale</i> + <i>Alpinia galanga</i> (EV.EXT77) versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-024-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 SKI306X versus placebo, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0074" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 SKI306X versus placebo, Outcome 1 Pain VAS 0‐100 change from baseline.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-025-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-025-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 SKI306X versus placebo, Outcome 2 Lequesne algofunctional index change from baseline." data-id="CD002947-fig-0075" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25 SKI306X versus placebo, Outcome 2 Lequesne algofunctional index change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-025-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-025-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 SKI306X versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0076" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25 SKI306X versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-025-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0077" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 1 Pain VAS 0‐100 change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 2 Lequesne algofunctional index change from baseline." data-id="CD002947-fig-0078" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 2 Lequesne algofunctional index change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-026-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-026-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0079" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26 SKI306X (600 mg) versus diclofenac, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-026-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Phytodolor N versus placebo, Outcome 1 Enduring pain (0 to 3)." data-id="CD002947-fig-0080" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Phytodolor N versus placebo, Outcome 1 Enduring pain (0 to 3).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-027-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-027-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Phytodolor N versus placebo, Outcome 2 Function: mobility limitations (0 to 3)." data-id="CD002947-fig-0081" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27 Phytodolor N versus placebo, Outcome 2 Function: mobility limitations (0 to 3). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-027-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-027-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Phytodolor N versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0082" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.3</div> <div class="figure-caption"> <p>Comparison 27 Phytodolor N versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-027-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Reumalex versus placebo, Outcome 1 AIMS2 arthritis pain score change from baseline." data-id="CD002947-fig-0083" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Reumalex versus placebo, Outcome 1 AIMS2 arthritis pain score change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-028-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-028-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Reumalex versus placebo, Outcome 2 Participants (n) reported adverse events." data-id="CD002947-fig-0084" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-028-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28 Reumalex versus placebo, Outcome 2 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-028-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Chinese DJW versus diclofenac, Outcome 1 Pain VAS 0‐100 (total)." data-id="CD002947-fig-0085" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Chinese DJW versus diclofenac, Outcome 1 Pain VAS 0‐100 (total).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-029-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-029-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Chinese DJW versus diclofenac, Outcome 2 Lequesne algofunctional index." data-id="CD002947-fig-0086" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29 Chinese DJW versus diclofenac, Outcome 2 Lequesne algofunctional index.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-029-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-029-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Chinese DJW versus diclofenac, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0087" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.3</div> <div class="figure-caption"> <p>Comparison 29 Chinese DJW versus diclofenac, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-029-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Chinese BNHS versus Chinese active control, Outcome 1 Pain VAS 0‐100 (walking)." data-id="CD002947-fig-0088" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Chinese BNHS versus Chinese active control, Outcome 1 Pain VAS 0‐100 (walking). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Chinese BNHS versus Chinese active control, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0089" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 Chinese BNHS versus Chinese active control, Outcome 2 WOMAC‐VAS (Function).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-030-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-030-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Chinese BNHS versus Chinese active control, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0090" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30 Chinese BNHS versus Chinese active control, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-030-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 (walking)." data-id="CD002947-fig-0091" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 (walking).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-031-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-031-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 2 WOMAC‐VAS (Function)." data-id="CD002947-fig-0092" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 2 WOMAC‐VAS (Function).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-031-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-031-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0093" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.3</div> <div class="figure-caption"> <p>Comparison 31 Chinese BNHS versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-031-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Ayurvedic A to E versus placebo, Outcome 1 Adverse event episodes (n) reported." data-id="CD002947-fig-0094" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 Ayurvedic A to E versus placebo, Outcome 1 Adverse event episodes (n) reported. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-033-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-033-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Ayurvedic Antarth versus placebo, Outcome 1 Pain VAS 0‐100." data-id="CD002947-fig-0095" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-033-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33 Ayurvedic Antarth versus placebo, Outcome 1 Pain VAS 0‐100.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-033-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-034-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-034-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 1 Pain VAS 0‐100." data-id="CD002947-fig-0096" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 1 Pain VAS 0‐100.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-034-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-034-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 2 WOMAC 0‐4 (Function)." data-id="CD002947-fig-0097" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.2</div> <div class="figure-caption"> <p>Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 2 WOMAC 0‐4 (Function).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-034-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-034-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0098" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.3</div> <div class="figure-caption"> <p>Comparison 34 Ayurvedic RA‐II versus placebo, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-034-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-035-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-035-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0099" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-035-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-035-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 2 WOMAC 0‐4 (Function) change from baseline." data-id="CD002947-fig-0100" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.2</div> <div class="figure-caption"> <p>Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 2 WOMAC 0‐4 (Function) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-035-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-035-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0101" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.3</div> <div class="figure-caption"> <p>Comparison 35 Ayurvedic SGC versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-035-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-036-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-036-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0102" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 1 Pain VAS 0‐100 change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-036-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-036-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 2 WOMAC 0‐4 (Function) change from baseline." data-id="CD002947-fig-0103" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.2</div> <div class="figure-caption"> <p>Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 2 WOMAC 0‐4 (Function) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-036-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-036-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0104" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.3</div> <div class="figure-caption"> <p>Comparison 36 Ayurvedic SGC versus celecoxib, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-036-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-037-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-037-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0105" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 1 Pain VAS 0‐100 change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-037-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-037-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 2 WOMAC 0‐4 (Function) change from baseline." data-id="CD002947-fig-0106" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.2</div> <div class="figure-caption"> <p>Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 2 WOMAC 0‐4 (Function) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-037-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-037-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0107" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.3</div> <div class="figure-caption"> <p>Comparison 37 Ayurvedic SGCG versus glucosamine sulphate, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-037-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-038-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-038-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 1 Pain VAS 0‐100 change from baseline." data-id="CD002947-fig-0108" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.1</div> <div class="figure-caption"> <p>Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 1 Pain VAS 0‐100 change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-038-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-038-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 2 WOMAC 0‐4 (Function) change from baseline." data-id="CD002947-fig-0109" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.2</div> <div class="figure-caption"> <p>Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 2 WOMAC 0‐4 (Function) change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-038-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-038-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0110" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.3</div> <div class="figure-caption"> <p>Comparison 38 Ayurvedic SGCG versus celecoxib, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-038-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-039-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-039-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 1 Pain: Knee Society Rating System 0‐100 (knee)." data-id="CD002947-fig-0111" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.1</div> <div class="figure-caption"> <p>Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 1 Pain: Knee Society Rating System 0‐100 (knee). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-039-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-039-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 2 Function: Knee Society Rating System 0‐50 (stairs)." data-id="CD002947-fig-0112" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.2</div> <div class="figure-caption"> <p>Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 2 Function: Knee Society Rating System 0‐50 (stairs). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002947-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/urn:x-wiley:14651858:media:CD002947:CD002947-CMP-039-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_t/tCD002947-CMP-039-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 3 Participants (n) reported adverse events." data-id="CD002947-fig-0113" src="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.3</div> <div class="figure-caption"> <p>Comparison 39 Japanese Boiogito + loxoprofen versus loxoprofen, Outcome 3 Participants (n) reported adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/media/CDSR/CD002947/image_n/nCD002947-CMP-039-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Boswellia serrata for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> 999 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain 0‐3 (higher scores mean worse)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 2.50 (0 to 3 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention groups was<br/> <b>2.24 lower</b> <br/> (2.64 to 1.84 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 56% (46% to 66%); Relative improvement in pain was 80% (66% to 94%)<sup>5</sup>; NNTB = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Loss of function 0‐3 (higher scores mean worse)<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 2.46 (0 to 3 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>2.16 lower</b> <br/> (2.56 to 1.76 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in function was 54% (44% to 64%); Relative improvement was 76% (62% to 90%)<sup>5</sup>; NNTB = 1 (95% CI 1 to 3). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse effects<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No (n=0) participants in the control group reported adverse events.</p> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Two (n=2) participants in the intervention group reported adverse events.</p> <p><b>0 per 1000</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.00</b> <br/> (0.26 to 96.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 13% higher in the <i>Boswellia serrata</i> group (6% lower to 33% higher); Relative percentage change 400% worsening (74% to 9513% worsening); NNT n/a.<sup>6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events not reported as discrete outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Criteria for diagnosis of OA not specified.<br/> <sup>2</sup> Exploratory study design; power, effect, and sample size not determined a priori.<br/> <sup>3</sup> Ethical oversight not reported. </p> <p><sup>4</sup> Downgrade estimate due to single study. </p> <p><sup>5</sup> Control group baseline pain (SD) 2.80 (0.41), baseline disability 2.86 (0.35), from <a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>. </p> <p><sup>6</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). Assumed a minimal clinically important difference of 1 point of a 0 to 3 point scale (pain, function). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Boswellia serrata for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) 100 mg for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 100 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) 100mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at the end of treatment was 40.02 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The weighted mean pain in the intervention groups was<br/> <b>16.57 lower</b> <br/> (26.47 to 8.47 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 17% (8% to 26%); Relative improvement in pain was 29% (15% to 43%)<sup>3</sup>; NNTB 2 (95% CI 1 to 6). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>1</sup> 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the control groups at the end of treatment was 33.13 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The weighted mean disability in the intervention groups was<br/> <b>8.21 lower</b> <br/> (14.21 to 2.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement was 8% (14% to 2%); Relative improvement was 20% (5% to 34%)<sup>3</sup>; NNTB 4 (95% CI 2 to 18). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Adverse event episodes (n) reported<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>625 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> <br/> (211 to 577) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.60</b> <br/> (0.39 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 25% lower in the <i>Boswellia serrata</i> group (6% to 44% lower); Relative percentage change 40% improvement (61% improvement to 9% worsening); NNT = 4 (95% CI 3 to 22). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>, <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>, <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> <p><sup>2</sup> Confirmatory study design: statistical power 80%, alpha set at 0.05, but downgraded due to potential imprecision due to small number of participants; and lower limit of 95% CI does not preclude clincially insignificant change </p> <p><sup>3</sup> Control group baseline measures taken from <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>, the study most heavily weighted in the meta‐analyses. Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6). </p> <p><sup>4</sup> Downgrade estimate due to potential imprecision, eg, small number of events and participants from a single study. </p> <p><sup>5</sup> Number needed to treat (NNT) is not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/); NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). Assumed a minimal clinically important difference of 15 points on 0 to 100 mm pain scale, and 10 points on 0 to 100 mm function scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Boswellia serrata (enriched) 250 mg for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) 250mg for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 250mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) 250mg</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 41.76 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention group was<br/> <b>27.54 lower</b> <br/> (34.64 to 20.44 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 28% (20% to 35%); Relative improvement in pain was 48% (36% to 61%)<sup>3</sup> ; NNT = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>1</sup> </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 34.07 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention group was<br/> <b>16.8 lower</b> <br/> (21.23 to 12.37 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 17% (12% to 21%); Relative improvement in disability was 41% (30% to 51%)<sup>3</sup>; NNT = 1 (95% CI 1 to 2). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Adverse event episodes (n) reported<br/> Follow‐up: mean 90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>526 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>474 per 1000</b> <br/> (302 to 653) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.90</b> <br/> (0.62 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 5% lower in the <i>Boswellia serrata</i> group (24% lower to 13% higher); Relative percentage change 10% improvement (38% improvement to 30% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> <p><sup>2</sup> Downgrade estimate due to single study. </p> <p><sup>3</sup> Control group baseline pain (SD) 56.88 (12.04), baseline disability 41.3 (9.6), from <a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a>. </p> <p><sup>4</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Boswellia serrata (enriched) 250 mg for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Boswellia serrata (enriched) plus non‐volatile oil for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> (enriched) plus non‐volatile oil for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> (enriched) 100mg plus non‐volatile oil </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> (enriched) plus non‐volatile oil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: 30‐90 days<sup>1</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at the end of treatment was 38.90 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the intervention groups was<br/> <b>16.09 lower</b> <br/> (20.37 to 11.81 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 16% (12% to 20%); Relative improvement in pain was 34%(25% to 42%)<sup>3</sup>; NNTB 2 (1 to 4)<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>5</sup> normalised units </p> <p>(higher scores mean worse)<br/> Follow‐up: 30‐90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the control groups at the end of treatment was 34.90 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean disability in the intervention groups was<br/> <b>15.01 lower</b> <br/> (19.21 to 10.81 lower). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 15% (11% to 19%); Relative improvement in disability was 37% (27% to 47%)<sup>3</sup>; NNTB 2 (1 to 3). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 30‐90 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>41 per 1000</b> <br/> (6 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.98</b> <br/> (0.14 to 6.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 0% lower in the <i>Boswellia serrata</i> group (8% lower to 8% higher); Relative percentage change 2% improvement (86% improvement to 569% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL withdrawals due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: 30 day intervention. <a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>: 90 day intervention.<br/> <sup>2</sup><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: Exploratory study design; power, effect, and sample size not determined a priori.<br/> <sup>3</sup> Control group baseline measures taken from <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>, the study most heavily weighted in the meta‐analyses. Control group baseline pain 47.6 (9.7), baseline disability 40.6 (9.5). </p> <p><sup>4</sup> Number needed to treat to benefit (NNTB), and harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> <p><sup>5</sup><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a>, <a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a>: WOMAC scores presented as subscale scores only. Overall WOMAC not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Boswellia serrata (enriched) plus non‐volatile oil for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Boswellia serrata compared to valdecoxib for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Boswellia serrata</i> compared to valdecoxib for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with treating osteoarthritis<br/> <b>Settings:</b> Community: India<br/> <b>Intervention:</b><i>Boswellia serrata</i> 999 mg<br/> <b>Comparison:</b> valdecoxib </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Valdecoxib</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Boswellia serrata</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> WOMAC‐VAS (Pain) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the valdecoxib group at the end of treatment was 17.08 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention groups was<br/> <b>0.51 lower</b> <br/> (7.26 lower to 6.24 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 1% (7% improvement to 6% worsening); Relative improvement in pain was 1%<sup>4</sup>; NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function)<sup>5</sup> <br/> (higher scores mean worse) </p> <p>Follow‐up: mean 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the valdecoxib group at the end of treatment was 16.64 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>2.49 higher</b> <br/> (4.07 lower to 9.05 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening in disability was 3% (4% improvement to 9% worsening); Relative improvement in disability was 4%<sup>4</sup>; NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> <br/> (23 to 448) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.0</b> <br/> (0.39 to 10.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 6% higher in the <i>Boswellia serrata</i> group (8% lower to 20% higher); Relative percentage change 100% worsening (61% improvement to 918% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.0</b> </p> <p>(0.13 to 71.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported one (1) withdrawal possibly due to adverse events.</p> <p>Absolute risk of withdrawal due to adverse events was 3% higher in the <i>Boswellia serrata</i> group (5% lower to 11% higher); Relative percentage change 200% worsening (87% improvement to 7007% worsening); NNT n/a.<sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported NIL serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Open trial. Medication regimens differ between active control and intervention. </p> <p><sup>2</sup> Downgrade estimate due to single study. Treatment effect crosses midline (no effect).<br/> <sup>3</sup> Exploratory study design; power, effect, and sample size not determined a priori. </p> <p><sup>4</sup> Baseline pain in valdecoxib group 49.2, baseline disability 51.6. Aggregate WOMAC scores converted to normalised scores for re‐analysis. </p> <p><sup>5</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Boswellia serrata compared to valdecoxib for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: France (3), Belgium (1).<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 (higher scores mean worse)<br/> Follow‐up: 3 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the control groups at end of treatment was 40.53 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Weighted mean pain in the intervention groups was<br/> <b>8.47 lower</b> <br/> (15.90 to 1.04 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>651<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 8% (1% to 16%); Relative improvement in pain was 15% (2% to 29%)<sup>2</sup>; NNTB 8 (4 to 77)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Multiple tools<sup>4</sup> <br/> Follow‐up: 3 to 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at end of treatment was 47.10 mm, on VAS 0 to 100 mm scale (higher scores mean worse)<sup>5</sup>. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention groups was<br/> <b>7 mm lower</b> <br/> (12 mm to 2 mm lower<sup>6</sup>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>642<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.42 (95% CI ‐0.73 to ‐0.11), in favour of ASU 300mg</p> <p>Absolute improvement in disability was 7% (2% to 12%); Relative improvement in disability was 13% (4% to 23%)<sup>7</sup>; NNTB 5 (3 to 19)<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 3 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>510 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>531 per 1000</b> <br/> (495 to 572) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.97 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1050<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events is 2% higher in the ASU group (2% lower to 7% higher); Relative percentage change 4% worsening (9% improvement to 12% worsening); NNT n/a<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>169 per 100</b> </p> <p>(108 to 267)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b> </p> <p>(0.73 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of participants withdrawing due to adverse events in 2% higher in ASU group (5% lower to 9% higher); Relative percentage change 14% worsening (27% improvement to 90% worsening); NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>325 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> <p>(306 to 517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.22</b> </p> <p>(0.94 to 1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>398</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of serious adverse events is 7% higher in the ASU group (2% lower to 17% higher); Relative percentage change 22% worsening (6% improvement to 59% worsening); NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> <p>Change in Joint Space Width (JSW) from baseline</p> <p>(higher scores mean worse).</p> <p>Follow up: 24 to 36 months.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Weighted mean JSW change from baseline in the control groups at end of treatment was 0.65. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>Mean JSW change from baseline in the intervention groups was <b>0.12 lower</b> (0.43 lower to 0.19 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>453</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute change</p> <p>NNT n/a.<sup>3,9</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgrade due to heterogeneity, inconsistency </p> <p><sup>2</sup> Calculations based on control group baseline pain measure taken from <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, the most heavily weighted study in the meta‐analysis. Control group baseline mean (SD) pain 54.3 (11.9). </p> <p><sup>3</sup> Number needed to treat to benefit (NNTB), or to harm (NNTH) = not applicable (n/a) when result is not statistically significant. NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/)NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office), assuming a minimal clinically important difference of 15 mm on a 0 to 100 mm pain scale, and 10 mm on a 0 to 100 mm function scale. </p> <p><sup>4</sup> Multiple tools: Disability VAS reported in one study only (<a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>); WOMAC change score reported in one study (<a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>); Lequesne algofunctional index reported in four studies, but to avoid over‐reporting, data were extracted on this outcome from three studies only (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>) </p> <p><sup>5</sup> From <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>: follow‐up disability score in the control group 47.10 mm (VAS 0 to 100 mm scale) </p> <p><sup>6</sup> Four trials pooled (<a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>, <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>) using SMD, and re‐expressed as MD by multiplying the SMD (95% CI) by the baseline SD in the control group of <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a> (16.78). </p> <p><sup>7</sup> Calculations based on data from <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>: control group baseline mean (SD) disability 52.5 (16.78), 0 to 100 mm VAS scale. </p> <p><sup>8</sup> Downgrade estimate due to imprecision: few participants. </p> <p><sup>9</sup> Treatment effect crosses midline (no effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: Belgium<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 600mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> Global pain VAS 0‐100 </p> <p>(higher scores mean worse)</p> <p>Follow up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the control group at the end of treatment was 42.4 (0 to 100 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the intervention group was<br/> <b>14.2 lower</b> <br/> (20.82 to 7.58 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in pain was 14% (21% to 8%); Relative improvement in pain was 26.5%<sup>2</sup>; NNT = </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> Lequesne algofunctional index 0‐24 </p> <p>(higher scores mean worse)<br/> Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the control group at the end of treatment was 7.8 (0 to 24 scale).</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean disability in the intervention group was<br/> <b>1.3 lower</b> <br/> (2.38 to 0.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute improvement in disability was 1% (1% to 0%); Relative improvement in disability was 13.7%<sup>2</sup>; NNT = </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events<br/> Follow‐up: 3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> <br/> (165 to 431) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.07</b> <br/> (0.66 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events is 2% higher in the ASU group (11% lower to 15% higher); Relative percentage change 7% worsening (34% improvement to 74% worsening); NNT n/a.<sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events not reported as a discrete outcome in ASU 600mg subgroup. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events not reported as a discrete outcome in ASU 600mg subgroup.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Single study. </p> <p><sup>2</sup> Control group baseline mean (SD) pain 53.5 (13.9), baseline mean (SD) disability 9.5 (2.2), from <a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>. </p> <p><sup>3</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 600 mg) for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002947-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> Community: Czech Republic, Slovak Republic, Hungary, Poland, Romania<br/> <b>Intervention:</b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)<br/> <b>Comparison:</b> chondroitin sulphate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chondroitin sulphate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Persea gratissma</i> + <i>Glycine max</i> (ASU 300mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> <br/> WOMAC‐VAS (Pain) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean pain in the chondroitin sulphate group at the end of treatment was 22.88 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain in the intervention group was<br/> <b>1.41 higher</b> <br/> (2.68 lower to 5.50 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening of pain was 10% (10% improvement to 31% worsening); Relative worsening of pain was 3%<sup>3</sup>; NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Function</b> <br/> WOMAC‐VAS (Function) </p> <p>(higher scores mean worse)<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean function in the chondroitin sulphate group at the end of treatment was 25.14 (0 to 100 scale). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean disability in the intervention group was<br/> <b>1.63 higher</b> <br/> (2.51 lower to 5.77 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute worsening of disability was 28% (43% improvement to 98% worsening); Relative worsening of disability was 3%<sup>3</sup>; NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Participants (n) reported adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>244 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> <br/> (139 to 304) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.86</b> <br/> (0.59 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>357<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk of adverse events was 3% lower in the ASU group (12% lower to 5% higher); Relative percentage change 14% improvement (41% improvement to 26% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) withdrew due to adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Withdrawals due to adverse events not reported as a discrete outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>Participants (n) reported serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>6 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>17 per 1000</b> </p> <p>(2 to 158)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.92</b> </p> <p>(0.31 to 27.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>357<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absolute risk of serious adverse events was 1% higher in the ASU group (1% lower to 3% higher); Relative percentage change 192% worsening (69% improvement to 2678% worsening); NNT n/a.<sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Radiographic joint changes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiographic joint changes not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life not measured.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> SIngle study. Treatment effect crosses midline (no effect). </p> <p><sup>2</sup> Chondroitin sulfate might not be active control. Non‐inferiority hypothesis may be flawed. </p> <p><sup>3</sup> Chrondroitin sulfate group baseline pain 49.08, baseline disability 49.07. Aggregate WOMAC scores converted to normalised scores for re‐analysis. </p> <p><sup>4</sup> Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial office). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) compared to chondroitin sulphate for treating osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002947-tbl-0009"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Herbal medicinal products used for the treatment of OA</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>PLANT</p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>MEDICINAL PRODUCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DOSE</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>MARKER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Botanical name</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Part/s</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tradename</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Preparation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug:Extract</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Constituent marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quantity of marker</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>References</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from single plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Boswellia serrata</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>gum resin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CapWokvel<sup>TM</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>extraction solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>boswellic acid</p> <p>(total organic acids 65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0024" title="KimmatkarN , ThawaniV , HingoraniL , KhiyaniR . Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee ‐ A randomized double blind placebo controlled trial. Phytomedicine2003;10:3‐7. ">Kimmatkar 2003</a>, <a href="./references#CD002947-bbs2-0044" title="SontakkeS , ThawaniV , PimpalkhuteS , KambraP , BabhulkarS , HingoraniL . Open, randomized, controlled trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of knee. Indian Journal of Pharmacology2007;39:27‐9. ">Sontakke 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐Loxin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 or 250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKBA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0042" title="SenguptaK , AlluriKV , SatishAR , MishraS , GolakotiT , SarmaKVS , et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5‐Loxin® for treatment of osteoarthritis of the knee. Arthritis Research &amp; Therapy2008;10:R85. [DOI: 10.1186/ar2461] ">Sengupta 2008</a> </p> <p><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aflapin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AKBA + non‐volatile oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0043" title="SenguptaK , KrishnarajuAV , VishalAA , MishraA , TrimurtuluG , SarmaKVS , et al. Comparative efficacy and tolerability of 5‐Loxin® and Aflapin® against osteoarthritis of the knee: A double blind, randomized, placebo controlled clinical study. International Journal of Medical Sciences2010;7(6):366‐77. ">Sengupta 2010</a> </p> <p><a href="./references#CD002947-bbs2-0046" title="VishalAA , MishraA , RaychaudhuriSP . A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin® in subjects with osteoarthritis of the knee. International Journal of Medical Sciences2011;8(7):615‐22. ">Vishal 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Curcuma domestica</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>curcumoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0025" title="KuptniratsaikulV , ThanakhumtornS , et al. Efficacy and safety of Curcumica domestica extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2009;15:891‐7. [DOI: 10.1089/acm.2008.0186] ">Kuptniratsaikul 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Derris scandens</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (50%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>genistein derivatve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0026" title="KuptniratsaikulV , PinthongT , BunjobM , ThanakhumtornS , ChinswangwatanakulP , ThamlikitkulV . Efficacy and safety of Derris scandens benth extracts in patients with knee osteoarthritis. Journal of Alternative and Complementary Medicine2011;17:147‐53. [DOI: 10.1089/acm.2010.0213] ">Kuptniratsaikul 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Garcinia kola</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0001" title="AdegbehingbeOO , AdesanyaSA , IdowuTO , OkimiOC , OyelamiOA , IwalewaEO , et al. Clinical effects of Garcinia kola in knee osteoarthritis. Journal of Orthopedic Surgery2008;3:34. ">Adegbehingbe 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Harpagophytum procumbens</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arthrotabs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5‐2.5:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>harpagoside<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0040" title="SchmelzH , HammerleHD , SpringorumHW . Analgesic effect of a Devil's claw extract in various chronic degenerative joint diseases [Analgetische Wirkung eines Teufelskrallenwurzel‐Extraktes bei verschiedenen chronisch‐degenerativen Gelenkerkrankungen]. In: ChrubasikS , WinkM editor(s). Rheumatherapie mit Phytopharmaka. Stuttgart: Hippokrates Verlag, 1997:86‐9. ">Schmelz 1997</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flexiloges</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (60%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5‐5.5:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;30 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0019" title="FrerickH , BillerA , SchmidtU . A treatment schedule for coxarthrosis: A double‐blind study with Devil's claw [Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle]. Der Kassenarzt2001;5:34‐41. ">Frerick 2001</a>, <a href="./references#CD002947-bbs2-0008" title="BillerA . Results of two randomized controlled studies and of a post‐marketing surveillance study investigating a Devil's claw extract [Ergebnisse zweier randomisierter kontrollierter Studien und einer Anwendungsbeobachtung mit Teufelskrallenextrakt]. In: SchulzV , RietbrockN , RootsI , LoewD editor(s). In: Phylopharmaka VII. Darmstadt: Steinkopf‐Verlag, 2002:81‐92. ">Biller 2002</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Harpadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cryoground powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0027" title="LeblanD , ChantreP , FourniéB . Harpogophytum procumbens in the treatment of knee and hip osteoarthritis: Four‐month results of a prospective, multicenter, double‐blind trial versus diacerhein [L'harpagophyton dans le traitement de la gonarthrose et de la coxarthrose. Résultats à quatre mois d'une étude prospective multicentrique, contrôlée en double aveugle, versus diacerhéine]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]2000;67(5):462‐7. ">Leblan 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Petiveria alliacea</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tipi tea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9g / 600 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0018" title="FerrazMB , PereiraRB , IwataNM , AtraE . Tipi. A popular analgesic tea: A double‐blind cross‐over trial in osteoarthritis (letter). Clinical and Experimental Rheumatology1991;9:205‐12. ">Ferraz 1991</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><i>Pinus pinaster</i> (synonym <i>Pinus maritima</i>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Pycnogenol®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>polyphenol concentrate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>proanthocyanidins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0016" title="CisárP , JányR , WaczulíkováI , SumegováK , MuchováJ , VojtaSSákJ , et al. Effect of pine bark extract (Pycnogenol®) on symptoms of knee osteoarthritis. Phytotherapy Research2008;22:1087‐92. [DOI: 10.1002/ptr.2461] ">Cisar 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0005" title="BelcaroG , CesaroneMR , ErrichiS , ZulliC , ErrichiBM , VinciguerraG , et al. Treatment of osteoarthritis with Pycnogenol®. The SVOS (San Valentino Osteoarthritis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytotherapy Research2008;22:518‐23. [DOI: 10.1002/ptr.2376] ">Belcaro 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0017" title="FaridR , MirfeiziZ , MirheidariM , RezaieyazdiZ , MansouriH , EsmaelliH , et al. Pycnogenol supplementation reduces pain and stiffness and improved physical function in adults with knee osteoarthritis. Nutrition Research2007;27:692‐7. [DOI: 10.1016/j.nutres.2007.09.007] ">Farid 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Ricinus officinalis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2,7 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ricinoleic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0032" title="MedhiB , KishoreK , SinghU , SethSD . Comparative clinical trial of castor oil and diclofenac sodium in patients with osteoarthritis. Phytotherapy Research2009;23:1469‐73. [DOI: 10.1002/ptr.2804] ">Medhi 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Rosa canina lito</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rose hip and seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyben Vital or Litozin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>galactolipid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0038" title="ReinE , KharazamiA , WintherK . A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis ‐ a double‐blind, placebo‐controlled, randomised trial. Phytomedicine2004;11:383‐91. ">Rein 2004a</a><a href="./references#CD002947-bbs2-0047" title="WarholmO , SkaarS , HedmanE , MolmenHM , EikL . The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: A double‐blind, randomized, placebo‐controlled clinical trial. Current Therapeutic Research2003;64(1):21‐31. ">Warholm 2003</a> </p> <p><a href="./references#CD002947-bbs2-0049" title="WintherK , ApelK , ThamsborgG . A powder made from seeds and shells of a rose‐hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: A randomized, double‐blind, placebo‐controlled clinical trial. Scandinavian Journal of Rheumatology2005;34:302‐8. ">Winther 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix daphnoides</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (70%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐14:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0007" title="BiegertC , WagnerI , LudtkeR , KotterI , LohmullerC , GunaydinI , et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: Results of 2 randomized double‐blind controlled trials. The Journal of Rheumatology2004;31(11):2121‐30. ">Biegert 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix pupurea x daphnoides</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanolic (70%) extract<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0041" title="SchmidB , LudtkeR , SelbmannHK , KotterI , TschirdewahnB , SchaffnerW , et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: Randomized placebo‐controlled double blind clinical trial [Wirksamkeit und vertraglichkeit eines standardisierten weidenrindenextraktes bei arthose‐patienten: Randomisierte, placebo‐kontrollierte doppelblindstudie]. Zeitschrift für Rheumatologie2000;59:1‐7. ">Schmid 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Uncaria guianensis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0037" title="PiscoyaJ , RodriguezZ , BustamanteSA , OkuhamaNN , MillerMJS , SandovalM . Efficacy and safety of freeze‐dried cat's claw in osteoarthritis of the knee: Mechanism of action of the species Uncaria guianensis . Inflammation Research2001;50:442‐8. ">Piscoya 2001</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Vitellaria paradoxa </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>seed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patented extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>triterpenes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0012" title="CherasPA , MyersSP , Paul‐BrentP , OuterbridgeKH , NielsenGVL . Randomised double‐blind placebo‐controlled trial on the potential modes of action of SheaFlex70 in osteoarthritis. Phytotherapy Research2010;24:1126‐31. [DOI: 10.1002/ptr.3075] ">Cheras 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i><sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EV.EXT 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acetone extract<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>510</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0009" title="BliddalH , RosetzskyA , SchlichtingP , WeidnerMS , AndersenLA , IbfeltHH , et al. A randomized, placebo‐controlled, cross‐over study of ginger extracts and ibuprofen in osteoarthritis. Osteoarthritis and Cartilage2000;8:9‐12. ">Bliddal 2000</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zintona EC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CO2 extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gingerol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0048" title="WiglerI , GrottoI , CaspiD , YaronM . The effects of Zintona EC (a ginger extract) on symptomatic gonarthritis. Osteoarthritis and Cartilage2003;11:783‐9. ">Wigler 2003</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from two plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Boswellia carteri</i> + <i>Curcuma longa</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gum + root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>study medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>boswellic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0004" title="BadriaFA , El‐FarahatyT , ShabanaAA , HawasSA , El‐BatotyMF . Boswellia‐curcumin preparation for treating knee osteoarthritis: A clinical evaluation. Alternative &amp; Complementary Therapies2002;8(6):341‐8. ">Badria 2002</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Persea gratissma</i> (P) + <i>Glycine max</i> (G) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oils</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Piascledine 300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unsaponifiable fraction 1/3 P;2/3 G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300 or 600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0003" title="AppelboomT , SchuermansJ , VerbruggenG , HenrotinY , ReginsterJY . Symptoms modifying effect of avocado/soyabean unsaponifiables (ASU) in knee osteoarthritis: A double‐blind, prospective, placebo‐controlled study. Scandinavian Journal of Rheumatology2001;30(4):242‐7. ">Appelboom 2001</a>, <a href="./references#CD002947-bbs2-0010" title="BlotmanF , MaheuE , WulwikA , CaspardH , LopezA . Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip [Efficacite et tolerance des insaponifiables d'avocat/soja dans le traitement de la gonarthrose et de la coxarthrose symptomatiques]. Revue du Rhumatisme [Éd Fr Joint Bone Spine]1997;64(12):825‐34. ">Blotman 1997</a>, <a href="./references#CD002947-bbs2-0028" title="LequesneM , MaheuE , CadetC , DreiserRL . Structural effect of avocado/soyabean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care &amp; Research2002;47:50‐8. ">Lequesne 2002</a>, <a href="./references#CD002947-bbs2-0029" title="MaheuE , MazieresB , ValatJ‐P , LoyauG , LeLoetX , BourgeoisP , et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip. Arthritis &amp; Rheumatism1998;41(1):81‐91. ">Maheu 1998</a>, <a href="./references#CD002947-bbs2-0030" title="MaheuE , CadetC , MartyM , MoyseD , KerlochI , CosteP , DougadosM , MazièresB , SpectorTD , HalholH , GrouinJM , LequesneM . Randomised, controlled trial of avocado‐soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Annals of the Rheumatic Diseases2013;Jan 23:[Epub ahead of print]. [DOI: 10.1136/annrheumdis‐2012‐202485] ">Maheu 2013</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Phellondenron amurense</i> + <i>Citrus sinensis</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> <p>peel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NP 06‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>370 mixture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>berberine</p> <p>polymethoxylated flavones</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> <p>30%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0035" title="ObenJ , EnonchongE , KothariS , ChamblissW , GarrisonR , DolnickD . Phellodendron and citrus extracts benefit joint health in osteoarthritis patients: a pilot, double‐blind, placebo‐controlled study. Nutrition Journal2009;8:38. [DOI: 10.1186/1475‐2891‐8‐38] ">Oben 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Uncaria guianensis + Lepidium meyenii</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reparagen®</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>freeze‐dried aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500</p> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0033" title="MehtaK , GalaJ , BhasaleS , NaikS , ModakM , ThakurH , et al. Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. BMC Complementary and Alternative Medicine2007;7:34. [DOI: 10.1186/1472‐6882‐7‐34] ">Mehta 2007</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i> + <i>Alpinia galanga</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EV.EXT 77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>acetone extract<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0002" title="AltmanRD , MarcussenKC . Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis &amp; Rheumatism2001;44(11):2531‐8. ">Altman 2001</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Medicinal products from three or more plants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Clematis mandshurica</i> + <i>Prunella vulgaris</i> + <i>Trichosanthes kirilowii</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root, flower, root; 1:1:2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ethanol 30% extracts, thereafter butanol extraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600‐1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>oleanolic acid 4%, rosmarinic acids 0.2%, ursolic acids 0.5%, hydroxybenzoic acid 0.03%,<br/> hydroxymethoxybenzoic acid 0.03%, trans‐cinnamic<br/> acid 0.05% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0022" title="JungYB , RohKJ , JungJA , JungK , YooH , ChoYB , et al. Effect of SKI306X, a new herbal anti‐arthritic agent, in patients with osteoarthritis if the knee: A double‐blind placebo controlled study. American Journal of Chinese Medicine2001;29(3‐4):485‐91. ">Jung 2001</a>, <a href="./references#CD002947-bbs2-0023" title="JungYB , SeongSC , LeeMC , ShinYU , KimDH , KimJM , et al. A four‐week randomized, double‐blind trial of the efficacy and safety of SKI306X: A herbal anti‐arthritic agent versus diclofenac in osteoarthritis of the knee. American Journal of Chinese Medicine2004;32(2):291‐301. ">Jung 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><i>Fraxinus excelsior</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Phytodolor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>fresh plant ethanolic (45,6%) extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>3:1:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>5‐8 ml</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total flavonoids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34 ‐ 0.56 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD002947-bbs2-0006" title="BernhardtM , KeimelA , BelucciG , et al. Double‐blind, randomised, comparative study of Phytodolor N and placebo as well as an open comparison with Felden 20 Tabs involving convalescent inpatients with arthrotic joint alterations. Unpublished Pharma Report1991. [Steigrwald Pharmaceuticals, Germany] ">Bernhardt 1991</a>, <a href="./references#CD002947-bbs2-0021" title="HuberB . Therapy of degenerative rheumatic diseases: Use of analgesic medication with Phytodolor N [Therapie degenerativer rheumatischer erkrankungen: Bedarf an zusatzlicher analgetischer medikation unter Phytodolor N]. Fortschritte der Medizin1991;109:248‐50. ">Huber 1991</a>, <a href="./references#CD002947-bbs2-0039" title="SchadlerW . Phytodolor for the treatment of activated arthrosis. Rheuma1988;8:288‐90. ">Schadler 1988</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicyl alcohol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48 ‐ 0.8 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Solidago virgaurea</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>isofraxidin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 ‐ 1.1 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Populus tremula</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark and leaf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 ‐ 8 mg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Salix alba</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Reumalex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>salicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40‐80mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p><a href="./references#CD002947-bbs2-0034" title="MillsSY , JacobyRK , ChacksfieldM , WilloughbyM . Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: A double‐blind study. British Journal of Rheumatology1996;35:874‐8. ">Mills 1996</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Guaiacun officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>resin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Cimicifuga racemosa</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Smilax</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Populus</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>bark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7:1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese mixture<sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>herb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duhuo Jisheng Wan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 x 3 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0045" title="TeekachunhateanS , KunanusomP , RojanasthienN , SananpanichK , PojchamarnwitputhS , LheiochaiphuntS , PruksakornS . Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. BMC Comlementary and Alternative Medicine2004;4:19. [DOI: 10.1186/1472‐6882‐4‐19] ">Teekachunhatean 2004</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Paeoniae alba</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Chinese mixture:</p> <p>Blood nourishing, hard softening (BNHS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>extract, solvent not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>paconiflorin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002947-bbs2-0011" title="CaoY , ShiY , ZhengY , ShiM , LoSK . Blood‐nourishing and hard‐softening capsule costs less in the management of osteoarthritis knee pain: A randomized controlled trial. eCAM2005;2(3):363‐8. ">Cao 2005</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Gentiana macrophylla</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>gentianine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Glycyrrhiza</i> (species not stated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>Auryvedic formaulae<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>powder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>total gingerols</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD002947-bbs2-0014" title="ChopraA , SalujaM , TilluG , VenugopalanA , SarmukaddamS , RautAK , et al. A randomized controlled exploratory evaluation of standardized Ayurvedic formulations in symptomatic osteoarthritis knees: A Government of India NMITLI project. Evidence‐based Complementary and Alternative Medicine2011;8:1‐12. [DOI: 10.1155/2011/724291] ">Chopra 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Zingiber officinale</i>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rhizome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A, B, C, D, and E</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tinospora cordifolia</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>stem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A, B, C, D, and E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tinosporosides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Withania somnifera</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>root</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae B and E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total withanolides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Emblica officinale</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fruit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tannins</p> <p>galic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Tribulus terrestris</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fruit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>component of formulae A and B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>aqueous extract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>total saponins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula<sup>6</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antarth<sup>3</sup> (for sandhigata vata) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0020" title="GuptaAK , AcharyaK , SanchetiPS , JoshiRS . A double‐blind, randomized, multicentric, placebo‐controlled clinical trial of Antarth, a phytomedicine, in the treatment of osteoarthritis. Indian Journal of Pharmacology2011;43:69‐72. [DOI: 10.4103/0253‐7613.75674] ">Gupta 2011</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RA‐11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0013" title="ChopraA , LavinP , PatwardhanB , ChitreD . A 32‐week randomized, placebo‐controlled clinical evaluation of RA‐11, an Ayurvedic drug, on osteoarthritis of the knees. Journal of Clinical Rheumatology2004;10(5):236‐45. ">Chopra 2004</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic formula</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ayuvedic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SGCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0015" title="ChopraA , SalujaM , TilluG , SarmukkaddamS , VenugopalanA , NarsimuluG , HandaR , et al. Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double‐blind, controlled equivalence trial. Rheumatology2013;52(8):1408‐17. [DOI: 10.1093/rheumatology/kes414] ">Chopra 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Japanese mixture<sup>7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Boiogito</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not stated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002947-bbs2-0031" title="MajimaT , InoueM , KasaharaY , OnoderaT , TakahashiD , MinamiA . Effect of the Japanese herbal medicine, Boiogito,on the osteoarthritis of the knee with jointeffusion. Sports Medicine, Arthroscopy, Rehabilitation, Therapy &amp; Technology2012;4:3. [DOI: 10.1186/1758‐2555‐4‐3] ">Majima 2012</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>1. Harpagoside content estimated indirectly and approximately from iridoid glycoside content in daily dose of raw material (<a href="./references#CD002947-bbs2-0156" title="SporerF , ChrubasikS . Preparations from Devil's claw (Harpagophytum procumbens) [Präparate aus der Teufelskralle (Harpagophytum procumbens)]. Zeitschrift für Phytotherapie1999;20:235‐6. ">Sporer 1999</a>). </p> <p>2. Ethanolic extract stated in unpublished thesis but not in published paper (<a href="./references#CD002947-bbs2-0150" title="SchmidB . Treatment of hip and knee osteoarthritis with willow bark extract [Behandlung von Cox‐ und Gonarthrosen mit einem Weidenrindenextrakt]. Dissertation Universität Tübingen1998. ">Schmid 1998b</a>). </p> <p>3. Information provided by manufacturer but not reported in paper.</p> <p>4. Chinese herbal medicine contains 7.75% each of: radix angelicae pubescentiis, radix gentianae macrophyllae, cortex eucommiae, radix achyranthis bidentatae, radix angelicae sinensis, herba taxilli, radix rehmanniae preparata, rhizoma chuanxiong, cortex cinnamomi, radix ledebouriellae. 5% each of: radix paeoniae alba, radix codonopis, radix glycyrrhizae, poria. 2.5% herba asari. </p> <p>5. All Ayurvedic formulae A‐E contain <i>Zingiber officinale</i> (dried rhizome powder, total gingerols as marker), and <i>Tinospora cordifolia</i> (dried stem aqueous extract, marker tinosporosides). Some formulae also included <i>Emblica officinale</i> , <i>Withania somnifera</i> , or <i>Tribulus terrestris</i>. Drug:extract ratio and marker content not stated. </p> <p>6. Ayurvedic phytomedicine Antarth contains <i>Boswellia serrata, Commiphora mukul, Curcuma longa</i> and <i>Vitex negundo, Alpinia galangal, Withania somnifera, Tribulus terrestris,</i>  and <i>Tinospora cordifolia</i>. </p> <p>7. Japanese herbal medicine Boiogito contains <i>Sinomenium acutum</i> , <i>Astragalus</i> (species not stated) root, <i>Atractylodes lancea</i> rhizome, Jujube (probably <i>Ziziphus zizyphus</i> ), <i>Glycyrrhiza</i> (species not stated), and ginger (species not stated, probably <i>Zingiber officinale</i>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Herbal medicinal products used for the treatment of OA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/full#CD002947-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Boswellia serrata 999 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function: loss of function (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Boswellia serrata 999 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 at 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.57 [‐24.67, ‐8.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.21 [‐14.21, ‐2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse event episodes (n) reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Boswellia serrata (enriched) 250 mg versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 at 90 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse event episodes (n) reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Boswellia serrata (enriched) 250 mg versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg plus non‐volatile oil versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.09 [‐20.37, ‐11.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.10 [‐24.95, ‐11.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.80 [‐20.29, ‐9.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.01 [‐19.21, ‐10.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.30 [‐20.07, ‐8.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.8 [‐21.92, ‐9.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.13, 7.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 30 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.06, 16.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 90 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 17.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Boswellia serrata (enriched) 100 mg plus non‐volatile oil versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Boswellia serrata 999 mg versus valdecoxib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC‐VAS (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐7.26, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [‐4.07, 9.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.39, 10.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants (n) withdrew due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 71.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Boswellia serrata 999 mg versus valdecoxib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Curcuma domestica versus ibuprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on walking NRS 0‐10 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function: 100m walk time (seconds) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.46, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Curcuma domestica versus ibuprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Derris scandens versus naproxen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC‐VAS (Pain) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐1.84, 11.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [‐0.13, 10.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events. <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.49, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Derris scandens versus naproxen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Harpagophytum procumbens versus diacerhein</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline at 120 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐6.52, ‐3.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.21, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Harpagophytum procumbens versus diacerhein</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Petiveria alliacea versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain (scale unknown) with mvt change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.31, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.28, 8.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Petiveria alliacea versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Pinus pinaster (Pycnogenol® 150 mg) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC‐VAS (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐142.0 [‐199.55, ‐84.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐529.0 [‐741.59, ‐316.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Pinus pinaster (Pycnogenol® 150 mg) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Pinus pinaster (Pycnogenol® 100 mg) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC 0‐4 (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.50 [‐8.43, ‐6.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐29.3 [‐30.99, ‐27.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Pinus pinaster (Pycnogenol® 100 mg) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Ricinus officinale versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Ricinus officinale versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Rosa canina versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Relief of pain (0 to 4) at 3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [‐0.12, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐10.20, 5.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐8.98, 6.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.63, 4.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Rosa canina versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Salix purpurea x daphnoides versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 at 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function VAS 0‐100 at 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.57, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Salix purpurea x daphnoides versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Salix purpurea x daphnoides versus diclofenac</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC‐VAS (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [5.91, 24.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 14 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 42 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.0 [2.70, 21.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.43, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Salix purpurea x daphnoides versus diclofenac</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Uncaria guianensis versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 (night) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.10 [‐26.44, 4.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.54, 5.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Uncaria guianensis versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Zingiber officinale (Zintona EC) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 (movement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐31.12, 13.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function (handicap) VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.0 [‐27.25, 15.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.16, 78.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Zingiber officinale (Zintona EC) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Boswellia carteri + Curcuma longa versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Function: pain free walking time (minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 2 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Boswellia carteri + Curcuma longa versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.47 [‐15.90, ‐1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>326</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.90 [‐23.95, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.40 [‐17.20, ‐3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐6.58, 8.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pain VAS 0‐100 change from baseline at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐7.39, 6.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pain VAS 0‐100 grouped by joint <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.06 [‐15.24, ‐2.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 VAS (hip OA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.80 [‐25.22, ‐2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 VAS (knee OA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.10 [‐14.45, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Function: disability VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 WOMAC‐VAS (Function) change from baseline at 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐7.14, 5.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Lequesne algofunctional index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.17 [‐2.54, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.68, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.78, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Function (various tools) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.73, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.97, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Participants (n) withdrew due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.73, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Particpants (n) reported serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.94, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 JSW change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.43, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 &lt; median group, at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.73, ‐0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 &gt; median group, at 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.31, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.22, 0.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 600 mg) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.2 [‐20.82, ‐7.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lequesne algofunctional index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐2.38, ‐0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.66, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 600 mg) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 WOMAC‐VAS (Pain) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.59, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Paricipants (n) reported serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.31, 27.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Persea gratissma + Glycine max (ASU 300 mg) versus chondroitin sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Phellondendron amurense + Citrus sinensis (NP 06‐1) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Lequesne algofunctional index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.82 [‐7.05, ‐0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Normal BMI participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.2 [‐3.37, ‐1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Overweight BMI participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.50 [‐6.95, ‐4.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Phellondendron amurense + Citrus sinensis (NP 06‐1) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Uncaria guianensis + Lepidium meyenii versus glucosamine sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.18, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Uncaria guianensis + Lepidium meyenii versus glucosamine sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Zingiber officinale + Alpinia galanga (EV.EXT77) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain immediately after walking 50 feet VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.60 [‐16.81, ‐2.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Zingiber officinale + Alpinia galanga (EV.EXT77) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">SKI306X versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low dose (600mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.1 [‐25.19, ‐7.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Medium dose (1200mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.5 [‐23.04, ‐5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 High dose (1800mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.3 [‐31.82, ‐12.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lequesne algofunctional index change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐3.71, ‐1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low dose (600mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐4.05, ‐0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Medium dose (1200mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.8 [‐4.62, ‐0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 High dose (1800mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐4.68, ‐1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.49, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low dose (600mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.32, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Medium dose (1200mg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.2 [0.43, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 High dose (1800mmg) SKI306X</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.16, 2.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">SKI306X versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">SKI306X (600 mg) versus diclofenac</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [‐2.78, 5.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lequesne algofunctional index change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.10, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.38, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">SKI306X (600 mg) versus diclofenac</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Phytodolor N versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Enduring pain (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function: mobility limitations (0 to 3) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Phytodolor N versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Reumalex versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 AIMS2 arthritis pain score change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.73, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.40, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Reumalex versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Chinese DJW versus diclofenac</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 (total) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.81 [‐9.67, 33.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lequesne algofunctional index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.89, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.66, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Chinese DJW versus diclofenac</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Chinese BNHS versus Chinese active control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 (walking) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐7.12, 11.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐7.57, 3.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.51, 160.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Chinese BNHS versus Chinese active control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Chinese BNHS versus glucosamine sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 (walking) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.81, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC‐VAS (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.53, 2.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.00 [0.51, 160.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Chinese BNHS versus glucosamine sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Ayurvedic A to E versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse event episodes (n) reported <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.71, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Formula A versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.63, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Formula B versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.92, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Formula C versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.50, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Formula D versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.34, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Formula E versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.82, 1.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Ayurvedic A to E versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Ayurvedic Antarth versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐9.79, 7.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Ayurvedic Antarth versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Ayurvedic RA‐II versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐1.18, ‐0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.80 [‐6.72, ‐4.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Ayurvedic RA‐II versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Ayurvedic SGC versus glucosamine sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐3.28, 9.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [‐0.72, 4.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.58, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">Ayurvedic SGC versus glucosamine sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Ayurvedic SGC versus celecoxib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.0 [‐8.98, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐1.60, 3.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.56, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">Ayurvedic SGC versus celecoxib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Ayurvedic SGCG versus glucosamine sulphate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐1.42, 9.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [‐1.40, 4.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.47, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">Ayurvedic SGCG versus glucosamine sulphate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Ayurvedic SGCG versus celecoxib</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain VAS 0‐100 change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐7.42, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC 0‐4 (Function) change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐2.59, 2.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.45, 1.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">Ayurvedic SGCG versus celecoxib</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002947-tbl-0048"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">Japanese Boiogito + loxoprofen versus loxoprofen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain: Knee Society Rating System 0‐100 (knee) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐8.90, 6.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Function: Knee Society Rating System 0‐50 (stairs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [0.51, 6.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participants (n) reported adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.88 [0.12, 67.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">Japanese Boiogito + loxoprofen versus loxoprofen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002947.pub2/references#CD002947-tbl-0048">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002947.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD002947-note-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD002947-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002947-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002947-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD002947-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD002947-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD002947-note-0004">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD002947-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002947-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="ta#CD002947-note-0008">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002947-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002947\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002947\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002947\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002947\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002947\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002947.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002947.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002947.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002947.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002947.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714380113"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002947.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714380117"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002947.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6d404d5a9377',t:'MTc0MDcxNDM4MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 